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Bacteriophages (phages) are obligate intracellular parasites of bacteria that usually kill 
the bacterial host. Bacteriophage therapy is a recently revived approach for treating 
bacterial infection that relies on the traits of the phage lytic cycle. A lot of attention has 
been given to phage therapy with new research being published weekly and 
international conferences organised every year, bringing together the academic and 
industrial phage communities. However, despite this huge effort and considerable 
scientific interest there is still a great lack of understanding on how to use phage 
effectively and overcome the many obstacles in the near future. One of the main 
triggers for such interest was the increasing evidence of antibiotic resistance among 
human bacterial pathogens, which were once efficiently eliminated by drugs but are 
now causing alarmingly high levels of morbidity and mortality.  
Also, bacteria when causing a disease are able to produce highly protective biofilm 
communities. Biofilms are major causes of impairment of wound healing and two of the 
most common and aggressive wound pathogens are Staphylococcus aureus (Gram-
positive) and Pseudomonas aeruginosa (Gram-negative), both displaying a large 
repertoire of virulence factors and reduced susceptibility to antibiotics. 
This work reports and explores the use of phages to target both S. aureus and P. 
aeruginosa pathogen biofilm producers. Firstly, isolation of promising phage candidates 
was performed and cocktails were established. Two phages (DRA88 and phage K) 
formed the cocktail to target S. aureus and six phages (DL52, DL54, DL60, DL62, 
DL64 and DL68) formed a cocktail to target P. aeruginosa.  A thorough characterisation 
of each of the selected phages was performed, including their range of host infectivity 
and their genome sequences were analysed. The phage’s ability to infect and kill 
planktonic cultures was successfully studied and afterwards such ability was assayed 
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on biofilms  using an in vitro static biofilm system (microtitre-plate), followed by an in 
vitro dynamic biofilm system (The Modified Robbins Device). Both cocktails were 
shown to be effective in reducing and dispersing  biofilms formed by the clinical strains 
showing them to be promising not only to combat topical bacterial  infections (related to 
biofilm production), but also to control biofilms produced on the surfaces of medical 
devices, such as catheters. Finally, the phage cocktail’s ability to treat systemic 
infections caused by the two pathogens was assessed in an in vivo G. mellonella 
infection model. In the case of the P. aeruginosa infection, although the phages were 
not able to fully treat the larvae, the cocktail allowed a delay of larval death, caused by 
the infection. For the S. aureus infection, the cocktail did not show the same trend, but 
most likely the high bacterial cell numbers involved in the experiment interfered with a 
successful study on the phage cocktail. 
The phage mixture may form the basis of an effective treatment for infections caused 
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1.1. The clinical problem and the challenge 
The discovery of antibiotics in the last century was one of the most important 
developments in medicine and a milestone in the history of modern human society. 
Before the introduction of antibiotics infectious diseases were a major cause of 
mortality due to the systemic infection and sepsis resulting from wound infections, 
pneumonia, childbirth and even, in modern-day terms, comparatively minor infections 
such as gonorrhoea. In the absence of antibiotics performing organ transplants, routine 
surgery and cancer chemotherapy would be impossible.  
Antibiotics have been poorly regulated, leading to inappropriate use, for example to 
treat viral infections, as growth promoters in animals and the widespread use of broad-
spectrum antibiotics. In many countries antibiotics are widely available over the 
counter. This behaviour, going on around the world for several decades, has led to the 
emergence of bacteria that have evolved resistance to multiple antibiotics and currently 
some infections once easily curable are now difficult or impossible to treat (1). Figure 
1.1 illustrates the development process for new antimicrobials which has become 
increasingly contracted (2) and every time a drug comes to market bacteria rapidly 
develop resistance to it (Figure 1.2). One notable exception to this is the newly 
formulated gram-positive antibiotic, teixobactin that inhibits cell wall synthesis yet in the 
initial report at least did not lead to the development of resistant mutants, which is 
some cause for optimism (3). This current situation alongside the massive costs 
associated with antibiotic discovery and clinical trials make investment in developing 
new antibiotic drugs by pharmaceutical companies less appealing (i.e. low return on 
investment) (4), instead they are redirecting their efforts towards the development of 
drugs targeting chronic diseases (with the potential for prolonged profits). For example, 
in 2004 only 1.6 % of drugs in clinical development by the major pharmaceutical 
companies were antibiotics (5). This lack of new agents aggravates the problem of 
emerging resistance which results in higher patient mortality and larger health care 
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costs (6). Infections caused by a pathogen resistant to the drug of treatment generally 
have a higher risk of poor clinical outcome (possibly death) and are also linked to a 
greater consumption of healthcare resources, when compared to infections caused by 
antibiotic-sensitive organisms. In the US it was estimated that annual healthcare costs 
of infections related to antibiotic resistance range from $21 billion to $34 billion and 
more than 8 million additional hospital days (7). Comparatively, in the EU it was 
estimated that costs  reach €1.5 billion annually for  hospital care  (8). Inappropriate 
antibiotic prescribing often starts in the young, with infants and children being 
prescribed improperly with antibiotics for self-limiting infections, viral upper respiratory 
tract infections and prophylactic use (9). Bergus and colleagues in a study conducted in 
Iowa, United States, concluded that of all the antibiotic prescriptions for children, 53 % 
were given to children under four years old and 70 % of infants received at least one 
antibiotic during their first 200 days of life (10, 11).  
































Figure 1.1: Number of new systemic antibiotics approved by the US FDA per five-year period 
(adapted from 6). 
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The misuse and overuse of antibiotics has not only been a problem seen in human 
clinical settings, but also a frequent scenario in agriculture, aquaculture and animal 
farming. Alarmingly, they are mainly used as a disease preventive measure and are 
used as a normal component, for instance, of the normal feed of the animals, often 
given in sub-therapeutic concentrations (12). This situation has also lead to selection 
and propagation of antibiotic resistant strains in such environments, turning them into 
reservoirs that contribute to transmission and introduction of new superbugs. These 
antibiotic resistance “networks” go on to cause diseases in humans, where foodborne 
transmission is the more likely route of transmission (13). 
 
Figure 1.2: History of antimicrobial agent development and the subsequent appearance of 
resistance by bacteria (adapted from 14). 
 
In recent years, awareness regarding bacterial antibiotic resistance has been 
increasing and several measures have come out worldwide to tackle and control the 
problem. In 1998, the first of a series of ‘World Health Assembly (WHA) resolutions on 
antimicrobial resistance (AMR)’ (15) were established, followed by the ‘2001 WHO 
Global Strategy for Containment of AMR’ (16), the ‘2011 EU AMR Strategic Action 
Plan’ (17) and the ‘2012 EU Council Conclusions’ (18). In 2003 the European Union 
banned the use of antibiotics for animal growth promotion (19) and in 2012 the FDA 
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stopped the arbitrary use of antibiotics on animals, so that they are only permitted 
when prescribed by a veterinarian (20). The British government also issued ‘The Five 
Year Antimicrobial Resistance Strategy 2013 to 2018’ where the main issues to 
address are (21): 
- A better prevention, management and surveillance of infections both in people 
and farming; 
- Improving education and training of both medical and nursery staff, but also of 
patients; 
- A better data collection on resistance profiles for an earlier and more efficient 
treatment of infections; 
- Providing funding for research, exploring alternative ways for development of 
new antibiotics, a rapid diagnosis and other therapeutic alternatives. 
Antibiotic resistance needs to be accepted as a huge, complex and multifactorial global 
problem that requires a substantial change of behaviour. The key feature of these 
strategies and the upcoming ones is the synchronisation of efforts from all sectors, all 
working together towards a common direction; these include not only the human health 
side, but also the animal and agriculture one, industry and Governments, doctors, vets, 
farmers, patients and obligatory, scientists.  
Research plays an important role in overcoming the antibiotic resistance problem; 
hence efforts are ongoing to discover and develop new ways of treating antibiotic 
resistant bacteria and to reduce their clinical impact on our lives. 
 
1.2. Wound infections 
The skin is our body’s largest defence from invading harmful microorganisms that can 
colonise and damage the underlying tissues, but it plays a multitude of other roles, 
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including thermoregulation and body fluid homeostasis. However, the skin being the 
most exposed organ can be vulnerable to environmental threats and when a breach of 
the skin occurs following a burn or a wound for example, normal skin colonising 
bacteria can enter the deeper tissues, where a moist, warm and nutritive environment 
allows bacteria to proliferate causing localised inflammation, sometimes followed by 
wider dissemination. In Figure 1.3 the anatomy of the skin is outlined.  
 
Figure 1.3: Skin anatomy with commensal flora viewed in cross-section. Reprinted from 
reference (22) and used with permission. 
 
1.2.1. Wounds: acute and chronic 
An acute wound is usually caused by an external factor that damages and breaches 
the skin. Examples of such wounds are surgical wounds, bites, burns, cuts and 
lacerations. The normal healing process of acute wounds shows four phases: 
coagulation, inflammation, formation of granulation tissue and scarring.  
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A chronic wound is described as a wound where the normal healing process observed 
for an acute wound does not take place.  Usually the occurrence of a chronic wound 
happens with a small traumatic injury. However, due to patient pre-disposition, such as 
diabetes, it will develop to chronicity instead (23). The most common chronic wounds 
are diabetic foot ulcers, pressure ulcers, venous leg ulcers and ischemic ulcers (24). 
These always involve  an unusually highly prolonged inflammatory phase, which 
predisposes for persistent infections and consequently the formation of persistent 
biofilm communities (24).  
The advent of an infection on an acute wound will delay the normal healing process 
and for a chronic wound might result in non-healing for months (25).  
 
1.2.2. Microbiology of wounds 
In the moist surface of a wound, subcutaneous tissues are exposed and provide a 
nutrient-rich environment, mainly in the form of long-chain fatty acids (26), which often 
shows signs of low blood supply (ischaemia), inadequate oxygen supply (hypoxia), 
necrosis and most likely a disrupted normal immune response. Hence, the wound 
environment becomes ideal for bacteria to colonise, proliferate and establish an 
infection. The main source of bacterial wound contamination is the patient’s normal 
body flora, whether living endogenously (essentially the gut, mouth and genitourinary 
tract) or from the skin as well as from the surrounding environment.  Generally, a 
wound infection, whether  acute or chronic, will be shown to have a mixture of several 
bacterial populations, where anaerobic and aerobic bacteria are present, but also fungi 
and viruses (27). However, standard culturing methods overlook many of these 
bacteria, especially the anaerobes, that can be revealed when molecular techniques 
are applied (28). The microbiome of the wound is also dependent on the wound type 
itself (site, depth) and the geographical area of the patient. For example, in a study in 
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an Indian hospital it was found that P. aeruginosa was the most common isolate from 
burn wounds (59 %), followed by S. aureus (17.9 %), Acinetobacter spp (7.2 %), 
Klebsiella spp (3.9 %), Enterobacter spp (3.9 %) and Proteus pp (3.3 %) (29). In 
another study in Turkey it was found that Acinetobacter baumannii was the isolate most 
frequently found in burn patients (23.6 %), followed by coagulase- 
negative Staphylococci (13.6 %), P. aeruginosa  (12 %), S. aureus (11.2 %), 
and Escherichia coli (10 %) (30). The fate of a wound infection is determined by 
several factors, such as the location, size and depth of the wound, the load, virulence 
profile and interaction of the pathogens growing and colonising the wound, the levels of 
blood getting to the wound and, of course, the health condition of the patient. For 
example, Djahmi and colleagues (31) reported that patients suffering from  diabetic foot 
ulcers had a worse outcome when colonised with PVL-positive S. aureus isolates (PVL 
is a potent cytotoxin).  
Despite the multifactorial factors influencing the microbiology and development of a 
wound infection it is possible to generally identify the main causative organisms. 
Hence, Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. 
aeruginosa) are the most common pathogens isolated from acute and chronic wounds 
(32, 33). The latter is usually the first pathogen to begin an infection on a chronic 
wound (34). Often, then associated with other less represented bacteria, such as 
Enterococcus spp, S. epidermidis and Klebsiella pneumoniae.  
These pathogens, in order to colonise and invade the host tissues, display an array of 
enzymes and toxins harmful to the host cells and connective matrix and have multiple 
mechanisms involved in subverting host immune system responses.  
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1.2.3. Nosocomial infections  
Generally, for patients suffering from a moderate to severe burn wound there is, at 
some point, a need to visit the hospital, where contamination from the hospital 
environment is of great concern. In this setting, bacterial pathogens may be transferred 
to the wounded patient through contact with contaminated surfaces, water, air and via 
health care worker’s hands. S. aureus  and P. aeruginosa are two of the pathogens 
most often isolated in hospital settings (35, 36), resulting  in  prolonged hospitalisation, 
increased morbidity (such as sepsis, bacteraemia) and large economic losses (37). 
Therefore, an effective infection control policy is needed in order to eradicate or reduce 
pathogenic bacteria, particularly antibiotic resistant ones, and prevent cross-infection 
(38). 
 
1.2.4. Wound infections and biofilm formation 
Wound infections can often develop into a biofilm and more often than not this is 
observed for chronic wound infection. It has been documented that more than 60 % of 
chronic wounds contain a biofilm, whereas only a small percentage (6 %) are of 
concern in acute wounds (39). The presence of a biofilm will delay the process of 
wound healing and scarring and in consequence adversely affect the patients’ health 
(Figure 1.4). Biofilms are much less susceptible to the action of the immune system, for 
example chemotaxis is inhibited and polymorphonucleocytes (PMNs) are prevented 
from engulfing the bacterial cells trapped in the biofilm, causing a massive release of 
cytokines that contribute to  the chronicity of the infection (necrotic tissue and 
inflammation) (40). Hence, it is very important to recognise the presence of a biofilm in 
order to deliver the best treatment approach.  




Figure 1.4: Representation of a biofilm established on a skin wound. 
 
1.3. Staphylococcus aureus 
Bacteria belonging to the genus Staphylococcus are gram-positive cocci that typically 
grow in clusters (from the Greek staphylé, meaning “a bunch of grapes”). Typical 
Staphylococci are 0.5 – 1.5 m in diameter, non-motile, facultative anaerobic and are 
able to grow at high salt concentrations and at temperatures ranging from 18C to 
40C. A number of species in the genus are human pathogens, including S. aureus, S. 
epidermidis, S. haemolyticus, S. lugdunensis and S. saprophyticus. 
A distinguish feature of Staphylococcus aureus (Figure 1.5) is the fact that is the only 
species of the genus producing coagulase, an enzyme that catalyses the conversion of 
fibrinogen into fibrin, which is a distinguishing feature of this species. S. aureus is a 
ubiquitous organism and a common coloniser of humans, usually found in the anterior 
nares, but also in the skin, oropharynx, gastrointestinal tract and urogenital tract. 
Approximately 20 % of the population have the anterior nares colonised permanently 
by S. aureus, and around 60 % carry the bacterium periodically (41). Because the 
pathogen colonises our skin and nares and additionally adheres to dry surfaces, it is 
easily spread between individuals, either through direct or indirect contact (i.e. from 
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contaminated surfaces). S. aureus is known to cause a varied spectrum of diseases 
affecting tissues such as the skin (impetigo, wound infections), the respiratory tract 
(pneumonia, empyema), bone (osteomyelitis), the central nervous system (meningitis) 
and the vascular compartment (endocarditis, thrombophlebitis) (Lowy, 1998). In 
addition, the pathogen is one of the main causes of infection from medical devices 
such as catheters and surgical implants (42).  
 
Figure 1.5: Scanning electron microscopy (SEM) of Staphylococcus aureus bacteria (courtesy 
of Dr Naing Thet). 
 
1.3.1. Virulence Factors 
S. aureus is known to be a dangerous pathogen able to counteract and avoid the 
human defences, causing serious disease. This is driven by a number of intrinsic 
aspects acting together that comprise structural components, toxins and enzymes 
(Figure 1.6). 




Figure 1.6: Staphylococcus aureus virulence factors. Reprinted from reference (43) and used 
with permission. 
 
1.3.1.1. Structural Components 
To initiate an infection, S. aureus adheres to host tissues and prosthetic devices driven 
by a range of surface proteins known as microbial surface components recognising 
adhesive matrix molecules (MSCRAMMS) (44). The majority of S. aureus strains 
express a polysaccharide capsule (45) which protects the bacterium from 
phagocytosis. There are 11 capsular serotypes described to date, but serotypes 5 and 
8 are the most predominant and most clinically relevant (46). The capsule can be 
covered by a slime-layer, consisting of proteins and monosaccharides that facilitate the 
adherence of the bacterium to host tissue and other surfaces.  The cell wall is 
composed of two major components: peptidoglycan and teichoic acids. Peptidoglycan 
displays endotoxin-like activity which stimulates the immune system and the teichoic 
acids facilitate the bacterium adhesion to mucosal surfaces. Anchored in the cell wall is 
Protein A, which plays an important role in the pathogenesis of S. aureus. It has high 
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affinity for the Fc region of Imunoglobulin G (IgG) (47), which results in IgG molecules 
coating the cell wall. However, the IgG molecules are in an incorrect orientation to be 
recognised by the neutrophil Fc receptors thus effective phagocyte recruitment is 
prevented (48). Experiments regarding animal infection models and protein A-deficient 
mutants of S. aureus demonstrate a reduction in virulence (49). S. aureus is able to 
resist the human bactericidal protein lysozyme by altering the structure of its cell wall 
muramic acid and lysis of the bacterial cell does not occur (50). 
 
1.3.1.2. Toxins 
S. aureus produces a large number of toxins that play an essential role in virulence: 
five cytolytic toxins, two exfoliative toxins, several enterotoxins and toxic shock 
syndrome toxin-1 (TSST-1) have been recognised. Cytolytic toxins – α, β, δ, γ and 
Panton Valentine leukocidin (PVL) - facilitate the lysis of host cells, such as 
erythrocytes, leukocytes, fibroblasts, macrophages and platelets, by forming β-barrel 
pores in the cytoplasmic membrane. This disruption causes the swelling of the cell due 
to an osmotic imbalance - efflux of K+ and influx of Na+ and Ca2+, among other 
molecules. The PVL protein has specific toxicity to leukocytes and it is strongly 
associated with increased virulence in necrotising diseases (51). The pvl gene, carried 
in a lysogenic phage, is found in 2 % of randomly selected S. aureus strains (52), with 
higher occurrence identified in community-acquired MRSA (CA-MRSA) (53) lineages. 
The exfoliative toxins (ETs), ETA and ETB, are serine proteases that cleave an 
important molecule in the cell-cell adhesion (54). These toxins are responsible for the 
staphylococcal scalded skin syndrome (SSSS) (for review see 55, 56), a serious 
dermatitis affecting mostly young children (57). Staphylococcal enterotoxins are a 
family of heat-stable toxins, resistant to gastric enzymes that can cause food poisoning 
(58).  
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Enterotoxins along with TSST-1 act as superantigens causing T-cell activation leading 
to massive pro-inflammatory cytokine release (see below). 
 
1.3.1.2.1. Toxic shock syndrome toxin-1 (TSST-1) 
The superantigen toxin TSST-1 is able to bind to the exterior region of the MHC class II 
protein in the surface of antigen-presenting cells (APC) and link it to the receptor of a 
T-helper cell. The non-specific activation of T-cells - up to 30 % can be activated (59) - 
leads to a massive and uncontrolled proliferation of cytokines causing a cytotoxic effect 
to host cells. The toxin is also able to penetrate mucosal barriers (e.g. burn wound 
sites) and enter the bloodstream contributing to toxic shock syndrome (TSS), which 
can culminate in death caused by hypovolemic shock, leading to multi-organ failure 
(60). A proposed model of cascade signalling and invasion of TSST-1 on the vaginal 
surface is illustrated in Figure 1.7 and a parallel can be made to what happens on the 
surface of a burn wound. Antibodies against TSST-1 toxin have been shown to 
increase with age and 95 % of individuals show protection at the age of 30, so children 
are presumably at greater risk as a result of lower antibody protection (61).  
 
1.3.1.3. Enzymes 
S. aureus are “armed” with a pool of enzymes that, once more, enable the bacteria to 
spread and manipulate the human body defences. All S. aureus are producers of 
coagulase. Coagulase appears under two forms: bound and free. Both forms result in 
the same outcome – conversion of fibrinogen to insoluble fibrin – however one is able 
to react directly (bound form) and the other goes through a reaction cascade (free 
form). Fibrin covers the bacterial surface and phagocytosis is prevented. The enzyme 
catalase acts to convert hydrogen peroxide to water and oxygen. Hydrogen peroxide is 
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a toxic molecule resulting from bacterial metabolism and is a commonly accumulated 
molecule inside phagocytic cells. Another enzyme that aids bacterial invasion of host 
tissue is hyaluronidase. Hyaluronidase breaks down the hyaluronic acids, a major 
element of the matrix in the connective tissue (63).  Staphylokinase interacts with and 
inactivates the bactericidal α-defensins (64) produced by neutrophils (65). Such 
enzyme interacts with plasminogen which results in a complex capable of dissolving 
fibrin, hence, enabling the bacteria to penetrate the human tissue (66).  
 
 
Figure 1.7: Proposed model for the cascade signalling caused by TSST-1 on the vaginal 
surface. S. aureus (purple) colonising a body surface secretes cytolysins, such as α-toxin (red), 
causing mucosal barrier disruption. Then, TSST-1 (yellow) can penetrate more easily the 
mucosa to reach the lower levels of the epithelium, where the superantigen toxin stimulates 
production of cytokines (such as, IL-8), that in turn recruit adaptive immune cells to the 
submucosa. TSST-1 interacts with T-cells (blue) and APCs (green) to stimulate a cytokine 
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1.4. Pseudomonas aeruginosa 
Bacteria belonging to the genus Pseudomonas are gram-negative non-fermentative 
motile rods,  typically measure 0.5 – 1 by 1.5 – 5 μm and are arranged in doublets that 
resemble a single cell (from the Greek “pseudes” and “monas”, meaning false unit) 
(Figure 1.9). The bacteria can tolerate a wide range of temperatures (from 4oC to 42oC) 
and despite being considered as obligate aerobes this is not entirely true, as these 
bacteria can also grow anaerobically by using nitrate or arginine as the final electron 
acceptor.  Colonies from this genus can appear mucoid and/or pigmented as many 
strains produce a thick and viscous polysaccharide capsid and produce diffusible 
pigments, such as pyocyanin (blue), pyorubin (red-brown) and pyoverdin (yellow-
green). More than 200 species compose the genus; however Pseudomonas 
aeruginosa is the major human pathogen considered the most important. 
P. aeruginosa are bacteria with minimal growth requirements that are highly versatile, 
triggering different metabolic pathways depending on the available energy source, this 
allows them to be ubiquitous in nature (67) and, if given the opportunity, are able to 
become serious and even fatal disease causing agents. P. aeruginosa, contrasting to 
what was described above for S. aureus, usually is not part of the normal commensal 
flora in humans. Hence, disease scenarios occur mainly in hospital settings, where the 
environmental bacterium closely related to water environments can cause infections 
via, for example aerosols aspiration of contaminated tap water or direct contact with 
contaminated humid surfaces (68), that readily colonises the human skin (69), being 
particularly problematic for patients with a compromised immune system (70). From the 
wide range of infections caused by P. aeruginosa, one can mention the chronic 
pulmonary infections in cystic fibrosis patients, skin and soft tissue infections of severe 
burn wound victims that can lead to bacteraemia, but nevertheless pneumonia and 
infections associated  to the urinary tract, the ear (external otitis) and the eye (corneal 
ulcers). 
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1.4.1. Virulence factors 
Pseudomonas aeruginosa (Figure 1.8) is armed with several virulence factors, ranging 
from adhesins, toxins and enzymes to a type III secretion system that together allow 




Figure 1.8: Pseudomonas aeruginosa virulence  (adapted from 70). 
 
1.4.1.1. Adhesins 
P. aeruginosa is provided with four types of structures that assist them in host 
adherence: flagella, pili, lipopolysaccharide (LPS) and alginate. Both the flagella and 
the type IV pili are responsible for motility (72) and adherence to epithelial tissues (73–
75). The LPS is responsible for the inflammatory effects that play an important role in 
virulence (76) and it slows down the entrance of antibiotics (77). It consists of a lipid A 
region that anchors the LPS to the outer membrane of the bacterium, the core 
oligosaccharide and a projected highly variable O-antigen side chain, that is composed 
of a series of saccharide units conferring serotype specificity. So far there are 20 
recognised P. aeruginosa serotypes (78). The O-antigen seems to be crucial for the 
virulence phenotype of the LPS; several studies using mutants deficient in O-antigen 
showed a reduced virulence along with a reduced dissemination when compared to the 
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wild-type bacteria (79, 80). Another virulence factor that many strains produce is the 
exopolysaccharide alginate. Its accumulation produces a thick capsule around the 
bacterial surface, which gives protection from external threats; this includes reduced 
chemotaxis and consequently phagocytosis and inhibition of complement (81, 82). 
Alginate, together with two other exopolysaccharides, PsI and Pel,  have a major role in 
P. aeruginosa biofilm formation stages and protection from antibiotic drugs (83), their 
regulation is complex posing an additional major problem for CF patients infected by 
the bacteria (discussed below).  
 
1.4.1.2. Toxins and enzymes 
Several toxins and enzymes produced by P. aeruginosa make them common, versatile 
and difficult pathogens to eradicate. Exotoxin A (ETA) contributes for its pathogenesis 
(84); the exotoxin once inside eukaryotic cells is able to disrupt protein synthesis, by 
causing the ADP ribosylation of the eukaryotic elongation factor 2 (85). This will result 
in tissue damaging, that is often observed in ocular and chronic pulmonary infections. 
The pigments also act as virulence factors: pyocyanin interferes with several eukaryotic 
cell functions, including cell respiration (86) and apoptosis of neutrophils (87); 
pyoverdin is a siderophore  which binds to iron and transports it through the bacterial 
membrane to be used in the bacterial metabolism (88); it also regulates production of 
other virulence factors, including ETA (89).  
Two elastases, LasA (a serine protease) and LasB (a zinc metalloprotease) are 
produced by the P. aeruginosa that by acting together degrade elastin (90). Elastin is a 
major component of human connective tissue and these enzymes are responsible for 
their damage causing the typical ecthyma gangrenosum (lung parenchymal damage 
and haemorrhagic lesions) associated with disseminated P. aeruginosa lung infections. 
It also regulates the secretion of two other extracellular enzymes:  exoenzymes S and 
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T (91). The type III secretion system is then responsible for introducing the enzymes 
into the eukaryotic cells, facilitating bacterial dissemination, tissue invasion and 
necrosis. Two homologous phospholipases C (PLC) are secreted - a non-haemolytic 
and a haemolytic one. Whereas the first seems not to be associated with pathogenicity, 
the haemolytic PLC is highly virulent being responsible for degrading lipids and lecithin, 
facilitating tissue destruction and death when it is administered into mice (92). 
 
 
Figure 1.9: Scanning electron microscopy (SEM) of Pseudomonas aeruginosa bacteria 
(courtesy of Dr Naing Thet). 
 
1.4.2. Cystic fibrosis 
Cystic fibrosis (CF) is a genetic disorder associated with high mortality rates which is 
caused by mutations in the cystic fibrosis conductance regulator (CFTR) gene (93). It is 
the most common genetic disease amongst Caucasian populations (94). The defect in 
the regulator, a channel expressed primarily in the epithelial cells that pumps chloride 
to the extracellular space, disrupts electrolyte secretion, commonly leading to several 
complications, including pancreatic insufficiency, abnormal function of secretory glands 
and highly viscous bronchial secretions. Such a situation in the lungs impairs the 
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normal control of bacterial colonisation as the thick mucus in the airways is not 
efficiently cleared; resulting in ideal environments for the establishment of chronic 
infections mainly populated by P. aeruginosa biofilms (95). 
.  
1.5. Antibiotic resistance 
Antibiotic resistance occurs through genetic mutations and/or acquisition through 
horizontal gene transfer (HGT) of resistant determinants (for review 92). The rate at 
which bacteria acquire resistance is determined by the bacterial mutation and 
recombination rates, the biological cost of resistance (97) and selective pressure, e.g. 
antibiotic use (98). Resistance genes can be found on transferable genetic elements, 
such as plasmids, integrons and transposons. These elements can spread very fast in 
bacterial populations crossing species barriers to accelerate the rate of resistance 
determinant acquisition (99). 
The most common mechanisms for antibiotic resistance are: alteration of antibiotic 
targets, enzymatic modification and degradation of the antibiotic and drug efflux from 
the bacteria cell (100). 
 
1.5.1. Methicillin-resistant Staphylococcus aureus (MRSA) 
The first S. aureus isolate resistant to methicillin was identified one year after the 
introduction of methicillin (Figure 1.2). Methicillin is a narrow-spectrum beta-lactam 
antibiotic and resistance to it is caused by production of a modified penicillin-binding 
protein – PBP2a. PBPs are enzymatic proteins responsible for peptidoglycan synthesis 
that occur in the bacterial cell wall. The modified PBP shows lower affinity for binding 
the beta-lactam drugs (101), and bacterial growth is not affected. It is encoded by the 
mecA gene carried in the staphylococcal cassette chromosome mec (SCCmec), a 
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mobile genetic element integrated in the MRSA chromosome (102). The SCCmec 
element is composed of the mec gene complex – mecA and its regulator - and the ccr 
gene complex – ccrA, ccrB and ccrC site-specific recombinases. The recombinases 
are the ones responsible for the dissemination of the genetic element within S. aureus 
populations (103). Depending on how the mec gene complex and the ccr are combined 
they can be classified into different types; so far eight types of SCCmec have been 
reported , however VI – VII are rarely observed (104). Hospital-acquired MRSA strains 
are more related to SCCmec types I-III, whereas community-acquired MRSA are 
associated to SCCmec types IV and V. The acronym MRSA is currently used to refer 
any S. aureus strain resistant to antibiotics of the β-lactam group, such as oxacillin, 
penicillin and amoxicillin.  
MRSA is currently one of the most prevalent pathogenic bacteria causing nosocomial 
and community infections, such as acute skin and soft-tissue infections, but also 
chronic wounds  (105–107). According to a study in 2005 there were almost 19,000 
deaths in United States caused by MRSA (108) and more than 65 % of all the 
community acquired S. aureus infections were methicillin-resistant (109). As a result, 
MRSA is recognised as a major public health threat. 
Additionally, vancomycin intermediate S. aureus (VISA) and glycopeptide-intermediate 
S. aureus (GISA) isolates have started to emerge (110), in fact vancomycin resistant S. 
aureus (VRSA) isolates were also already reported (111) and the same is being 
observed for antibiotics such as linezolid (oxazolidinone) and daptomycin (lipopeptide) 
(112, 113). Therefore, even antibiotics such as vancomycin, the so called antibiotic of 
‘last resort’ that used to be effective against MRSA are becoming increasingly 
ineffective in treating S. aureus infections.  
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1.5.2.  Multidrug Resistant (MDR) P. aeruginosa 
P. aeruginosa antibiotic resistant isolates have been significantly increasing for the past 
two decades (114) and we are therefore dealing with a bacterium that  has been shown 
to display almost all known mutational mechanisms of bacterial resistance (115). The 
combination of all the mechanisms is translated into a bacterium showing a multidrug 
resistant phenotype (resistance to at least 3 antibiotics) and is a result of several 
situations. The low permeability of the cell wall makes the bacteria intrinsically resistant 
to many drugs, the expression of several efflux pumps and the acquisition of 
chromosomal mutations in the genes that code for the drug target are examples of 
some of the resistance mechanisms in P. aeruginosa (115). Its high rate of 
recombination and acquisition of new genes also contributes to such fast evolution 
causing a high gene diversification among isolates (116). Chromosomal mutations, 
accelerated certainly by the use of antibiotics, are related as well to the hypermutability 
character found in several P. aeruginosa isolates. Hypermutability is related to defects 
in the methyl-directed mismatch repair (MMR). Such a system is responsible for 
recognition and repair of any mutation inserted while DNA replication takes place; if this 
system fails as a consequence higher mutation rates are going to arise in the 
population. Hence, P. aeruginosa isolates have the chance to become resistant to a 
drug very quickly, sometimes this is even observed while the treatment is running 
(117). This is a major problem concerning CF patients, where it has been documented 
that rates of mutation are higher for strains isolated from this patients than rates 
observed in other settings (118). In fact, it was reported in a study in CF patients 
suffering from a chronic P. aeruginosa infection that 36 % of the isolates showed a 
hypermutability phenotype (118). For this reason, it was suggested that monotherapy 
for P. aeruginosa in CF patients should be restricted and only drug combinations 
should be administered in an attempt to avoid resistance emergence (119).  
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1.5.3. Alternatives to treat antibiotic resistant bacteria 
The occurrence of antibiotic resistance in such globally prevalent pathogens, such as 
S. aureus and P. aeruginosa, has triggered an immense focus on research for 
alternatives that might complement or replace the conventional drug therapeutics. 
Several alternatives are now in the spotlight, including bacteriocins and 
bacteriophages. The latter is going to be further explored in the forthcoming sections. 
Bacteriocins, a type of antimicrobial peptide (AMP), are small ribosomally synthesised 
peptides that are produced by practically all types of bacteria and are lethal to other 
bacteria as a mechanism of defence. The peptides insert into the membrane of the 
target bacteria, causing pores on the membrane and consequently lysis is the general 
mode of action (120). Being considered relatively safe, many bacteriocins are indeed 
already in use by the food industry. This includes nisin, a bacteriocin secreted by lactic 
acid bacteria, with potential to disrupt biofilms produced by MRSA isolates (121). It has 
GRAS (generally recognised as safe) status and has been  long used as a food 
preservative. Resistance can be observed usually if alterations on the membrane take 
place (122). 
Bacterial cell wall hydrolases (BCWH) are enzymes able to bind to target sites in the 
peptidoglycan and cleave specific bonds, hence degrading the peptidoglycan of the 
bacterial cell wall and consequently lysing the cell. There are several enzyme types 
being studied and assessed for clinical use, including lysozymes, produced by 
eukaryotic cells; autolysins, produced by the bacteria itself and virolysins, encoded by 
phages. The latter ones are commonly referred as endolysins and these enzymes are 
produced by phages at the end of their lytic life cycle. Several studies, both in vitro and 
in vivo, showed that endolysins are effective to eliminate bacterial infections (123), 
when applied exogenously. CHAPK, the phage lysin generated from the S. aureus 
endolysin LysK showed lytic activity not only against bacterial cultures of S. aureus, but 
also showed to eliminate S. aureus colonising the nares of BALB/c mice (124). 
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However, due to the presence of an outer protective membrane on gram-negative 
bacteria, BCWH are not as effective against these bacteria. 
In order to take advantage and restore the activity of some antibiotics, strategies are 
under research focus to overcome several of the resistance mechanisms observed. As  
examples: efflux pump inhibitors to neutralise antibiotics to be pumped out of the cell 
just after uptake by plasma membrane translocases (125); LPS inhibitors to disrupt the 
LPS protective barrier, usually inhibiting KDO 8-p synthase, an enzyme essential  in 
the LPS pathway (126). 
Each one of these approaches is always associated with some advantages and 
limitations and is not universally effective; therefore it will be important when facing a 
bacterial infection to tackle it with the best approach on a case by case basis.  It may 
be that one single approach will never be the best option, but rather a synchronised 
combination of them.  
 
1.6. Bacteriophages  
Bacteriophages, or phages for short, are viruses that infect bacterial cells (from 
bacteria and the Greek phagein, meaning ‘to eat’). Phages were first discovered 
independently by Frederick Twort in 1915 and Felix d’Hérelle in 1917 (127, 128). Yet, it 
was d’Hérelle that devotedly pursued the study of phage and their uses (128, 129). He 
was the author of the terms bacteriophages as well as plaque (130), the small clear 
areas seen in agar plates caused by bacterial killing by phage. He performed 
experimental treatments of patients with bacterial infections, like dysentery, and he 
demonstrated the usefulness of phage lysates in treating bacterial infection (130).  
After several promising studies (131–133), phage preparations were widely used in the 
treatment of infectious diseases over the world, including cholera, diphtheria, bubonic 
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plague and anthrax. Commercialisation of phages was the next step. This began in 
d’Hérelle’s commercial laboratory, that later became the well-known company L’Oreal. 
The phage preparations were named, for instance, Bacté-intestini-phage and Bacté-
staphy-phage, and were widely marketed (130). Other large companies joined the 
phage market, including Bacteriophage/Robert et Carriere in France, Antipol in 
Germany, Medico-Biological Laboratories in the United Kingdom and Eli Lilly & Co, 
Parke-Davies, Squibb & Sons and Swan-Myers in the United States. Unfortunately, at 
that time the nature of phages was still poorly understood and this gave rise to an 
erroneous targeting of treatment, where conditions like herpes, eczema and gallstones 
were claimed to be curable using phage lysates. Failure in establishing scientific proof 
of phages, mainly due to clinical trials lacking placebo controls, phage preparations 
with low viability and stability and/or containing high levels of endotoxins that would 
compromise phage effectiveness, led to a lack of confidence in the capacity of phages 
to eliminate infectious diseases. With the discovery of penicillin in 1928 by Alexander 
Fleming a new period began where treatment of infectious diseases relied almost 
exclusively on antibiotic drugs and phage therapy was largely forgotten in United 
States and Western Europe. Despite this, the former Soviet Union and Eastern Europe 
(134–136) kept the interest in the bacteria-killing-virus to the present day, studying and 
treating a wide spectrum of bacterial diseases.  
Although therapeutic use of phages was left behind in the western countries, phage 
particles as models were intensively studied and contributed in a significant manner for 
the understanding of basic molecular mechanisms of genes and, consequently for the 
development of modern molecular biology (137). In 1952 using bacteriophages 
selectively tagged, Alfred Hershey and Martha Chase demonstrated one of the genetic 
breakthrough discoveries (Figure 1.10):  the observation that DNA was the molecule 
carrying genetic information (138). 




Figure 1.10: The Hershey-Chase experiment. Two parallel experiments are performed, where 
phages have their protein capsule labelled with radioactive sulfur or their DNA labelled with 
radioactive phosphorous. Phages are then allowed to infect the host bacteria and the mixtures 
are blended and centrifuge in order to obtain a phage supernatant (bacteria free) and a bacterial 
pellet.  Radioactive phosphorus will be found in the bacterial pellet, where sulfur will be found in 
the supernatant, leading to the conclusion that the DNA holds the genetic information, being 
transmitting it to the next generation. 
 
The dissemination of bacterial antibiotic resistance and the emergence of pan-resistant 
bacterial strains have led some to predict a return to the pre-antibiotic era. The efficacy 
of bacteriophages over antibiotics (discussed below) and a greater understanding of 
phage biology has led to a renaissance of interest in bacteriophage therapy.  
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1.6.1. Ecology and Classification 
Phages are the most abundant and ubiquitous microorganisms on Earth, ten times 
more abundant in the environment than bacteria, with numbers estimated to be in the 
order of 1031 (139). Phages are ubiquitous, found in sites such as water, soil, humans 
and animals - skin, feces, gut (140) - and even in our food (141). One gram of fresh or 
processed meat contains about 108 viable phages (142). In a general way, one might 
say that a phage can be found in any environment where bacteria or archaea are 
present.  
Phages present an extensive diversity of shape, size, capsid symmetry and structure. 
Phages can have double-stranded (ds) or single-stranded (ss) DNA or RNA (Table 
1.1). Phages are classified by the policies of the International Committee for Taxonomy 
of Viruses (ICTV) under a myriad of properties (143), but  most important are the type 
of nucleic acid, morphology, physiochemical properties and genomic composition. 
 
1.6.2. Polyvalent bacteriophages 
Phages can be exquisitely specific in host range infecting only a small proportion of a 
species. However polyvalent phage exist that can multiply in most strains of a species 
and even other species within the same genus. Polyvalent phages are not difficult to 
find, in fact there is a whole diversity of phages infecting different bacteria described in 
the literature, particularly phages effective against Staphylococci, such as the twort-like 
phages (146), 812 (147) or P27/HP (148), among others. These phages are the most 
promising therapeutically due to their extensive host range that sometimes extends into 
coagulase-negative staphylococcal species (147). A polyvalent phage or cocktail is 
valuable for situations when the bacterial pathogen causing the infection has not yet 
been identified and a prompt action has to be taken to deal with the infection. Also, 
some studies have demonstrated a lack of genetic diversity among antibiotic resistant 
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bacteria (149), meaning small differences between isolates and hopefully the same 
polyvalent phage is able to easily deal with bacterial infections caused by different 
isolates. 
 
Table 1.1: Classification of phage families (adapted from 144). L, linear, C, circular. 
 
It is estimated that over 96 % of phages worldwide belong to the Caudovirales order 
characterised by tailed helical particles, provided with adhesion structures (baseplate, 
spikes and fibres) and dsDNA genome, that can show a range size of 18 kb – 500 kb 
(145). The order is composed by three families: Myoviridae (contractile tail), 
Siphoviridae (long non-contractile tail) and Podoviridae (short non-contractile tail).  
 
1.6.3. Phage life cycle 
Like their counterpart viruses, phages are obligate parasites that require a specific host 
cell to reproduce which, in this case, are bacterial cells. This specificity is highly 
sophisticated. Adsorption of the phage to the host cell is mediated by the tail fibers, or 
Shape Family Nucleic acid Characteristics Member 
 
Myoviridae dsDNA (L) No envelope, contractile tail T4 
Siphoviridae dsDNA (L) No envelope, non-contractile long tail  
Podoviridae dsDNA (L) No envelope, non-contractile short tail T7 
Microviridae ssDNA (C) Knoblike capsomers X174 
Corticoviridae dsDNA (C) No envelope, complex capsid PM2 
Tectiviridae dsDNA (L) Inner lipidic vesicle, pseudo-tail PRD1 
Leviviridae ssRNA (L) No envelope MS2 
Crystoviridae dsRNA (C) Segmented, lipidic envelope 6 
Inoviridae ssDNA (C) No envelope, filaments or rods Fd 
Plasmaviridae dsDNA (C) Lipidic envelope, no capsid MVL2 
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other equivalent structure on those phages lacking tail fibers, that recognise specific 
sites on the bacterial cell surface. The nature of the receptor sites is diverse: for 
instance, surface proteins, LPS, pili and lipoproteins. Note that phages evolve in order 
to target these bacterial receptors, which are required for normal bacterial function. 
Small differences in these receptors (e.g. between two strains of the same species) will 
prevent efficient adsorption occurring. Once the phage is irreversibly bound to the 
bacteria, injection of the genomic material into the cell takes place, commonly through 
formation of a hole in the bacterial cell wall. At this stage, two different scenarios can 
be established: lytic or lysogenic infection (Figure 1.11). 
 
Figure 1.11: Structure of a typical tailed bacteriophage (a) and the stages of the lytic and 
lysogenic life cycle (b). Reprinted from reference (150) and used with permission. 
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1.6.3.1. Lytic infection 
The viral genome now inside the bacterial cell is transcribed by the host RNA 
polymerases to produce mRNA, which is responsible for arresting all host cell synthetic 
machinery on  behalf of phage reproduction (151) through a methodic and temporal 
regulated set of events: genome replication, gene expression and morphogenesis 
(assembly of the virion capsids and genome packaging). Once production of the virions 
is completed it is necessary to breakdown the bacterial cell wall in order to release the 
phage progeny (burst). Several lytic enzymes, including lysozymes, endopeptidases 
and amidases (152), are produced by the phage. Lysis of the bacterial cells, which can 
be accomplished within minutes or hours, is followed by release of hundreds of phage 
particles into the environment (153). These virulent phage particles are then able to 
infect other bacteria host and initiate new phage lytic cycles.  
 
1.6.3.2. Lysogenic infection   
Phages displaying a lysogenic infection integrate their genome into the chromosome of 
the host bacteria (prophage). As a result, the phage genome becomes dormant in a 
latent state, named lysogeny, and the genome is transmitted to each daughter cell 
always when a cell division occurs. A phage presenting this sort of growth is referred to 
as a temperate phage and cells carrying a prophage are called lysogenic. 
Nevertheless, the viral prophage can become activated (induction) and enter in a lytic 
growth by certain stimuli that impose a stress to the bacteria, such as DNA damage. 
Often, the prophage is excised incorrectly from the chromosome taking with it 
neighbouring bacterial genes. This situation is an important source of horizontal gene 
transfer (HGT) between bacteria, driving their evolution, and this has been widely 
exploited as a central technique in molecular biology. For therapeutic purposes, 
temperate phages are not desirable, not only because bacterial killing is not efficient 
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enough but there’s an increased chance of HGT. This may lead to specific transfer of 
virulence factors (154). 
A third life cycle is known, a chronic infection, where phages infect their host, replicate 
and are released into the environment without killing or disturbing the bacterial cell, 
which keeps growing and dividing. The phage M13 that infects E. coli is an example of 
such chronic infection. 
 
1.6.4. Bacteriophage therapy 
For a therapeutic approach, phages should be able to reduce bacterial numbers until 
eradication or to a point where the immune system is able to clear out the remaining 
infection-causing bacteria (155) and at the same time do not pose any health issue for 
the patient. Hence, there are some features that the selected phages as well as the 
phage preparation per se have to attain: 
- Phages with obligate and effective lytic cycles that result in a rapid killing of the 
target host.  
- The interaction of phage and bacteria should be understood, for instance, 
identification of the phage receptor(s). 
- The phage preparation must meet all safety and regulatory requirements, 
equivalent to other medicines.   
- The efficacy of the phage preparation should be tested in animal models, 
because efficacy in vitro is not always translated in vivo. 
- The phage preparations should actually contain viable virus, therefore stability 
evaluations should be taken to identify preferably conditions for a longer shelf-
life of the phages – storage conditions between individual phages exhibit great 
variability (156).  
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1.6.4.1. Bacteriophage therapy: advantages 
Unlike antibiotics, phages are easily isolated from nature, often from human or 
environmental sources e.g. sewage samples, and have a relatively low cost of 
development (156). Most phages present a narrow host-range (infecting only a single 
strain and to some extent other strains within a bacterial species) as mentioned above. 
This specificity leads to a minimal risk of normal body flora disruption (148) when 
compared to antibiotics even those with a narrow-spectrum. Phages are natural 
constituents of the environment, being mainly composed of nucleic acids and proteins, 
and humans are constantly exposed to them, therefore they are not considered toxic or 
dangerous for human health (157–159). Phage treatment would only require few and 
low doses to be given to the patient, because of its self-replicating property – as long 
as the target cells are present the lytic cycle takes place. Observation of such a 
phenomenon might be limited to a certain degree in cases where bacterial densities 
are relatively high (160). Phage infection has a completely different mode of action to 
antibiotics and therefore antibiotic resistant bacteria present no special challenge to 
therapy (161, 162). Phages are versatile particles that can be used in liquids, 
impregnated into hydrogels or solids and are suitable for use by most delivery routes, 
such as oral and parenteral, but also local and by inhalation (for review 157). An 
additional phage advantage, showing so far promising results (164), is their ability to 
disrupt and eradicate bacterial biofilms; discussed later in this review. 
 
1.6.4.2. Bacteriophage therapy: concerns 
Some concerns have been expressed concerning phage therapy, however these may 
have been overstated. No therapeutic method is free of concerns regarding patient’s 
safety but with certain safeguards phage therapy can be as safe, if not safer, than 
alternative anti-infectives. 
Chapter One – Literature Review 
33 
 
Bacterial resistance to phages - for instance, mutation/loss of the phage receptor or 
acquisition of restriction-modification systems - is one cause for concern. Phages used 
in therapeutics are lytic and able to rapidly kill their biological target; this event besides 
the clearance of the pathogenic cell diminishes the chances for bacteria to evolve 
towards phage resistance. However, resistance emergence is still an issue and can be 
overcome, to some extent, by using combinations of phages (cocktails) displaying 
unrelated modes of infection (165). It is of note that antibiotics are chemical products 
not able to evolve, therefore when bacteria become resistant discovery of a new drug is 
required – this is costly from a patient point of view but also commercially expensive. 
On the other hand, phages are able to evolve and adapt in the same way their hosts 
are, and so, simply the isolation of new effective virus is required, which is considerably 
easier and cheaper. 
Owing to the narrow-spectrum of phage infection the bacterial target has to be 
identified prior to phage isolation. This could result in a treatment delay which when 
dealing with infectious diseases can seriously compromise the patient’s situation. One 
can outpace this by resorting, as mentioned, to broad-host spectrum phages, for 
instance, phage K is a polyvalent Staphylococcal phage (166) and/or a phage cocktail 
that together result in a broader range of activity. 
DNA sequencing of phage genomes is a required step prior to their use in therapy in 
order to guarantee that the phages administered are not lysogenic (not carrying any 
functional lysogenic components) and do not harbor any virulence factor or toxin gene 
harmful for humans. Occurrence of virulence or toxins in phage particles  is extensively 
described in the literature (167), as a result DNA sequencing is an imperative step. 
Transduction is a common event linked to lysogenic phages and an undesirable trait 
regarding therapy. To counter such a possibility a PCR-based screen for transducing 
genes could be employed (168) or, again, DNA sequencing. 
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Although it is accepted that phages are not dangerous as human therapeutics, several 
studies show that they interact with antibodies, triggering strong immunogenic 
responses (169). Nonetheless, other drugs and treatments in use are as immunogenic 
and regulatory hurdles can be overcome by demonstrating safety in clinical trials. On 
the other hand, such interaction may result in an undesirable quick clearance of the 
virus particles before they achieve their purpose.  
Phage preparations may contain bacterial debris containing endotoxins, compounds 
derived from the lysate preparation itself that if given to humans, might cause 
inflammatory responses. Hence, highly purified lysates should be produced, for 
instance, by ultracentrifugation/advanced filtration methods, for example monolith 
columns. 
 
1.6.4.3. Bacteriophages - future applications 
Bacterial resistance to antibiotics, such as is the case with MRSA, is an overwhelming 
situation seen every day and almost everywhere (170). Selection and spread of 
antibiotic resistance is a result, in part, of their uncontrolled and unjustifiable use for 
decades, among clinicians and also in agriculture and animal farming. Development of 
a drug is a slow process and in recent decades fewer and fewer antibiotics have come 
to light. Therefore, bacteriophages and the natural attributes that they possess have 
been seen as a reasonable alternative to antibiotics. 
Treatment of bacterial diseases using phages is not restricted to humans, it is also an 
alternative for animals (171) and plants (172) and several studies have been carried 
out, showing different levels of efficacy. In addition, phages are currently in use in 
environmental decontamination and in food processing (173). 
From a commercial point of view, phages have not been an attractive choice for big 
pharmaceutical companies. It is difficult to obtain clear intellectual property (IP) rights, 
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due to phages having been used in therapy during the past hundred years. Without 
adequate patent protection, there is a certain apprehension regarding the profitability of 
phage therapy, making funding expensive clinical trials hard to justify and achieve.   
Other promising therapeutic approaches have also been studied, involving the use of 
lytic bacteriophage endolysins, as discussed previously (174), or genetically modified 
phages, that do not lyse the bacteria, but derail it by delivering DNA encoding 
antibacterials (175).  
Recently it has been found that certain phages seem to show an antimetastatic activity 
and tumour inhibition (176, 177). It was shown (178) that this might be involved with the 
presence of a KGD (Lys-Gly-Asp) amino-acid motif present in a protein of the phage 
capsid. This motif in the phage is a homologue of the RGD motif, which blocks the 
activity of beta-3 integrin in cancer cells, involved in cancer cell motility and adhesion, 
promoting metastasis. Strikingly, this integrin is produced at higher levels in cancer 
cells and perhaps phages displaying these motifs can play an important role in the 
cancer therapeutics field. 
Antibiotics and phages could be used together in therapy to enhance treatment 
efficiency and minimise the evolution of antibiotic and phage resistance. Bacteriophage 
therapy should not be seen as the only answer to (antibiotic resistant) bacterial 
infections, but as an additional one, complementing and working together with the 
many therapeutic alternatives that the scientific community is currently researching. 
 
1.7. Bacterial biofilms 
In nature, it is possible to find biofilm structures originated from fungi to protozoa and 
algae. Nonetheless, bacterial biofilms are the most widely described in the literature 
and may represent the most common form of bacterial life in nature (179). A bacterial 
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biofilm, first characterised almost 70 years ago (180), is described as an aggregation of 
bacterial multispecies embedded in a self-secreted extracellular polysaccharide matrix 
associated to a biotic or abiotic surface (181). Biofilms occur in most natural and 
artificial environments and play an important role in the pathogenesis of burn wound 
infections (182). A biofilm is a distinct way of living compared to the planktonic state, 
which provides several advantages to its ‘residents’. 
 
1.7.1. Biofilm formation 
In a general way, formation of a biofilm occurs by a sequence of stages (Figure 1.12): 
bacterial attachment, formation of microcolonies, biofilm maturation and detachment.  
Firstly, planktonic cells adsorb to a surface, a transient event, where cell-surface and 
cell-cell interactions (e.g. through surface proteins) occur. For P. aeruginosa cells 
several factors are required for this initial binding to a surface, such as the flagella 
(183), the type IV pili (184), extracellular DNA (eDNA) (185) and the Psi polysaccharide 
(186). Irreversible association of the bacterial cells to the surface occurs by production 
of extracellular polymeric substance (EPS). Production of such a substance is a result 
of a metabolic shift from a planktonic to a biofilm state (181). Subsequently, there is a 
proliferation of the cells that is dependent upon nutrient availability (179) to constitute a 
three-dimensional mature biofilm. The biofilm structure, with their heterogeneous 
communities and presence of channels where water and nutrients circulate (187), is 
preserved and protected by the EPS matrix surrounding the microbial populations. 
Such heterogeneous communities are composed of cells experiencing different levels 
of growth states (active growth, stationary and quiescent) (179), where events of 
quorum-sensing (cell-cell communication) commonly take place playing important roles 
in the biofilm formation per se (188). Occasionally, sessile bacteria will detach from the 
biofilm matrix, for example as a consequence of disruption of cell-cell interactions for 
the production of the water and nutrient channels along the biofilm. This will not only 
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enable the biofilm to thicken and expand its structure, but also detached cells will be 
able to colonise other surfaces. Biofilm detachment plays an important role in infection 
expansion by spreading the cells to new infection sites (189). The mother-biofilm, 
despite all the disassembled “pieces” can  return very quickly to its previous maturation 
state in no more than 24 hours (190).  
 
Figure 1.12: Representation of the biofilm formation stages. Free cells (I) adsorb to a surface to 
form microcolonies (II) that start producing an EPS matrix for protection and maturation of the 
biofilm (III,IV). Proliferation and maturation of the biofilm results in a three-dimensional 
mushroom structure (V) and occasionally sessile cells are going to detach from the structure to 
initiate other biofilms (VI). 
 
In S. aureus the process of biofilm maturation and detachment is essentially controlled 
by a quorum sensing system encoded by the accessory gene regulator (agr) locus 
(Figure 1.13B). During growth an autoinducing peptide (AIP) is secreted by bacterial 
cells that upon accumulation (which happens if cells are growing on a biofilm) is 
recognised by a receptor on the cell surface and triggers a regulatory cascade ending 
with the control of toxin and adhesion factors production. In summary, the Agr system 
is composed by two operons with P2 and P3 promotors regulating them. The P2 
operon, which contains agrBDCA genes, codes for an RNAII transcript where most of 
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the components are translated from, including the AIP molecule. On the other hand P3 
operator codes for a RNAIII, which is responsible for the upregulation of some toxin 
factors, for instance δ-hemolysin, and downregulates the translation of adhesion 
factors, such as Protein A and fibronectin-binding protein. All the system gets 
upregulated when the secreted AIP is detected by the two-component system AgrA-
AgrC on the cell membrane and both P2 and P3 operons are transcribed. Hence in a 
general way, biofilm colonisation is controlled by switching off the Agr system, whereas 
biofilm maturation and dispersal is performed when the Agr system is switched on and 
assisted by surfactant-like phenol-soluble modulins (PSMs) that degrade biofilm 




Figure 1.13: Quorum sensing pathways in (A) P. aeruginosa, reprinted from reference (193) 
and used with permission, and (B) S. aureus (courtesy of Dr Toby Jenkins). 
B 
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P. aeruginosa biofilm formation is largely controlled by quorum sensing systems; 
however it is more complex and intricate than the one observed for S. aureus (Figure 
1.13A). In a general way for biofilm formation two main quorum-sensing systems 
arranged into two distinct operons are present - Las and RhI. Both respond to a 
specific type of acylhomoserine lactone (AHL), a 3-oxo-C12-HSL (3OC12) and a N-
butyryl-L-homoserine lactone (C4-HSL), respectively. The autoinducer molecule 
3OC12 produced by LasI is recognised by LasR in the cell membrane. Such 
recognition will trigger the transcription of several genes, including rhIR gene coding for 
a second receptor protein. RhIR will recognise the second autoinducer - C4-HSL, 
produced by RhlI and several pathways are activated, including some genes belonging 
to the Las system. A third quorum sensing system based on quinolone signals (PQS) is 
also present in P. aeruginosa and all together play important roles in biofilm 
development and maturation (193–195). However factors such as medium composition 
and flow conditions also play a major role in biofilm development (196). Biofilm 
dispersal is also controlled by these systems, for instance the Rhl system controls the 
production of rhamonolipids (197), a surfactant molecule which other than acting as 
virulence factors also play important roles in disruption of cell-cell interactions (198), for 
maintenance of water channels, biofilm maturation and finally biofilm dispersion (199). 
The matrix surrounding S. aureus bacterial cells is composed of several secreted 
polymers, including exopolysaccharide, teichoic acid, proteins and DNA from cells that 
eventually die (189). P. aeruginosa biofilm matrix is composed of at least three 
polysaccharides: alginate, Pel and Psl (200). They are an important factor for the 
stability of the biofilm and their concentration within the biofilm depends on the type of 
strain. For example, mucoid strains are great producers of alginate in comparison to 
non-mucoid strains (201). Generally, production of Pel and PsI play a key role in initial 
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colonisation and formation of biofilm, whereas alginate is crucial for the stability of the 
biofilm at later stages of its formation (201, 202).  
 
1.7.2. Biofilm community advantages  
Bacterial diseases, particularly those caused by S. aureus, are strictly linked to 
production of biofilm, being one of the first steps in infection initiation (203, 204). Once 
in a biofilm, bacterial cells are protected against antibiotics and the host immune 
system.  
The EPS matrix blocks antibody penetration into biofilm matrix (205) and phagocytes 
are unable to interact with bacterial cells (206). 
Bacterial tolerance to antibiotics within a biofilm is greatly enhanced compared to 
planktonic cells (207). In a biofilm, horizontal gene transfer is common due to increased 
cell-cell interactions; as a result resistance determinants are more easily spread (208). 
Moreover, resistance has been attributed to a lower ability of antimicrobial drugs to 
penetrate the EPS matrix, causing exposure of cells to sub-lethal antibiotic 
concentrations promoting resistance emergence. There is also a decrease in metabolic 
activity of the biofilm inner cells, due to reduced oxygen and nutrient concentrations 
(207), that makes antibiotics that are effective against dividing bacteria ineffective. The 
lower metabolic activity of some cells can also be related to the presence of ‘persister’ 
cells. Although not resistant to antimicrobials (209) they display tolerance to them and 
do not die. This ability of multidrug tolerance (MDT), while the causes are yet not very 
clear, is possibly due to a state where bacteria are deeply dormant. Antibiotics, in 
general effective against actively growing bacteria, reach their target in the cell and 
prevent its normal task, leading to a failure of the cell system (death). On the other 
hand, persister cells are not metabolizing, so even if the drug molecule reaches its 
target no function will be blocked because no function is taking place (210). Therefore, 
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persister cells are not eliminated and represent a possible source of repopulation of the 
biofilm, making the antibiotic therapy useless (211). In addition, bacteria in a biofilm are 
protected against other environmental stresses, such as UV light and acid exposure 
(212, 213), metal toxicity (214), dehydration and salinity (215). 
Biofilm association therefore allows bacteria to colonise with fewer restrictions, persist 
and continue to establish infections and spread between hosts (32). 
 
1.7.3. Interaction of phages and biofilms 
Phages are natural constituents of biofilms, playing major roles in their architecture and 
also in their dispersal. Studies assessing phage efficacy on biofilm eradication are still 
at an early stage, but there are promising observations of the clear potential of phage 
therapy (216). However and according to a recent review (217) phages are no doubt a 
strategic device for biofilm removal: 1) their amplification allow them to get access to 
the deeper cells in the biofilm; 2) phages can carry or express depolymerising enzymes 
degrading the complex EPS matrix present in biofilm, an advantage regarding 
application of antimicrobial drugs; 3) if not coding for a depolymerase enzyme phages 
can induce their production from within the host genome; 4) persister cells can still be 
infected by phages, although no proliferation will occur once these cells are ‘awakened’ 
phage replication will take place and burst the cell. 
Polysaccharide depolymerases degrade the EPS matrix that surrounds the bacteria 
‘opening the way’ so that phages can interact with the bacterial receptors and the lytic 
cycle takes place; actually in a biofilm bacterial cells are static and in close proximity 
when compared to the planktonic state (e.g. liquid culture). Therefore, the interaction 
between phage and bacteria taking place is more stable and once phages are released 
from the infected host new lytic cycles can take place more quickly. Hence, phages are 
able to access to the deeper layers of the biofilm gradually. Illustrating this are Lu and 
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Collins (218) that engineered a bacterial depolymerase - dispersin B (DspB) – being 
expressed by a phage able to propagate on the cells (Figure 1.14). They observed a 
great disruption of E. coli biofilm over 24 hours. In the absence of depolymerase, 
phage access to the biofilm inner layers can also occur, probably slower, through the 
water-filled channels inherent to the biofilm architecture (219) or perhaps they are able 
to induce a depolymerase once inside the host. Kelly and colleagues (220) observed 
that S. aureus biofilms treated with phage K - a non-depolymerase producer (221) - 
showed a significant decrease in biofilm formation after 72 hours. In this experiment, 
the potential of phages to prevent biofilm formation was also observed.  The same can 
be seen in experiments where only depolymerase molecules were used. In addition, 
the success of a phage to infect a biofilm is dependent on environmental factors, such 
as temperature, growth stage, media and phage concentration (222). 
Biofilm-associated S. aureus infections are a major and concerning cause of morbidity 
and mortality. As a result the use of lytic phages, preferably accompanied by 
depolymerase activity, acts as an efficient and rapid treatment/prevention of such 
diseases that should be deeply understood both in vitro and in vivo. 
 
 
Figure 1.14: Engineered DpsB-expressing T7 infects an E. coli biofilm resulting in rapid 
multiplication of phage and expression of the DpsB enzyme. Reprinted from reference (218) 
and used with permission from PNAS. 
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1.8. Concluding remarks and project aims 
The infectious diseases caused by S. aureus or P. aeruginosa and described in 
this chapter can be considered as major causes of public health concern, not 
only in their infectious effect but their ability to acquire resistance to causing 
increased mortality, morbidity and higher hospital costs. Hence, bacteriophages 
can be used as an alternate/adjunctive treatment for such bacterial pathogens.  
The aim of this project was the development of two efficacious therapeutic 
bacteriophage cocktails targeting both S. aureus and P. aeruginosa. The work 
is divided into three main sections, where: 
- Isolation from environmental samples and characterisation of 
bacteriophages was performed in order to establish cocktails potentially 
safe to be used. 
- Assessment of the phage lytic activity and bacterial eradication on in vitro 
models, including on bacterial planktonic growth and in both static and 
dynamic biofilm models produced by clinical isolates. 
- Assessment of the treatment efficacy of the phages cocktails on an in vivo 
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2.1. Preparation of bacterial cultures 
2.1.1. Principles of bacterial growth 
Bacterial cells reproduce by binary fission increasing their cell numbers in an 
environment. Bacterial growth is affected by several factors, including temperature, pH, 
salinity and oxygen. If those factors are optimal the bacterial growth is going to take a 
sequence of four stages (Figure 2.1). When setting up a culture there is an initial lag 
phase (A) where cells are preparing for reproduction (DNA replication and enzymes 
production, for instance), following that the cells start the division process and increase 
their numbers exponentially (B). During this phase each bacterium grows at a specific 
rate, that being dependent on external growth conditions as well as being intrinsic to 
each bacterial type. After this exponential phase the culture goes into a stationary 
phase (C) where growth rate equals death rate. Cells show a lower metabolic rate and 
more resistance to external stresses. Eventually, the cell numbers show a decline (D) 
as they are unable to grow further in a depleted environment. 
 
 
Figure 2.1: Growth curve of a bacterial culture. A – lag phase, B – log/exponential growth 
phase, C – stationary phase, D – death phase. 
 




2.1.1.1. Estimation of bacterial cell numbers 
Bacterial cell numbers in a culture can be estimated by several methods. The most 
common and direct is the standard plate count where serial dilutions of the original 
culture are performed and plated onto a nutrient agar plate. Each cell present will 
reproduce and form a visible colony that can be recorded and used to estimate the 
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Where d stands for dilution factor and V for volume of inoculum. Another commonly 
used but indirect method is optical measurement. When bacterial cells are reproducing 
the turbidity of the culture increases resulting in more light scattered, that is recorded 
as an increase in optical density. 
 
2.1.2. Bacterial strains  
S. aureus strains (listed in Chapter III, Table 3.2) used in this study were from 
Professor Mark C. Enright’s collection of >5,000 clinical isolates. They were selected to 
be genetically diverse (by multilocus sequence typing [MLST], see section 2.7) and 
also to contain members of the major MRSA and methicillin susceptible S. aureus 
(MSSA) clones present worldwide.  
Examples of eight coagulase-negative staphylococci (listed in Chapter III, Table 3.3), 
S. xylosus, S. sciuri subsp. sciuri, S. chromogenes, S. hyicus, S. arlettae, S. vitulinus, 
S. simulans, and S. epidermidis, were also included in this study.  




P. aeruginosa strains (listed in Chapter III, Table 3.1), including the common laboratory 
reference strain PAO1 and a diverse collection of clinical isolates from both chronic and 
acute conditions. 
 
2.1.3. Growth conditions 
Staphylococcus bacterial single colonies from tryptic soy agar (TSA) plates were grown 
at 37 °C with constant shaking (170 rpm) in tryptic soy broth (TSB). For Pseudomonas 
aeruginosa bacterial single colonies from Luria-Bertani agar (LA) plates were grown at 
37 °C with constant shaking (170 rpm) in Luria-Bertani broth (LB). Aliquots of bacteria 
were stored at -80 °C in the respective broth containing 15 % (v/v) glycerol. 
 
2.2. Bacteriophage methods 
2.2.1. Growth conditions 
TSA and TSB-soft agar containing 0.65 % bacteriological agar were used for 
bacteriophage propagation and plaque count assays of bacteriophages targeting 
Staphylococcal strains. In the case of bacteriophages targeting Pseudomonas 
aeruginosa strains TSB media was replaced by LB. Note that media was supplemented 
with 1 mM CaCl2 and 1 mM MgSO4 to improve phage adsorption (223). 
 
2.2.2. Bacteriophage isolation  
Bacteriophages for S. aureus were isolated from crude sewage (Thames Water PLC, 
Luton, United Kingdom) and for P. aeruginosa from flood water (Bath, UK) and crude 
sewage (Wessex Water, Somerset, UK).  




Bacterial enrichments with bacterial isolates were performed to increase phage 
numbers as follows: 5 ml of actively growing bacterial cells (from overnight liquid 
culture in TSB or LB) and TSB or LB supplemented with 1 mM MgSO4 and 1 mM 
CaCl2. The enrichment was incubated overnight at 37°C. A 10 ml aliquot was taken 
from the overnight culture, and 1 M NaCl and 2 % chloroform were added. The culture 
was then centrifuged (30 min, 3,000 x g) to remove bacteria, and the supernatant was 
filter-sterilised (0.22 μm, pore size). This lysate (supernatant) was used to check the 
presence of lytic phages using the double layer method described below in section 
2.2.4.1.  
 
2.2.3. Single plaque purification 
From each plate, isolated single plaques were picked using a pipette tip, a method 
called single plaque purification. Different plaque phenotypes, if present, from each 
plate were picked. Each plaque was re-suspended in 300 μl of SM buffer (5 M NaCl, 1 
M MgSO4, 1 M Tris–HCl [pH 7.5], gelatine solution distilled water). Dilutions were then 
prepared and plating performed to allow the purification and isolation of a single phage. 
Consecutive rounds of plaque purification were carried out, by repeated subculture on 
the respective host strain. The plaque purification process was repeated a minimum of 
three times for each plaque or until a purified plate of uniform plaques was obtained, 
reflected by single plaque morphology. Purified phages were stored in 50 % glycerol 
(v/v) in TSB at -80 ºC for long term use. Short term stock preparations were maintained 
at 4 °C. 
 




2.2.4. Bacteriophage propagation 
2.2.4.1.  Double layer method 
Phage lysates were propagated on their respective bacterial hosts (Figure 2.2) as 
described elsewhere (224). Briefly, 100 μl of phage lysate and 100 μl of host growing 
culture were mixed and left for 5 min at room temperature. Afterwards, 3 ml of soft agar 
was added and poured onto agar plates. The following day, after an overnight 
incubation at 37 °C, plates displaying confluent lysis were selected and 3 ml of SM 
buffer and 2 % (v/v) chloroform were added before incubation at 37 °C for 4 h. High-
titre phage solution was removed from the plates, centrifuged (8,000 x g, 10 min) to 
remove cell debris, and then filter-sterilised (pore size, 0.22 μm) and stored at 4°C.  
 
Figure 2.2: Representation of the double-layer method. 
 
2.2.4.2.  Liquid lysate method 
For the liquid lysate method, 1 ml of an overnight bacterial culture was added to 100 ml 
of TSB. After incubation at 37 °C with shaking for 1 hour, phage lysate was added at a 




multiplicity of infection (MOI) of approximately 0.1 and incubated for a further 5 hours. 
Following lysis the culture was centrifuged (4000 x g, 30 min) to remove bacterial 
debris, filter-sterilised (0.22 μm pore size) and stored at 4 °C. 
 
2.2.5. Bacteriophage Titration 
Bacteriophage titre was determined by the spot test (Figure 2.3). 3 ml of soft-agar was 
added to 100 l of host growing culture and poured onto agar plates. Plates were left to 
dry for 20 min at 37 °C. Afterwards, 10-fold serial dilutions of the phage lysate were 
performed in SM buffer (5 M NaCl, 1 M MgSO4, 1 M Tris–HCl [pH 7.5], 0.01 % w/v 
gelatine) and 10 l of each dilution was spotted onto the bacterial lawn. This was 
performed twice. The plates were allowed to dry before incubating overnight. On the 
following day plaques were counted to determine phage titre, expressed as plaque 
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where d stands for dilution factor and V for volume of inoculum. 
 
 





Figure 2.3: Representation of the spot test method for bacteriophage titration. 
 
2.2.6. Sensitivity assays 
2.2.6.1. Agar plates 
To determine phage sensitivity of bacterial isolates, spot tests were performed. Briefly, 
3 ml of TSB-soft agar was added to 100 μl of host growing culture and poured onto 
TSA. Plates were left to dry for 20 min at 37 °C. The different phage lysates were 
standardised to a titre of 109 pfu/ml, and 10 μl of each lysate was spotted onto the 
bacterial lawns. This assay was performed in triplicate. The plates were allowed to dry 
before incubation overnight at 37 °C. The following day, the sensitivity profiles of each 
of the bacterial strains were determined: if the bacterial lawn was lysed, slightly 
disrupted, or not disrupted, the bacterial isolate was described sensitive, intermediate, 
or resistant to the phage infection, respectively. To simplify the analysis of the recorded 
sensitivity results it was attributed a colour code, where green, yellow and red 

























Bacterial lawn Phage lysate 
dilutions 





Figure 2.4: Representation of the spot test method for bacterial sensitivity screening. 
 
2.2.6.2. Broth cultures 
Alternatively, sensitivity screening was performed by monitoring optical density in broth 
cultures in 96-well microtitre plates. In the microplate wells a 1:100 dilution was 
prepared by adding 5 μl of an overnight culture to 195 μl of TSB. After 2 hours of 
incubation at 37 °C, the phage lysates at a desired MOI were added and the 
microplates were incubated for a further 24 hours. The incubation was followed on a 
plate reader (FLUOstar Omega, BMG LabTech, UK) where a growth curve is 
established at an optical density at 600 nm (OD600). This approach allows observation 
of the phage-bacteria interaction over time and also allows for monitoring of the 
appearance of resistant mutants for each phage lysate. 
 




2.2.7. Bacteriophage phage growth parameters  
2.2.7.1. Theoretical Background 
Bacteriophage propagation takes several distinct steps described by the one-step-
growth curve and those can be measured (Figure 2.5). First, bacteriophage particles 
are required to adsorb to their host cell (A). Bacteriophages do not have specific 
structures or appendices for motility, consequently this adsorption step results from 
random phage-cell collision. Following that there is an eclipse stage (E) where 
replication of the viral particles takes place only and no infectious virus are completed 
yet. Mature viral particles start to accumulate inside the host cell and everything is 
ready to initiate the cell burst and release the phage progeny into the environment, 
named the latent period (L). After the cell burst there is an exponential release of 
phages and estimation of the number of phages released by a single host can be 
accomplished (B). 
 
Figure 2.5: Bacteriophage growth parameters. A – adsorption, E – eclipse  period, L – latent 
period and B – burst-size. 
 




2.2.7.2.  Bacteriophage adsorption 
The experiment was carried out at 37 °C under constant shaking (60 rpm) and a phage 
inoculum with a multiplicity of infection (MOI) of 0.01. The number of free phages was 
calculated from the pfu of chloroform-treated samples within 5 min after inoculation. 
The adsorption rate assumes first-order kinetics and was calculated in terms of the 
percentage of free phage loss by fitting the phage decay curve (normalised as a 
percentage) to the rate equation: 
 
ln (% phage)t  = ln (% phage)o – k’t        (2.3) 
 
Where k’ is the pseudo-first order rate constant for free phage loss:  
 
k’ = k[bacteria]         (2.4) 
 
From this, the percent phage remaining at any time t can be easily calculated. 
 
2.2.7.3. One-step growth curve 
Bacteriophage growth cycle parameters - the latent period (L), eclipse period (E), and 
burst size (B) - were determined from the dynamic change in the number of free and 
total phages. Hence, one-step growth curves were measured as described by Pajunen 
et al. (225) with some modifications: 10 ml of a mid-exponential-phase culture was 
harvested by centrifugation (7,000 x g, 10 min, 4 °C) and resuspended in 5 ml of broth 
to obtain an optical density at 600 nm (OD600) of 1.0. To this suspension, 5 μl of phage 
solution was added to obtain a multiplicity of infection (MOI) of 0.001. Phages were 




allowed to adsorb for 5 min at room temperature. The mixture was than centrifuged as 
described above, and the pellet was resuspended in 10 ml of fresh TSB medium. Two 
samples were taken every 5 min over a period of 1 h at 37 °C under constant shaking. 
The first samples were plated immediately without any treatment, and the second set of 
samples was plated after treatment with 1 % (v/v) chloroform to release intracellular 
phages. 
 
2.3. Measurement of phage zeta potential and size 
2.3.1. Theoretical background dynamic light scattering  
Dynamic light scattering (DLS) is one of the most commonly used methods to measure 
the size of particles. A monochromatic laser light irradiates onto a suspension and 
fluctuations in the intensity of the scattered light can be measured as a function of time. 
Fluctuations over time happen as particles are undergoing Brownian motion (defined 
as the random motion of particles in a suspension). Hence, smaller particles will move 
more than larger particles causing the intensity of the scattered light to become higher. 
The recorded intensity data goes through an autocorrelator and the size distribution of 
particles in the sample can be determined. 
 
2.3.2. Theoretical background of electrophoretic mobility 
The zeta-potential of suspended particles describes the difference of potential between 
the bulk of the conducting medium where they are dispersed and the stationary layer of 
fluid surrounding the particles. The zeta-potential is associated with the electrophoretic 
mobility of the particles. When phages are exposed to an external electrical field they 
will migrate towards an electrode of the opposite charge at a certain velocity. The 




velocity is the particle electrophoretic mobility. Using appropriate equipment the 
magnitude of the particle electrophoretic motility is measured and zeta-potential is 
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Where uE is the electrophoretic mobility (μm cm V
-1s-1), ε is the dielectric constant, z is 
the Zeta potential (mV), f(ka) is the Henry’s function, and η is the viscosity (cP).  
 
2.3.3. Methodology 
The particle size and electrophoretic mobility of phages were measured by dynamic 
light scattering (DLS) using a Zetasizer Z/S system (Malvern, United Kingdom) at 37 
°C. Cuvettes, called capillary cells (Figure 2.6), are provided with two electrodes and 
hold approximately 1 ml of sample. Cuvettes were filled with the sample and were 
carefully inspected to avoid air bubbles. Phage lysates were diluted in distilled water 
(dH2O) to a final concentration of 10
5 pfu/ml.  For dilutions dH2O was required as the 
presence of ions in the dispersing medium disturbs the quality and outcome of results. 
Measurements were repeated at least three times. 
 
 







Figure 2.6: Image of Zetasizer Z/S system (A) and of a disposable capillary cell DTS1070 (B) 
and the schematic representation of particles moving in the capillary cell (C). 
 
2.4. Bacteriophage DNA extraction 
Bacteriophage DNA was isolated using a DNA extraction kit according to the 
manufacturer’s instructions when titres of phages lysates were high (1010 pfu/ml) or 
performing a PEG-precipitation for rapid concentration of the phage particles followed 
by a phenol-chloroform extraction for lower phage lysate titres followed by a (see 
below). 
 
2.4.1. Bacteriophage Concentration and Purification 
Prior to DNA extraction bacteriophage lysates were concentrated using centrifugal 
concentrators until the desirable volume. When necessary, further concentration and 









Bacteriophage lysates purification was performed by adding 1 M NaCl and left at 4 °C 
overnight. The following day the solution was centrifuged (4000 x g, 1 hour) and the 
supernatant was carefully transferred to a new tube. 10 % (w/v) polyethylene glycol 
(PEG) m.w.8000 was added to the lysate and left at 4 °C overnight. On the next day, 
the solution was centrifuged (4000 x g, 30 min) to obtain a PEG-phage pellet. The 
pellet was resuspended gently in 1 ml of SM buffer and vortexed thoroughly.  
 
2.4.2. Cesium chloride gradient  
A CsCl gradient composed of three different solutions densities – 1.35, 1.50 and 1.7 
g/ml - was prepared in a 36.5 ml ultracentrifuge tube (Beckman Coulter, Seton 
Scientific, UK). For the preparation of CsCl solution at a given density,  (g/ml), we 
used the following formula to calculate the final CsCl concentration, c (g/ml) (226):  
 
c = 0.04782 + 1.23 – 1.27        (2.6) 
 
Subsequently, a layer of the phage lysate was added (2-5 ml) and finally mineral oil 
was used to fill up the unused space of the tube (Figure 2.7). This process was 
performed very gently in order to avoid disturbance and mixture of the different layers. 
After ultracentrifugation at 25,000 rpm for 3 hours at 4 °C the phage band was 
collected. To collect the phage band, a whitish band observed when the tube contents 
were UV illuminated, a sterile needle-syringe was used. Following collection of the 
phage suspension, dialysis was performed in order to remove the CsCl. Briefly, phage 
suspension was introduced into dialysis cassettes, which in turn were introduced in 500 
volumes of dialysis buffer (10 mM sodium phosphate, pH 7) for 30 min. After 
B 




performing the process three times the concentrated and purified phage suspension 
was collected. 
 
Figure 2.7: A - Schematic diagram for the set-up of CsCl density-gradient ultracentrifugation 
tubes, B – Image of the ultracentrifuge and JA-25.50 rotor (Beckman Coulter, USA). 
 
2.4.3. Phenol-chloroform DNA extraction 
Phenol/chloroform extraction was performed according to Pickard (227). 1.8 ml aliquots 
of phage lysate were treated with 18 μl of DNase I (1 mg/ml) and 8 μl of RNase A (10 
mg/ml). The mixture was incubated at 37 °C for 60 min. Subsequently, 18 μl of 
proteinase K (10 mg/ml), 46 μl of 20 % sodium dodecyl sulphate (SDS) and 1 mM 
EDTA Na2 were added to the samples and incubated at 65 °C for a further 60 min. 
Samples were aliquoted into 1.5 ml phase-lock gel eppendorf tubes and an equal 
volume of phenol:chloroform:isoamyl alcohol (25:24:1) was added to remove 
proteinaceous material. Extraction was repeated twice and between each step, the 
upper, aqueous phase layer was transferred into a new phage-lock gel tube and 
centrifuged (5 min, 8,000 x g). The aqueous top phase was retained and a final 
extraction with chloroform:isoamyl alcohol (24:1) was carried out by centrifugation (5 
min, 6,000 x g). The supernatant was transferred to a new sterile 1.5 ml eppendorf tube 
 
 = 1.7 g/ml, 8 ml 
Phage lysate, 2 - 5 ml 
Mineral oil, 2 ml 
 = 1.35 g/ml, 8 
ml 
 = 1.5 g/ml, 8 ml 
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and DNA was precipitated by adding 45 μl of 3M sodium acetate and 500μl of 100 % 
isopropanol. The mixture was incubated at -20 °C overnight. The following day the 
samples were centrifuged (20 min, 8,000 x g) and supernatant was removed. The DNA 
pellet was washed with 1 ml of 70 % ethanol (v/v) and incubated at room temperature 
for 20 min. Centrifugation was performed for 20 min at 8,000 x g and the supernatant 
was removed. Pellets were rinsed with 70 % ethanol twice. Phage DNA was re-
suspended in 200 μl of TE buffer (Tris-EDTA buffer solution, pH 8.0) and incubated at 
65 °C for 10 min. After incubation the DNA was rehydrated at 4 °C overnight. Nucleic 
acid concentration and quality was measured with a NanoDrop spectrophotometer 
(Thermo Scientific, UK). 
 
2.5. Agarose Gel Electrophoresis  
Agarose gel electrophoresis was performed for uncut and digested DNA. A 1 % 
agarose gel was prepared using 1x TAE buffer. 2 % of ethidium bromide dye (10 
mg/ml) was mixed with the agarose prior to pouring into the gel mould. The molecular 
weight DNA marker was prepared by mixing 1 μl of 6 x loading dye, 1 μl marker DNA 
and 4 μl of sterile deionised water. DNA samples were prepared by mixing 2 μl of 6X 
loading dye with 10 μl of DNA. The gel was run at 100 volts. The bands were visualised 
under UV light and a gel image was taken.  
 
2.6. Restriction Fragment Length Polymorphism (RFLP) 
Bacteriophage DNA was digested using the restriction enzymes XbaI, XhoI and EcoRI 
(FastEnzyme, Fermentas, UK). Digestion was carried out according to manufacturers’ 
instructions. Bacteriophage K (GeneBank - AY176327) was used as a positive control 




for the digestions performed. In order to find suitable restriction enzymes we used the 
NEBcutter tool (New England Biolabs, http://tools.neb.com/NEBcutter2/).  
 
2.7. Multilocus sequence typing (MLST) 
2.7.1. Theoretical background 
Multilocus sequence typing (MLST) was proposed in 1998 as a universal and 
standardised sequencing-based method  to characterise pathogenic bacteria (228). It 
examines the nucleotide sequence of multiple loci coding encoding housekeeping 
genes (generally seven loci). Housekeeping genes are genes required for the cell to 
normally function, for that reason they are present within all isolates within a species 
core genome. They are not under a high selective pressure; however there is enough 
variability within the nucleotide sequences that allows them to be put into different 
groups. The alleles of the sequenced genes are compared and their combination 
allows the assignment to a specific sequence type (ST). MLST databases showing the 
housekeeping gene sequence and ST’s are available for a wide number of bacterial 
species, including for S. aureus. From the user point of view it is an extremely easy 
tool, one can upload directly the sequenced loci, wait for the software to compare them 




2.7.2.1. S. aureus DNA extraction protocol  
Chromosomal DNA was extracted using the bacterial DNA extraction kit QIAamp DNA 
Mini Kit, according to manufacturers’ instructions. However, the method was modified 




for S. aureus by the inclusion of a cell wall lysis step. Briefly, bacterial cells were 
harvested (10 min, 5000 x g) and resuspended in an enzymatic lysis buffer (20 mM Tris 
[pH 8.0], 2 mM EDTAN2, 1.2 % Triton x-100, immediately before use 20 μg/ml 
lysostaphin) for 30 min at 37 °C. 
 
2.7.2.2. PCR conditions 
Primers designed for the seven loci were purchased from Eurofins (UK) (Table 4). 
PCRs were carried out with 50 μl reaction volumes containing 2 μl of chromosomal 
DNA (approximately 0.5 μg), 5  μl  of each primer working solution (100 pmol/µl), 0.25 
μl (5 u/μl) of Taq DNA polymerase, 10 μl of 10X green buffer (supplied with the Taq 
polymerase), and 1 μl (10 mM) deoxynucleoside triphosphates. PCR was performed in 
a S1000TM thermal cycler with an initial 4 min denaturation at 95 °C, followed by 30 
cycles of denaturation at 95 °C for 30 sec, annealing at 55 °C for 30 sec, extension at 
72 °C for 30 sec, followed by a final extension step of 72 °C for 10 min.  
Following PCR run, all the reaction products went through a clean-up step to remove 
excess of primers, dNTTPs and salts that can interfere with the sequencing. The clean-
up step was performed using a PCR clean-up kit, according to manufacturers’ 
instructions. All the reactions were confirmed by electrophoresis in an agarose gel and 
sent for sequencing at Source Bioscience (Nottingham, UK). 
 
2.7.2.3. Sequencing, analysing and alignment 
All the fragments were sequenced by Sanger sequencing. Once the nucleotide 
sequences for the seven loci were available, each of them was inserted in FASTA 
format in the MEGA 5.0 software, where they were aligned with the reference alleles 




for each locus and analysed. Afterwards, the sequences were submitted to the S. 
aureus database (http://saureus.mlst.net) to get the corresponding ST. 
 
Table 2.1: The seven loci and the primers used for PCR. 
loci Function coded Sequencing primers 
arc Carbamate kinase 
arc up - 5' TTG ATT CAC CAG CGC GTA TTG TC -3' 
arc dn - 5' AGG TAT CTG CTT CAA TCA GCG -3' 
aro Shikimate dehydrogenase 
aro up - 5' ATC GGA AAT CCT ATT TCA CAT TC -3' 
aro dn - 5' GGT GTT GTA TTA ATA ACG ATA TC -3' 
glp Glycerol kinase 
glp up - 5' CTA GGA ACT GCA ATC TTA ATC C -3' 
glp dn - 5' TGG TAA AAT CGC ATG TCC AAT TC -3' 
gmk Guanylate kinase 
gmk up - 5' ATC GTT TTA TCG GGA CCA TC -3' 
gmk dn - 5' TCA TTA ACT ACA ACG TAA TCG TA -3' 
pta Phosphate acetyltransferase 
pta up - 5' GTT AAA ATC GTA TTA CCT GAA GG -3' 
pta dn - 5' GAC CCT TTT GTT GAA AAG CTT AA -3' 
tpi Triosephosphate isomerase 
tpi up - 5' TCG TTC ATT CTG AAC GTC GTG AA -3' 
tpi dn - 5' TTT GCA CCT TCT AAC AAT TGT AC -3' 
yqi 
Acetyl coenzyme A 
acetyltransferase 
yqi up- 5' CAG CAT ACA GGA CAC CTA TTG GC -3' 
yqi dn- 5' CGT TGA GGA ATC GAT ACT GGA AC -3' 
 
2.8. Bacteriophage DNA sequencing, analysis, and assembly 
DNA sequencing libraries were prepared using the Nextera XT DNA kit (Illumina, San 
Diego, CA, USA) according to the manufacturer’s protocol. Individually tagged libraries 
were sequenced as a part of a flow cell as 2- by 250-base paired-end reads using the 
Illumina MiSeq platform (Illumina, San Diego, CA, USA) at The Danish National High-
Throughput DNA-Sequencing Centre. Reads were analysed, trimmed, and assembled 
using 6.5.1 CLC Genomic Workbench as described before by Kot et al. (231). Genes 
were predicted and annotated using the RAST server (232). 
 
2.9. Antibiotic Minimum Inhibitory Concentration (MIC) 
Antibiotic MICs were determined according to the Clinical and Laboratory Standards 
Institute (CLSI) guidelines (233). The medium used for the assay was TSB and 




Staphylococcus aureus ATCC 29213 was used as quality control strain. The 
determination of the MICs was performed by the broth micro-dilution method as 
described in the same guidelines. Briefly, 96-well microplates, each containing a 
volume of 200 μl with 1:2 dilution of the antibiotic (64 to 0.0625 g/ml range) were 
inoculated with an initial standard inoculum of a 105 cfu/ml of an overnight culture. A 
0.5 McFarland scale was used for inoculum standardisation. Incubation at 37 °C with 
shaking (90 rpm) followed for 18 hours. The MIC for each isolate was scored by direct 
visualisation. A negative control containing only broth was added and the experiments 
were run in triplicate.  
 
2.10. Microscopy 
2.10.1. Transmission electron microscopy (TEM) 
2.10.1.1. Theoretical background 
Electron microscopes are equipped with a beam of electrons, generated at high 
accelerating voltages, allowing them to achieve higher resolutions and magnifications 
than those obtained with light microscopes. The wavelength of an electron beam is 
greatly shorter than that of light, resulting in a much higher resolution. For observation 
of viral particles, such as bacteriophages, the transmission electron microscope (TEM) 
has been used for more than 70 years (234) and is the most common and widely used 
microscopy technique. In fact, electron microscopy still remains the basis for 
identification and classification of phage particles. A hot tungsten filament in an 
electron gun allows electrons to be pulled from the filament in an accelerated manner 
establishing a fine electron beam. This electron beam passes through an anode 
followed by an electromagnetic condenser lens that focuses the beam on the 
specimen. The beam passes thought the specimen and image is formed caused by the 




interaction of the electrons transmitted through the specimen. A vacuum system is 
included in these microscopes to remove air, as gas molecules could interact and 
consequently scatter the electron beam, resulting in a poor resolution of the image. 
Figure 2.8 shows a diagram of the electron microscope. Samples are negatively 
stained and embedded with heavy metal salts, such as uranyl acetate (UA) or 
phosphotungstic acid (PTA). The heavy ions interact with the electron beam when this 
last one passes through the specimen producing a phase contrast image. 
 
 
Figure 2.8: Representative diagram (A) and image (B) of the transmission electron microscope.  
 
2.10.1.2. Sample preparation 
Bacteriophage lysates were purified through PEG-precipitation (mentioned above in 
section 2.2.). Following purification, bacteriophage solution, containing ~1x109 pfu/ml, 
were deposited onto carbon-coated copper grids. To  improve phage adsorption the 
grids were previously made hydrophilic by a 30 min exposition to UV light (235). A drop 
of phage suspension was placed on the grid and phages were allowed to adsorb for 1 
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min. The excess of suspension was drained off with filter paper and a drop of distilled 
water was placed on the grid and blot dried straight after. This was repeated another 
time. Finally, a drop of 1 % uranyl acetate (pH 4) was dropped on the grid for 30 sec 
and blot dried to negatively stain the phage particles. The sample grids were left to dry 
for 3 hours before observation on the electron microscope. Visualisation was 
performed using a transmission electron microscope (JEM1200EXII; JEOL, Bath, 
United Kingdom) operated at 120 kV. 
 
2.10.2. Confocal laser scanning microscopy 
2.10.2.1. Theoretical background 
Confocal laser scanning microscopy is considered nowadays part of the gold-standard 
methodology for biofilm studies and analysis. It is described as an advanced and more 
versatile microscope technique overcoming some of the limitations of the conventional 
fluorescence microscopy, including visualisation of thick samples or in vivo studies, 
which patent was created in 1955 by Marvin Minsky (236). In a conventional optical 
light microscope, the sample is placed on the stage and despite light being shed to a 
point on the specimen the entire sample gets illuminated. This results in an image of 
low resolution. A confocal microscope comprises confocal apertures, named pinholes, 
that permit only light from the plane of focus to reach the detector and only a single 
point in the specimen is illuminated at a time (Figure 2.9), blocking the scattered light 
and the out-of-focus light observed in the conventional microscope, and resulting in an 
image of high quality. This allows for the collection of sections of the X-Y plane (a 
stack) that after collection of several stacks it can be put together to reconstruct a 
three-dimensional image of the specimen. Sections in the X-Z plane can also be 
acquired. 
 






Figure 2.9: Representative diagram (A) and image (B) of the confocal microscope. (A) is 
reprinted from reference (236) and used with permission. 
 
The fluorescence confocal microscope is used with samples stained with dyes, more 
specifically fluorophores, that get excited by the light source and the resulting emitted 
fluorescence is detected and collected to produce a detailed image of the specimen. In 
a laser scanning confocal microscope the excitation light is a laser beam. The laser is 
set at the required wavelength to excite the fluorophore. For the presented work two 
fluorescence DNA stains were used: SYTO 9 and propidium iodide. The first one stains 
all bacterial cells, independently of the integrity of the cell membrane and is excited at 
480/500 nm, hence emits green light. Propidium iodide stains only bacteria with their 










Figure 2.10: Fluorescence Ex/Em light spectra of propidium iodide (A) and SYTO 9 (B) nucleic 
acid stains (237). 
 
2.10.2.2. Sample preparation 
Biofilms were established on the surface of stainless steel pegs. Disks were carefully 
removed and the biofilm surface was washed twice with PBS.  Biofilm cell viability was 
determined using LIVE/DEAD staining following the manufacturer’s instructions. The 
disks were immersed in the staining solution and incubated at room temperature for 15 
min in the dark. After staining, the disks were gently rinsed with PBS and this was 
repeated six times more. The biofilm images were acquired in a Zeiss LSM510META 
confocal scanning laser microscope. Biofilms were observed using the 20x objective 
(20x/0.5 W) or the 60x water-immersion objective (60x/1.2 W). Images were acquired 
with 1024 x 1024 resolution in at least three different regions of the biofilm surface. In 
order to determine the biofilm height for each region analysed the top and bottom layer 
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of the biofilm was determined and the average and maximum height of biofilm was 
calculated. Manipulation of the images and 3D reconstructions were performed using 
LSM Image Browser and Imaris 7.4.2 softwares. 
 
2.11. In vitro Biofilm Methods 
2.11.1. Biofilm formation for S. aureus isolates 
The biofilm assay was performed similarly to previously described methods (238) but 
with some modifications in order to optimise the system. Biofilm formation was 
performed in 96-well polystyrene tissue culture microplates to achieve an improved cell 
attachment. TSB supplemented with 1 % D-(+)-glucose (TSBg) and 1 % NaCl (TSBg-
NaCl) was used to perform this assay, as this helps to improve biofilm formation (227, 
239). An overnight culture was diluted to a titre of 108 cfu/ml. Briefly, in the microplate 
wells a 1:100 dilution was performed by adding 5 μl of the bacterial suspension to 195 
μl of TSBg-NaCl, making a starting inoculum of 106 cfu/ml. 200 μl of broth was added 
to a set of wells as a negative control. All wells were replicated three times. Afterwards, 
microplates were incubated at 37 °C for 48 h with no shaking for biofilm formation. 
Microplates were carefully wrapped with a layer of  moistened blue paper towel roll and 
plastic to prevent the media in the microplates  evaporating. During the incubation time 
(~24 h after incubation), 50 μl of fresh TSBg-NaCl was added to all control and test 
wells.  
 
2.11.2. Biofilm formation for P. aeruginosa isolates 
The biofilm assay for formation of P. aeruginosa biofilms was based on the previously 
described methods of Pires et al. (240) with some modifications when appropriate. 




Formation of the biofilms was carried out in 96-well polystyrene tissue culture microtitre 
plates. An overnight culture was diluted to a titre of 108 cfu/ml. Briefly, in the microplate 
wells a 1:100 dilution was performed by adding 5 μl of the bacterial suspension to 195 
μl of 50 % LBg media, making a starting inoculum of 106 cfu/ml. 200 μl of broth was 
added to a set of wells as a negative control. All wells were replicated three times. 
Afterwards, microplates were incubated at 37 °C for 48 h with constant shaking (120 
rpm) for 48 hours. Microplates were carefully wrapped with a layer of moistened blue 
paper towel roll and plastic to prevent the media in the microplates  evaporating. At 24 
hours, 50 μl of fresh 50 % LB was added to all control and test wells.  
 
2.11.3. Biofilm treatment with phage mixture  
Biofilm formation was carried out as described above. Once biofilms were established 
and washed once with PBS, 100 μl of phage mixture in PBS was added to a set of 
wells. Two different MOIs were set up for the single or mixed phage. 100 μl of PBS 
were added to both the positive and negative controls. All the experiments were 
performed three times. After static incubation at 37 °C, microplates were washed and 
stained with crystal violet, as described below, at predetermined time points. Optical 
density readings of the staining intensity at 600 nm (OD600) were performed and 
recorded using a plate reader. 
 
2.11.4. Biofilm staining with crystal violet 
Following incubation, medium was poured off and wells were carefully washed twice 
with sterile phosphate-buffered saline (PBS) solution to remove any planktonic cells. 
Microplates were allowed to dry for 1 hour at 50°C.To determine total biofilm biomass, 
microplate wells were stained with 0.1 % crystal violet (CV). After staining, the wells 
were washed twice with PBS solution and dried. Biofilm formation was determined by 




visual comparison of the stained wells and photographed. CV was then dissolved, the 
wells were washed with PBS twice and 95 % ethanol was added. This was left for 30 
min to dissolve the stain, following a 10-fold dilution the absorbance was measured by 
the FLUOstar plate reader at 600 nm. 
 
2.11.5. XTT Reduction Assay 
This assay determines the number of viable cells present in a biofilm by using XTT (a 
complex salt) which can only be reduced by metabolically active cells. This reduction of 
XTT turns the solution orange, and so the concentration of the dye is proportional to 
the number of metabolically active cells in the biofilm. Hence, biofilm cellular activity 
was determined by the XTT reduction assay. Medium from each well was poured off 
carefully and washed twice with sterile PBS. Following this 1 ml of XTT solution was 
added to each well and the microtitre plates were then incubated in the dark for 3 hours 
at 37 °C with constant shaking (120 rpm). Absorbance was then measured using the 
FLUOstar plate reader at 490 nm. 
 
2.11.6. Colony and plaque counting 
This assay determines the number of viable cells and phages particles within the 
biofilm. 200 μl of PBS buffer was added to the wells where biofilms have been grown 
and the bottom and walls of the wells were scraped with a loop. The contents of each 
well was recovered with a pipette after five times pipetting up and down for complete 
disruption and detachment of cells to the surface. Serial dilutions were performed in 
ferrous ammonium sulphate (FAS), a virucide (241) that ensures the inactivation of free 
phages prior to viable bacterial counts. The mechanism of activity of FAS has not yet 
been clarified and it has been suggested that the oxidative damage is not the mode of 




action (242). A FAS stock solution was prepared, immediately before use, in 10 ml 
distilled water and filter sterilised (0.22 μm pore size) and was used at a working 
concentration of 10 mM. After standing at room temperature for 15 min, dilutions were 
plated out and bacterial colonies enumerated. For enumeration of phages present in 
the biofilm, an aliquot of 100 ml of the disrupted suspension was used to produce serial 
dilutions in PBS. Titres were determined using the method previously described in this 
chapter in Section 2.2.5. 
 
2.11.7. Minimal Biofilm Eradication Concentration (MBEC) 
Established biofilms were formed as described already in sections 2.11.1 and 2.11.2 in 
96-well microtitre plates. Medium was gently removed and the wells were washed twice 
with PBS. 1:2 serial dilutions of the antibiotic was performed and 200 μl was added to 
the biofilm wells and the microtitre plate incubated for 24 hours. PBS only was added to 
biofilm wells as a negative control. MBECs were determined from the lowest 
concentration that was able to reduce the biofilm compared to the control after staining 
with crystal violet. All tests were performed in triplicate. 
 
2.12. Data Analysis 
Comparisons between the different time points and the positive controls were made by 
performing Student’s t test, and a P-value of 0.05 was considered statistically 
significant for all cases. All tests were performed with a confidence level of 95 %. 
Spread of data at the 95 % confidence interval (CI) was estimated using the Winpepi 
freeware statistical analysis program (243). Graph plotting and analysis were 
performed with SigmaPlot 10.0 and OriginPro 8 Softwares. 
 




2.13. List of materials and reagents used 
Table 2.2: List of reagents and materials. 
Material / Reagent Supplier / Catalogue number 
Agarose Sigma / A9539 
Bacteriological agar n
o
 1 Sigma / A5306 
CaCl2 Sigma / C1016 
Centrifugal concentrators  Fisher / 10550243 
Cesium chloride Sigma / 289329 
Chloroform Sigma / C7559 
Chloroform:isoamyl alcohol (24:1) Sigma / C0549 
Crystal Violet Sigma / C6158 
D-(+)-glucose Sigma / G8270 
Deoxynucleoside triphosphates Promega / U1511 
Dialysis cassettes (Slide-A-Lyser, Fisher, UK) Fisher / 10625655 
DNA extraction kit QIAamp DNA Mini Kit Qiagen / 51304 
DNA ladder (1 kb) New England Biolanbs / N3232S 
DNA ladder (100 bp) New England Biolabs / N3231S 
DNase I Qiagen / AM2222 
EDTA Na2 Sigma / E5134 
Ethanol Sigma / 51976 
Ethidium bromide Sigma / E1510 
FAS Sigma / 215406 
FastDigest EcoRI Fisher / 15302495 
FastDigest XbaI Fisher / 15342535   
FastDigest XhoI Fisher / 15362535 
Gelatine Sigma / 48723 
Glycerol Sigma / G5516 
Helmanex III Sigma / Z805939-1EA 
Isopropanol Sigma / I9030 
LA Sigma / L2025 
LB Sigma / L3022 
LIVE/DEAD Life technologies / L-7007 









Table 2.3: List of reagents and materials (continuation of Table 2.2). 
Material / Reagent Supplier / Catalogue number 
Lysostaphin Sigma - L7386 
MgSO4 Sigma / M7506 
MinElute Gel Extraction Kit Qiagen / 28604 
Mineral Oil Sigma / M5904 
Mucin Sigma / M2378 
NaCl Sigma / S7653 
PCR clean-up kit Fisher / 10405703 
Phase-lock gel Eppendorf tubes 5 PRIME / 2302800 
Phenol:chloroform:isoamyl alcohol (25:24:1) Sigma / P3803 
Polyallomer ultracentrifuge tubes (50 ml)  Beckman Coulter 
Polyethylene glycol (PEG) m.w.8000 Sigma / 1546605 
Polystyrene tissue culture microplates (96-well) Fisher / TKT-180-090X-F96 
Proteinase K Qiagen / 19131 
QIAamp MinElute Virus Spin Kit Qiagen / 57704 
RNase A Qiagen / 19101 
Sodium dodecyl sulphate  Sigma / 436143 
Sodium phosphate Sigma / S8282 
Taq DNA polymerase Promega / M8305 
TE buffer (Tris-EDTA buffer solution, pH 8.0) Sigma / 93283 
Thermal cycler biorad S1000TM 
Tris Acetate-EDTA buffer Sigma / T8280 
Triton x-100 Sigma / X100 
TSA Sigma / 22091 
TSB Sigma / 22092 
Uranyl acetate Sigma / 73943 
XTT solution Sigma / X4626 
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3.1. Chapter summary 
This chapter is focused on the isolation and characterisation of lytic bacteriophages 
and is divided into two main sections: a first section describing bacteriophages that 
effectively infect Staphylococcus aureus clinical isolates and a second section, where 
bacteriophages able to infect Pseudomonas aeruginosa clinical strains are described. 
In both sections, after isolating the phages, the best candidates are identified and 
characterised in order to establish a therapeutic and safe cocktail showing broad host 
range coverage against clinically relevant members of the two bacterial species.  The 
work focus on S. aureus has been published in a scientific journal (244). 
 
3.2. Background 
The first stage for the establishment of a bacteriophage therapeutic is the isolation and 
respective characterisation of the phages as candidates for formulation. Isolation and 
characterisation play a crucial role for the success and effectiveness of bacteriophage 
therapy and negligence of steps, such as ineffective phage selection or poor phage 
stability, has been responsible for several failures in the past (this has been reviewed in 
Chapter One). This was promptly noted by d’Hérelle who published in 1938 a guide to 
the isolation and preparation of phage therapy (245), after testing several commercially 
available, but ineffective, phage formulations.  
For phage isolation, although a relatively easy step when compared to discovery of 
other alternatives, it is important to consider the ecology of the bacterial species to be 
targeted in order to maximise the recovery of suitable viral particles. For example, 
phages against bovine mastitis causing S. aureus have been sampled from farmyard 
slurry and effluent (246) and phages targeting the marine pathogen Vibrio vulnificus 
have been isolated from estuarine sediment known to be a habitat for the pathogen 
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(247). Once environmental samples are obtained and prior to direct inspection for 
phage, the best approach for isolation of promising phages is by performing bacterial 
enrichments using preferably, some of the relevant clinical isolates causing the 
infection. Sample enrichments, in a situation when small numbers of the targeted 
phage are present, will allow them to propagate when samples are incubated making 
them easily detected. As mentioned elsewhere, any method used for phage isolation 
will always influence the type of phage to be selected (248). For enrichment-based 
methods phages that proliferate faster in the bacterial strains used for the enrichments 
will have a selective advantage over phage strains that despite their slower growth 
could potentially infect and be effective against other clinical strains. 
The next crucial step is the characterisation of the phage, where determination of host 
range, level of virulence, morphology and lack of toxin-encoding genes or lysogeny 
determinants are to be evaluated. For the determination of the host range of the 
phages selected, they are going to be used to challenge a collection of bacterial clinical 
isolates and their efficiency of plating (EOP) evaluated. Ideally this collection should be 
as representative as possible with the most prevalent isolates of the targeted infection 
aimed. Usually, phages showing a broader host range will prevail and be chosen over 
phages with narrower host coverage ranges. Often, formulations composed of several 
phages (cocktails) are employed not only because bacterial resistance is less likely to 
emerge, but also because the combination has a broader therapeutic range. 
Ideally phages that show a high level of virulence infecting their bacterial hosts are 
preferred. Phage virulence refers to phages infecting in an efficient fashion and being 
responsible for a quick bacterial extinction. This can be due to efficiency in recognising 
the cell wall receptor (adsorption) or in injecting the genome inside or being able to 
proliferate more rapidly and in high numbers (burst size). 
The determination of phage morphology is achieved by TEM analysis and viral 
particles can be classified taxonomically. Most likely particles will belong to the capsid 
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lipid-free Caudovirales order due to a biased isolation method where chloroform is 
often used. Also, it is most likely phages will carry a linear dsDNA genome, a feature of 
phages of Caudovirales order. 
The improvement and the technical advances in DNA sequencing have allowed this 
technology to become more efficient and more affordable making it easily accessible 
and it is common nowadays (in 2015) to include genome data when new phages are 
isolated. The availability of the genomes allow us to better predict the phage behaviour 
and, in case of commercial and therapeutic uses, to look for a lysogenic phage life-
style or any unwanted toxin and resistance factor that would be enough to exclude the 
phage from future therapeutic use. However, phage genomes still contain many 
“cryptic” regions, where the great majority of putative coding genes lack known 
function. Phage genomics is still at a relatively early stage and more intense genome 
sequencing and characterisation of their gene products is required to increase our 














3.3.1. Bacterial strains used for the study 
In this chapter several bacterial strains including P. aeruginosa, S. aureus and 
coagulase-negative staphylococci were used in order to isolate, proliferate and 
efficacy evaluation of lytic phages. Their provenances are listed in Table 3.1, 
Table 3.2 and Table 3.3, respectively. 
 
Table 3.1: List of human bacterial P. aeruginosa strains isolated from acute and chronic sites of 
infection, with their respective country of origin and related information. 
 Isolate ST Country Source 













 PA45311 - Bristol, UK nd 
PA45291 - Bristol, UK nd 
PA45235 - Bristol, UK nd 
PA45379 - Bristol, UK nd 















BC00918 - Genova , Italy CF, Male, 23 
BC01026 - Australia nd 
BC00909 - Paris, France CF, Male, 25 
BC00888 1517 Utrecht, The Netherlands CF, M, 11/01/2007 
BC00907 1528 Paris, France CF, Female, 24 
BC00917 1544 Genova , Italy CF, Male, 29 years 
BC00920 1547 Lisbon, Portugal CF, Male, 32 years 
BC00921 1535 Lisbon, Portugal CF, Female, 37 Years 
BC00922 155 Lisbon, Portugal CF, Female, 8 Years 
BC00923 1548 Lisbon, Portugal CF, Female, 19 years 
BC00931 - Bordeaux, France CF, Female 
BC00932 1529 Bordeaux, France CF, Male 
BC00933 1530 Bordeaux, France CF, Female 
BC00934 1552 Bordeaux, France CF, Male 
BC00935 - Bordeaux, France CF, Male 
CF, cystic fibrosis; n.d. no data available 
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Table 3.2: List of human bacterial S. aureus isolates with their respective sequence type (ST) 
and their country of origin. 
Isolates ST Country    Isolates ST Country 
WBG8343 1 Australia    C427 42 UK 
MSSA H476 1 England    Fin76167 45 Finland 
HT2001749 1 USA    C316 49 UK 
H148 3 UK    H417 50 UK 
BK519 5 USA    C3 51 UK 
CDC980193-USA800 5 USA    D49 53 UK 
Mu3 5 Japan    D98 54 UK 
963Small 5 USA    D318 57 UK 
97.1948.S. 5 Scotland    D535 59 UK 
C56 6 UK    HT20050306 59 Australia 
C2 7 UK    H40 60 UK 
CDC201114-USA300 8 USA    D473 69 UK 
15981 8 Spain 
   CDC201078-
USA700 
72 USA 
HT20030203 8 USA    HT20040991 80 Algeria 
HT20030206 8 USA    SwedN8890/99 80 Sweden 
C125 8 UK    BK1563 88 USA 
Fra97392 8 France    HT20020635 93 Australia 
EMRSA6 8 UK    HT2001634 93 Australia 
99st22111 8 -    Cuba4005 94 Cuba 
H169 9 UK    D302 97 UK 
D316 11 UK    Not38 101 UK 
D329 12 England    D472 109 UK 
H117 12 UK    H560 121 UK 
H402 13 UK    D139 145 UK 
C154 14 UK    D22 182 UK 
C357 15 UK    Can6428-011 188 Canada 
H291 18 UK    D470 207 UK 
H42 20 UK    98/10618 217 UK 
HO50960412 22 UK    CDC12 225 USA 
H182 22 England    Germany131/98 228 Germany 
C720 22 England    CDC16 231 USA 
C13 22 Eire    99.3759V 235 Scotland 
C49 23 UK    SwedenON408/99 246 Sweden 
D279 25 UK    KD121618 250 Switzerland 
Not116 27 UK    KD12943 257 UK 
H118 28 UK    Not271 264 UK 
SwedenAO17934/97 30 Sweden    Not380 266 UK 
Cuba4030 30 Cuba    Not98-53 280 UK 
C390 31 UK    CAN6820-0616 289 Canada 
H399 33 UK    Fin62305 296 Finland 
C160 34 UK    Not266 301 UK 
Btn766 36 UK    Btn2164 312 UK 
MRSA 252 36 England    Btn2299 322 UK 
H325 36 UK    Btn2289 322 UK 
EMRSA16 36 UK    515/09
†
 398 n.d. 
H137 38 UK    Not161 517 UK 
H137MRSA 38 UK    Not290 529 UK 
C253 40 UK       
† 
bovine mastitis isolate; n.d. no data available. 
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Table 3.3: List of bacterial coagulase-negative staphylococci strains. 
Species Isolates 
S. xylosus ATCC 29971 
S. sciuri subsp. sciuri ATCC 29062 
S. chromogenes CCM 3387 
S. hyicus CCM 29368 
S. arlettae N910 254 
S. vitulinus ATCC 51145 
S. simulans N920 197 
S. epidermidis ATCC 14990 
 
3.3.2. Genome search of antibiotic resistance determinants and virulence 
factors  
Phage genomes were searched for antimicrobial resistance determinants (98 % ID 
threshold) using the web-tool Resfinder that uses the BLAST algorithm (250). The 
antibiotic resistance genes search was focused on the main antibiotics (Table 3.4). The 
web-tool VirulenceFinder (251) was used for the search of genes potential coding for 
virulence factors (98 % ID threshold)  found in E. coli, Enterococcus spp and S aureus. 






















3.4.1. S. aureus phages isolation and characterisation 
3.4.1.1. Bacteriophage isolation and plaque morphology 
A total of 21 phages were isolated from sewage samples after enrichments with the S. 
aureus strains listed on Table 3.2. Plaque morphology of S. aureus phages observed is 
circular with regular borders and generally small, between 0.5 mm to 1.5 mm diameter, 
and without halo zones, although some present a small halo surrounding plaques. 
Halos are caused by the diffusion of enzymatic molecules produced by the phage. 
Table 3.5 describes the morphology of plaques produced by the phages isolated for 
this work and Figure 3.1 shows examples of plaques. 
 
 
Figure 3.1: Examples of S. aureus isolated phage plaques (clear spots caused by bacterial 
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Table 3.5: Phages isolated with respective S. aureus bacterial hosts and plaque morphology. 
Isolated phage S. aureus host 
Plaque morphology 
~ mm (); halo 
DRA88 BC0691 <0.5 
DRA145 Not290 <0.5 
DRA147 D551 0.5 
DRA189 BC1009 1.5 
DRA226 D551 0.5 – 1.0 
DRA278 H560 1.0 
DRA279 H560 1.0 
DRA280 H560 1.0 
DRA281 BTN2306 2.0 
DRA282 BTN2306 2.0 
DRA283 EMRSA3 0.5 
DRA284 EMRSA16 1.0 
DRA285 BTN766 1.5; halo 
DRA286 98/10618 0.5; halo 
DRA287 HT20010254 1.0; halo 
DRA288 EMRSA16 1.0 
DRA289 98/10618 1.0 
DRA290 BTN766 1.5 
DRA291 FFP221 <0.5 
DRA292 FFP221 <0.5 
DRAE2260 E2260 0.5 
Phage K EMRSA16 1.0 
 
3.4.1.2. Host range determination and selection of phage cocktail 
The lytic phages previously isolated for S. aureus were evaluated regarding their host 
range of infectivity in order to select the phages showing the broadest range of host 
infectivity.  Phages were tested against a small but diverse S. aureus collection of 23 
clinical isolates, including geographical as well as antibiotic resistance profile diversity, 
the latter including examples of methicillin sensitive S. aureus (MSSA) and methicillin-
resistant S. aureus (MRSA). An isolate of S. epidermidis was also included in the 
collection. Phage K is a polyvalent phage of the staphylococcal genus and we 
observed 71 % (CI 95 %, 51 % to 86 %) of coverage of the tested isolates. The 
majority of the isolated phages present a broad host range, varying between 29 % (CI 
95 %, 14 % to 49 %; 7 isolates out of 24 were susceptible) for DRA283 to 75 % (CI 95 
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%, 55 % to 89 %; 18 isolates out of 24 were susceptible) of host coverage for BCP287. 
Others showed a narrower host range, such as phage DRAE2260 that was only able to 
infect three strains of the collection (12.5 %, CI 95 %, 3.2 % to 30.3 %) and phage 
DRA279 only infecting one of the isolates (4 %, CI 95 %, 2 % to 18 %).   Phages 
DRA145, DRA147 and DRA226 showed to have an even higher narrow host range and 
were not able to infect any of the S. aureus isolates. Apart from phage K, that produced 
small plaques in the bacterial lawn of the S. epidermidis isolate and S. aureus 
HT20040991, any other of the isolated phages were able to infect them. 
For the phage cocktail composition phages DRA88, DRA288 and K were selected in 
order to obtain the best combination possible to achieve a broad host range of 
infectivity and prevent the emergence of resistant mutants. The latter result is 
presented in Chapter Four. 
 
3.4.1.3. Genome restriction analysis 
Isolation of phage genomic DNA and the subsequent enzymatic restriction digest 
analysis was carried out to determine whether phages were genetically closely related 
(Figure 3.2). The restriction analysis was performed with XbaI and EcoRI 
endonucleases. Phage K was the positive control for the restriction analysis. DNA 
extraction straight after phage propagation resulted in low DNA yield and presence of 
smears, possibly due to the presence of proteins and RNA. High DNA yield and greatly 
improved purity was achieved only with CsCl gradients. The restriction profiles 
produced by two enzymes yielded a large number of fragments that showed a similar 
pattern for all the three phages on a 1 % agarose gel. Although similar, it is possible to 
visualise the presence or lack of some bands, for example the band pattern of the XbaI 
digest in the region of 2027 bp and 564 bp was different for all phages. This suggests 
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that DRA88, DRA288 and phage K are different phage particles, however very closely 
related. 
 












































































































159181 S R R S R S I S S S I S S S S S S S S S R I 
C316 S R R R R R R R R R I R R R S I I I S R R S 
D329 S R R S R S I S S S S S S S S S S S S S I S 
H137 I R R I R I I I I I I I I I I I I I S I R I 
H560 S R R S R S S S S S S S S S S S S S S S R S 
Btn766 S R R S R S I S S S S S S S S S S S I S R S 
HT20030203 I I I I R R I I R R S R R R S I I I   I S S 
HT20030206 I I I R R R R R R R I R R R S R R R   R S S 
HT20040991 R R R R R R R R R R R R R R R R R R R R R I 
HT20020635 I R R R R R R R R R R R R R R I R R I R R S 
ATCC14990 R R R R R R R R R R R R R R R R R R R R R I 
HO50960412 S R R I R S I S S S I S S S S S S S I S R I 
H182 S R R I R S I S S S I S S S S S S S I S R S 
C720 S R R   R S I S S S I S S S S S S S I S R R 
98/10618 S R R I R S I S S S I S S S S S S S S S R S 
MRSA 252 S R R S R S I S S S I S S S S S S S S S R S 
H325 S R R S I S I S S S I S S S S S S S S S R S 
WBG8343 I R R R R R R R R R R R R R S R R R R R R S 
MSSA H476 S R R S R S I S S S I S S S S S S S S S R S 
Mu3 R R R R R I I I I I I I I I I I I I I I R S 
963Small S R R S R S   S S S S S S S S S S S S S R S 
97.1948.S. R R R R R R R R R R R R R R R R R R R R R R 
515/09 S R R S R I I S I I S S S S S S S S I S R S 


































































Bacterial isolates were susceptible (clear spot; S; green), intermediate (turbid spot; I; yellow), 
or resistant (no disturbance of bacterial lawn; R; red) to phage infection. 
 




Figure 3.2: Restriction analysis of phages K, DRA88 and DRA288. Lane identification is as 
follows: M – marker λ/HindIII; A, B and C – undigested DNA of phages K, DRA88 and DRA288, 
respectively; 1 – DNA digested with XbaI; 2 – DNA digested by EcoRI. 
 
3.4.1.4. Bacteriophage morphology  
The isolated phages DRA88 and DRA288 were further characterised regarding their 
morphology. Images of the phages were produced using transmission electron 
microscopy (TEM). The results revealed that both phages showed a similar 
morphology, with an icosahedral head of ~78 nm and ~85 nm in diameter, a long 
contractile tail of ~179x18 nm and ~208x16 nm with tail fibres, for DRA88 and DRA288 
respectively (Figure 3.3). The protein neck connecting the capsid and the tail of ~9x10 
nm and ~7x10 nm, for DRA88 and DRA288, respectively, is revealed on the images.  
Therefore, both phages can be classified as belonging to the Myoviridae family and 
sub-family Spounaviridae (order Caudovirales), according to the classification system 
of Ackermann (144). It was observed for phage DRA88 that, besides single dispersed 
particles, there was also various particles aggregated through contact of their tail fibres 
(Figure 3.10). Phage K was also observed under TEM, revealing viral particles also 
belonging to the Myoviridae family and previously documented (221). 
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DRA88 DRA288 Phage K 
   
Figure 3.3: Electron micrograph images of phage DRA88, phage DRA288 and phage K 
negatively stained with 1 % uranyl acetate. DRA88 and DRA288 are showing the tail in a 
contracted position. Scale is indicated by the bars. 
 
3.4.1.4.1. Contamination with prophages 
Although the phages were always passed through several rounds of purification when 
we were observing them under the electron microscope two different viral particles 
were being revealed for DRA88: a Myoviridae in higher proportion (described in the 
section above) and a Siphoviridae in a lower ratio. This was also observed when 
plating the phage onto bacterial lawns, where besides the expected phage plaques it 
also revealed very small diameter plaques were appearing on the agar lawn, usually a 
sign of the presence of more than one phage type. The bacterial strain S. aureus 
EMRSA 16 was been used as host for phage propagation and this strain is known to 
harbour four prophages in its genome. Perhaps, one of the prophages was being 
induced when DRA88 infects the bacterial cell and consequently excised from the 
chromosome. To confirm this, the S. aureus prophage-free strain RN4220 was used as 
a host and several purification passages were performed to ensure purity and the 
lysate was observed by TEM (Figure 3.4). This time it was not fond Siphoviridae 
particles in the sample, but only the Myoviridae particles. Hence, S. aureus EMRSA16 
was ignored as a host for phage replication being replaced by S. aureus RN4220. 
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However, phage DRA288 was not able to infect this strain and for that reason was 
pulled out from the further studies. 
 
3.4.1.5. Host range determination of phage mixture 
Phage DRA88, phage K and their combination were assessed regarding their host 
infectivity range against a larger and more representative collection of 95 S. aureus 
isolates (Table 3.7) assigned to 14 different multilocus sequence typing (MLST) types 
(Table 3.3, Figure 3.5). DRA88 presented a host infectivity coverage of 60 % (95 % CI, 
50 % to 69 %; 57 isolates out of 95 were susceptible). Phage K showed host coverage 
of 64.2 % (95 % CI, 54 % to 73 %; 61 isolates out of 95 were susceptible). These two 
phages when in combination gave a total coverage of 73.7 % (95 % CI, 64 % to 82 %) 
of the S. aureus isolates. Infectivity of both phages was also assessed on a group of 
coagulase-negative isolates, where DRA88 did not infect efficiently any of the isolates. 
Phage K also showed weak infectivity; however, two of the isolates - S. simulans and 
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S. aureus RN4220 S. aureus EMRSA 16 
  
Figure 3.4: Electron micrograph images of phage DRA88 when growing (A) in the S. aureus 
RN4220 host (only Myoviridae particles are observed) and when growing in (B) S. aureus 
EMRSA 16 host (particles of Myoviridae and Siphoviridae can be observed). Samples were 
negatively stained with 1 % uranyl acetate. Scale is indicated by the bars. (C) A bacterial lawn 
of S. aureus EMRSA 16 on an agar plate show the heterogeneous plaques produced by the two 
different phage particles. 
A B C 
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CDC201114-USA300 S S S   C253 I I I 
CDC201078-USA700 I I I   C427 S S S 
CDC980193-USA800 S S S   Fin76167 S S S 
WBG8343 S I S   C316 S S S 
MSSA H476 S S S   H417 S S S 
HT2001749 S I S   C3 S S S 
H148 S S S   D49 S S S 
Mu3 S R S   D98 I I I 
963Small S S S   D318 S S S 
97.1948.S. R R R   D535 I I I 
C56 S S S   HT20050306 I I I 
C2 I I I   H40 S S S 
15981 I S S   D473 I I I 
HT20030203 I S S   HT20040991 S R S 
HT20030206 S I S   SwedN8890/99 I I I 
C125 I I I   BK1563 I S S 
Fra97392 I R I   HT20020635 S I S 
EMRSA6 I I I   HT2001634 I S S 
99st22111 S S S   Cuba4005 S S S 
H169 S S S   D302 S S S 
D316 I I I   Not38 S S S 
D329 S S S   D472 S S S 
H117 S S S   H560 S S S 
H402 S S S   D139 I I I 
C154 S S S   D22 I I I 
C357 S S S   Can6428-011 S S S 
H291 S I S   D470 I I I 
H42 S S S   98/10618 S S S 
HO50960412 I S S   CDC12 S S S 
H182 S S S   Germany131/98 S S S 
C720 R S S   CDC16 S S S 
C13 S S S   99.3759V S I S 
C49 S S S   SwedenON408/99 I I I 
D279 I I I   KD121618 S I S 
Not116 S S S   KD12943 I I I 
H118 S I S   Not271 I I I 
SwedenAO17934/97 S I S   Not380 I S S 
Cuba4030 I I I   Not98-53 I S I 
C390 S S S   CAN6820-0616 I I I 
H399 S S S   Fin62305 S I S 
C160 I I I   Not266 S S S 
Btn766 S S S   Btn2164 S S S 
MRSA 252 S S S   Btn2299 I I S 
H325 S S S   Btn2289 S S S 
EMRSA16 S S S   515/09 S S S 
H137 I I I   Not161 S I S 
H137MRSA S S S   Not290 S S S 
BK519 I S S       
† 
Bacterial isolates were susceptible (clear spot; S; green), intermediate (turbid spot; I; yellow), 
or resistant (no disturbance of bacterial lawn; R; red) to phage infection.  



































S. xylosus ATCC 29971 I I I 
S. sciuri subsp. Sciuri ATCC 29062 I I I 
S. chromogenes CCM 3387 I I I 
S. hyicus CCM 29368 S I S 
S. arlettae N910 254 I I I 
S. vitulinus ATCC 51145 I I I 
S. simulans    N920 197 S I S 
S. epidermidis ATCC 14990 I R I 
† 
Bacterial isolates were susceptible (clear spot; S; green), intermediate (turbid spot; I; yellow), 
or resistant (no disturbance of bacterial lawn; R; red) to phage infection. 
 
3.4.1.6. Genomic characterisation of DRA88 and comparison with phage K 
To gain a more complete understanding of phage DRA88, its DNA was extracted and 
genome sequencing was performed. Upon assembly and annotation, it was found that 
phage DRA88 has a large double-stranded DNA (dsDNA) genome with terminal 
redundancy, which suggests that phage DRA88 has a headful packaging system (252). 
The genome comprises 141,907 bp and can be grouped into class III of staphylococcal 
phages (>125 kbp) (253); 204 putative coding regions and four tRNA genes were 
identified (Figure 3.6). The gene coding potential, with 1.44 genes per kb, exhibits a 
high gene density. The majority of genes, 145 (71 %), are found in the forward strand, 
and 59 (29 %) are found in the opposite strand. tRNA genes are all located in the 
reverse strand of the genome. Regarding the G+C % content, it is 30.4 %, a lower 
percentage than the one found in the S. aureus host, 32.9 %. The amino acid 
sequence was found to share strong similarities (>95 %) with those of several other 
phages, such as JD007 and GH15, previously sequenced (254, 255). A comparison 
between phage DRA88 and phage K was performed using the BLASTN algorithm 
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(256). The DRA88 genome seems to be organised into functional modules - cell lysis, 
DNA replication, and structural elements - similar to the organisation of phage K and 
other staphylococcal Myoviridae phages belonging to the Twort-like viruses (253, 257, 
258). Between these modules, we can find several putative coding regions that are not 
yet found in the NCBI database or have no attributed function (phage and hypothetical 
proteins). These unknown functions represent 84.81 % of the coding capacity. Three 
potential coding regions (ORF178, ORF192, and ORD195) did not have any identical 
match with phage genes in the NCBI database. DRA88 lysin and DNA polymerase are 
not interrupted by introns (255), in contrast to phage K but similarly to phage GH15. At 
the end of the genome (between ORF164 and ORF182), there is a large coding region 
with unidentified functions inserted into the DRA88 genome that is not observed in 
phage K. Also, DRA88 genome analysis did not reveal the presence of known 
virulence-associated and toxin proteins or antibiotic resistance determinants.  
The genomic sequence of the phage DRA88 can be found in the NCBI GenBank 
database under accession number KJ888149. 
 
3.4.1.7. Phage growth characteristics 
The life cycle and adsorption affinity of phage DRA88 and phage K were assessed 
when growing in S. aureus RN4220 at 37°C.In order to identify the different stages of 
the phage infection process (Chapter Two, Figure 2.5) one-step growth studies were 
performed. Hence, after inoculation, the phage growth cycle parameters (L, latent; E, 
eclipse; B, burst size) were determined (Figure 3.8). In the system established, the 
eclipse and latent periods of DRA88 were 15 min and 25 min, respectively. DRA88 
yielded a burst size of 76 PFU and phage K yielded a burst size of 125 PFU per 
infected cell after a 60 min incubation period. Such values identified are in conformity 
with the values that are normally observed for phages from the T7 group (259). 
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For estimation of the adsorption efficiency of phages to S. aureus RN4220 host, a 
study during cells early logarithmic growth phase was performed (Figure 3.7). From 
equation 1, the rate constants for the adsorption (loss of free phage) for phage K and 
DRA88 were calculated, k’ = 0.352 min-1 and k’ = 0.252 min-1, respectively. Hence, 
although the phages were similar, after 5 min, 80.3 % of phage K and 71.6 % of 
DRA88 were adsorbed to the bacteria. After 10 min of incubation, values for free 
phages were below 5 % for both phage K and DRA88. 
 
 
Figure 3.7: Percentage of free DRA88 (A) and phage K (B) phages after infection of actively 
growing S. aureus RN4220 at an MOI of 0.001 at several time points over 10 min. Rate 
constants for loss of phage are 0.352 min
-1
 for phage K and 0.252 min
-1
 for DRA88. Each data 
point is the mean of three independent experiments, and error bars indicate the means ± 
standard deviations. Reprinted from reference (244) and used with permission. 
 
 




Figure 3.8: Curve for one-step growth of phage DRA88 (left) and phage K (right) in S. aureus 
RN4220 at 37°C. Shown are the PFU per infected cell in untreated cultures (●) and in 
chloroform-treated cultures (○) at several time points over 60 min. The phage growth 
parameters are indicated in the figure and correspond to eclipse period (E), latent period (L), 
and burst size (B). Each data point is the mean of three independent experiments, and error 
bars indicate the means ± standard deviations. Reprinted from reference (244) and used with 
permission. 
 
3.4.1.8. Aggregation experiments 
The zeta potential of phage DRA88 and phage K calculated from the electrophoretic 
mobility was, respectively, -17 mV and -26.3 mV. The particle size measured for phage 
K was 122 nm (121.5 nm, SD ± 2.7) (Figure 3.8A), however according to the TEM 
micrographs and the literature, phage K has an average size of 280 nm in length (146). 
Such discrepancy could be due to the contraction of the phage tails, which was often 
observed on the TEM, resulting in interference with the measurements. Dynamic light 
scattering (DLS) may show lower accuracy when measuring particles with an irregular 
shape, hence not uniform in all dimensions and this holds true for tailed phages. 
Regarding phage DRA88, that has a size of ~257 nm, we were not able to obtain an 
accurate size measurement (Figure 3.9B) and this might be related to the phenomenon 
of aggregation observed under TEM. When observing phage DRA88 under the electron 
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microscope, besides dispersed single phage particles it was also observed various 
aggregates were made through contact of their tail fibres (Figure 3.10). Also, several 
heads and tails were observed separately, suggesting that in a certain step of the 





Figure 3.9: Size distribution intensity of phage particles in suspension at 37 
o
C revealed by 
DLS. A – phage K, B – phage DRA88.  
 
 
Figure 3.10: Electron micrograph images of phage DRA88 infecting S. aureus forming 
aggregates negatively stained with 1 % uranyl acetate. Scale is indicated by the bars. Reprinted 
from reference (244) and used with permission. 
A 
B 
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3.4.2. P. aeruginosa phages isolation and characterisation 
3.4.2.1. Bacteriophage isolation and plaque morphology  
A total of 17 phages were isolated from sewage and flood water samples after 
enrichments with the P. aeruginosa strains listed on Table 3.1. Phages showing clear 
isolated plaques were selected over phages where plaques showed turbidity. 
Regarding the plaque morphology of phages isolated for P. aeruginosa strains they 
were generally circular with both regular and irregular edges were identified, however 
showing larger diameters than ones observed for S. aureus phages (between 0.5 mm 
and 3.0 mm). Halos, caused by the diffusion of enzymatic molecules were frequently 
observed for these phages. Interestingly, phage DL64 produced a plaque that 
consisted of a clear small centre with a turbid halo and this one surrounded by a clear 
halo. Table 3.9 describes the morphology of the plaques produced by the isolated 
phages and Figure 3.11 shows examples of plaques.  
 
Table 3.9: Phages isolated with respective P. aeruginosa bacterial hosts and plaque 
morphology. 
Phage P. aeruginosa host strain 
Plaque morphology 
~ mm (); halo 
DL52 PA45291 1.0; halo 
DL53 PAO1 0.5; halo 
DL54 PAO1 1.0 
DL55 PAO1 1.0; halo 
DL56 PAO1 1.5, halo 
DL57 BC00907 1.5 
DL58 BC00907 1.0; halo 
DL59 BC00907 2.0; halo 
DL60 BC00907 1.0; halo 
DL61 PA45321 3.0; halo 
DL62 BC00918 2.5; halo 
DL63 PA45291 1.0; halo 
DL64 PAO1 1.5; halo 
DL65 PA45291 2.0 
DL67 PA45291 0.5; halo 
DL68 PAO1 1.0; halo 
DL69 PAO1 1.5 




Figure 3.11: Examples of P. aeruginosa isolated phage plaques (clear spots caused by 
bacterial lysis). A – DL54; B – DL60; C – DL67; D – DL52; E – DL57; F – DL63. 
 
3.4.2.2. Host range determination and selection of phage cocktail 
The lytic phages previously isolated for P. aeruginosa were evaluated regarding their 
host range of infectivity. Phages were tested against a P. aeruginosa collection of 
geographically diverse clinical isolates coming from both acute and chronic situations 
listed in Table 3.10 in order to isolate phages with broad host ranges. For 11 phages 
the host coverage was <32 %, where phage DL63 was only infecting one out of 22 
isolates tested (95 % CI, 5 %, 2 % to 20 %), the acute isolate PA45291. The remaining 
six phages showed a host cover ranging from 45 % for DL61 (95 % CI, 24 % to 65 %; 
10 isolates out of 22 were susceptible) to 59 % for DL68 (95 % CI, 38 % to 78 %; 13 
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BC00932 I I I R S S I R I S S I I S S S S 
BC00931 I R R I R R I R I R I R I I I S I 
BC00923 R R I R R R I R I R R I R R I R R 
PAO1 S S S S S R S S S R S R S S S S S 
BC01026 I I I R R R R R R I S I S I I S S 
BC00935 S S S S R I S S S I I R S S S S S 
BC00934 R I S R R I S R S I I R I I I S S 
PAB45379 I R I I R I R R R I S I R I I I I 
BC00907 S S S S R S S S S I S I S S S S S 
PAB45235 R R R R R R I I R I I I S I I I I 
PAB45321 R R R I I R I R I I R R R S S R R 
PAB45291 S I S S R R S I S R S S S S S S S 
BC00909 R R R R R R R R R S S I R I I I R 
BC00918 R R R R R R R R R R S R R R R R R 
BC00917 R R I R R R R R R I I R S S S S S 
BC00920 S S S R R R S S S S I I S S S S S 
BC00921 R R R R R R I R I R R R R S S R R 
PAB45311 I I R R I I R R R I R R R S S R R 
BC00922 I I I I I I R R R I S I S I I I I 
BC00888 I R I I I R R R R I R R S I I S S 
BC00933 S I S R R R I I I I R R S I I S S 
BC00920 I R R R R I I I I I S I S S S S S 
Hit % 30 20 35 20 10 10 30 20 30 15 50 5 60 55 55 65 60 
† 
Bacterial isolates were susceptible (clear spot; S; green), intermediate (turbid spot; I; yellow), 
or resistant (no disturbance of bacterial lawn; R; red) to phage infection. 
 
Determination of the host range allowed us to formulate a phage combination that 
would give the highest percentage of coverage. For that reason six phages were 
selected to make part of the phage cocktail – DL52, DL54, DL60, DL62, DL64 and 
DL68 – giving a total coverage of 90 % (95 % CI, 62 % to 94 %; 18 isolates out of 22 
were susceptible). All the phages selected to establish the cocktail were able to infect 
P. aeruginosa PAO1 (Table 3.11.), for that reason for further studies the strain was 
used as host for phage propagation. 
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BC00932 I I I S I S S 
BC00931 I R I I I S S 
BC00923 R I I R R R I 
PAO1 S S S S S S S 
BCO1O26 I I R S S S S 
BC00935 S S S I S S S 
BC00934 R S S I I S S 
PAB45379 I I R S R I S 
BC00907 S S S S S S S 
PAB45235 R R R I S I S 
PAB45321 R R I R R R I 
PAB45291 S S S S S S S 
BCOO909 R R R S R I S 
BC00918 R R R S R R S 
BC00917 R I R I S S S 
BC00920 S S S I S S S 
BC00921 R R I R R R I 
PAB45311 I R R R R R I 
BC00922 I I R S S I S 
BC00888 I I R R S S S 
BC00933 S S I R S S S 
BC00920 I R I S S S S 
Hit % 30 35 30 50 60 65 90 
† 
Bacterial isolates were susceptible (clear spot; S; green), intermediate (turbid spot; I; yellow), 
or resistant (no disturbance of bacterial lawn; R; red) to phage infection. 
 
3.4.2.3. Morphology of phages 
The six P. aeruginosa phages were also characterised regarding their morphology and 
for this samples were prepared to be observed under the electron microscope. The 
results found two different types of morphology. DL52, DL60 and DL68 phages have an 
icosahedral head of ~60 nm, ~76 nm and ~72 nm in diameter, respectively. Long 
contractile tails, with tail fibres, of approximately ~123x18 nm, ~95x19 nm and ~177x23 
nm, respectively (Figure 3.12) were also observed. Phages DL54, DL62 and DL64 
have an icosahedral head of approximately ~45 nm, ~63 nm and ~65 nm in diameter, 
respectively and a short tail of ~12x9 nm and ~13x9 nm with no tail fibres visible. For 
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DL64 the tail was clearly visible, however fibres protruding from the capsid are 
observed. Therefore, according to the system of Ackermann (144) such traits allow 
classification of the first group of phages as belonging to the Myoviridae family and the 
second group as belonging to the Podoviridae family, both from the order 
Caudovirales. The samples of the observed Myoviridae phages showed the presence 
of many disintegrated phages, where several free capsids and free tails could be 
observed. Samples of phages DL54 and DL60 showed the presence of phage 
aggregates. 
DL52 DL54 DL60 
   
DL62 DL64 DL68 
   
Figure 3.12: Electron micrograph images of phage L52, DL54, DL60, DL62, DL64 and DL68 
infecting P. aeruginosa negatively stained with 1 % uranyl acetate. Scale is indicated by the 
bars. 
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3.4.2.4. Genome analysis 
DNA from the six P. aeruginosa phages was extracted and genome sequencing was 
performed in order to achieve more information about the phages. Table 3.12 
summarises the key features of the six genomes. 
The genome sizes observed for phages DL52, DL60 and DL68 were larger, comprising 
65,867 bp, 66,103 bp and 66,111 bp, respectively. Figure 3.13 shows a comparison 
between these Myoviridae phages, performed using the BLASTN algorithm (256). This 
comparison shows that they are 90 % identical in their nucleotide sequence and in 
particular DL52 and DL60 are 96 % identical. Genes are arranged in a typically 
compact manner with a coding percentage ranging from 89.7 % to 91.6 %. For all the 
phages tRNAs genes are absent. P. aeruginosa shows a G+C % content of 66.6 % 
and for all the phages their content was much lower (between 52.4 % – 62.2 %). 
Phages DL52 and DL60 show strong similarities to phage PB1 (>96 %) and phage 
LBL3 (>92 %), that recently have been sequenced (260). Phage DL68 shares high 
similarities with phage KPP12 DNA (96 %) (261), but is still strongly related with PB1 
and LBL3 phages (>90 %). Hence, the three phages can be put in the PB1-like lytic 
virus group. It has been documented that these phages use the bacterial 
lipopolysaccharide as a receptor to attach to the cell (262) and we can assume that the 
same attachment mechanism might be employed by these three phages. In 
accordance with other related phages such as PB1 (260), RNA polymerases are 
absent in all three phages, which is commonly observed in this type of phages where 
their transcription relies entirely on the host machinery. All three phages carry a DNA 
polymerase III alpha-subunit that catalyses the polymerisation reaction of the host DNA 
polymerase III holoenzyme, which is the main observed DNA polymerase within 
bacteria (263). The presence of phage-encoded DNA primase and helicase suggests 
that viral dsDNA elongation is performed by the phage and independent of the host 
replication machinery.  
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For the three phages the majority of genes are found rightward orientated (57.8 %, 
59.6 % and 57.6 %, for DL52, DL60 and DL68, respectively), while the others are 
leftward orientated (42.2 %, 40.4 % and 42.4 %, for DL52, DL60 and DL68, 
respectively).  
The genome size observed for the Podoviridae phages DL54 and DL62 was similar, 
comprising 45,673 bp and 42,508 bp, respectively. Phage DL64 genome was much 
larger comprising 72,378 bp (Figure 3.14). A comparison between the nucleotide 
sequence of DL54, DL62 and DL64 showed no similarities shared between them. DL54 
show share strong similarities (>98 %) with other lytic Podoviridae infecting P. 
aeruginosa, such as phiIBB-PAA2 and LUZ24 (264, 265). Phage LUZ24 has two tRNA 
genes present in its genome, however for DL54 tRNA genes were not observed in the 
genome sequence (265). It is possible to recognise a conserved coding region 
responsible for phage assembly (large subunit of the terminase and upstream of the 
portal, capsid and scaffolding protein genes) and a region for DNA metabolism 
similarly, where the DNA polymerase was fragmented into three parts by an 
endonuclease gene, as observed for phage LUZ24 (265). The DNA primase/helicase 
gene can also be found in the middle of the DNA polymerase. The two main modules 
are separated by several potential coding genes for phage proteins with unknown 
roles. The majority of genes, 50 (70.4 %), are found in the leftward orientated strand, 
and 21 (29.6 %) are found in the opposite strand. 
The search using the BLASTN algorithm in the NCBI database showed that phage 
DL62 is closely related to phiKMV-like phages (>95 %), such as phiKMV and LUZ19 
(266, 267) and these phages are grouped into the T7-like phages genus in the 
subfamily of the Autographivirinae. Genomes of T7-types have been previously 
sequenced for phages of Klebsiella pneumonia for example (268), where genes are 
arranged into three clusters: early genes (cluster I), DNA metabolism (class II) and 
structural proteins for phage assembly and for host lysis (class III) (266). Such genome 
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organisation is easily observed for phage DL62. However, differences can be found, 
such as the RNA polymerase that in T7-like phages is present in the cluster I of early 
genes and both in DL62 and phiKMV phages is present within the class II cluster. 
Typically there is the presence in the genome of a gene pairing lysin-holin in order to 
breakdown the bacterial cell. Phage DL62 carries a lysin (ORF51) found within cluster 
III, possibly with muraminidase activity, and the position and small size (66 residues) of 
ORF52 might code for the holin (269, 270). Like phiKMV (266), phage DL62 has a 
higher G+C % content (62.2 %) when in comparison to the other phages of the 
cocktail, being close to the G+C % content of the bacterial host (65 %) (271) and in 
accordance with the homologue phiKMV phage (272). Genes were all found in the 
forward strand, but the first gene is located in the reverse strand. 
Lastly phage DL64 showed a unique genome sequence. The most striking feature of 
the genome is the presence of two genes (ORF41 and ORF42) homologous to rIIA-like 
and rIIB-like proteins from phage N4 that, although not yet clear, might play a role in 
the phenomenon of lysis inhibition and in other functions, such as interference in cell 
metabolism (273). Lysis inhibition is defined as a delay of the phage in producing the 
enzyme holin while phage particles are being produced resulting in their accumulation 
inside the host. Phage DL64 genome can be grouped in the N4-like phages, such as 
LIT1 (98 %) and LUZ7 (73 %) that have been previously sequenced (274) and many 
others on which work has not yet been published. N4-like phages use three distinct 
RNA polymerases during their lytic infection cycle: a giant virion-encapsulated RNA 
polymerase that is co-injected with the phage genome into the host upon infection, a 
heterodimeric phage RNA polymerase transcribed from the middle region and a DNA-
binding protein that is able to arrest the host RNA polymerase to transcribe late phage 
proteins (275). Although, the BLAST search in the database only predicted one RNA 
polymerase, we can presume that ORF15 might code for the giant RNA polymerase, 
as it is positioned in the early gene regions and its large size (3398 residues). 
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It is suggested that the DNA-binding protein coding gene might be ORF66 positioned 
strictly upstream of the predicted RNA polymerase 1 (ORF67) with 88 residues. N4 
phage codes for three tRNAs, however no tRNAs were predicted for phage DL64 and 
phages LUZ7 and LIT1 (274). No potential coding gene was predicted for the lytic 
enzyme for DL64, but also for LUZ7 and LIT1, and it is suggested that these phages 
might code for a novel type of endolysin or execute a different lysis mechanism (274). 
A DNA polymerase I and DNA helicase and primase are included in the genome of 
phage DL64, suggesting a host independency for DNA replication. The genome 
organisation seems to be divided into two large clusters positioned on different strands 
and in their middle two small clusters are present which are transcribed from opposite 
directions. This can also be observed for phages LUZ7 and LIT1 (274). Hence, the first 
larger cluster includes transcription, DNA replication and lysis inhibition, a first small 
cluster that comprises a DNA primase, a second small cluster for structural proteins 
followed by the second large cluster for DNA package. The great majority of the genes, 
70 (77.8 %), are found in the leftward strand, and the other 20 genes (22.2 %) in the 
opposite strand. 
 











Gene Density (genes 
per kb) 
Coding% 
DL52 Myoviridae 65,867 90 54.9 1.366 89.7 
DL54 Podoviridae 45,673 71 52.4 1.554 92.4 
DL60 Myoviridae 66,103 89 54.9 1.346 89.8 
DL62 Podoviridae 42,508 55 62.2 1.293 94.4 
DL64 Podoviridae 72,378 90 55.0 1.243 92.5 
DL68 Myoviridae 66,111 92 55.7 1.391 91.6 
 
The gene coding potential of these phages ranges from 1.243 to 1.391 genes per kb. 
Phage DL54 stands out from the other phages exhibiting the highest gene density of 
1.554 genes per kb. Although for the great majority of potential coding regions (more 
than 60 % for all cases) no known function has yet been found. The six DNA 
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sequences were searched for the presence of antimicrobial resistance genes and for 
any known virulence factors using the BLASTN algorithm (250). The antibiotic 
resistance genes search was focused on the main antibiotic classes (Table 3.4). The 
virulence genes search was performed against known virulence factors found in E. coli, 
Enterococcus spp and S. aureus. Results from this search revealed that all six phages 
do not carry any potential genes coding for known antibiotic resistance or virulence 
factors. The genomic sequences of the six phages are deposited in the NCBI GenBank 
database under accession numbers KR054028-KR054033. 
 
  




The work of this chapter resulted in the isolation and characterisation of two groups of 
lytic bacteriophages against two of the main bacterial targets involved in serious and 
common infectious diseases. Therefore, 21 phages infecting S. aureus clinical isolates 
and another group of 17 phages infecting P. aeruginosa clinical isolates were isolated. 
Such isolation and initial characterisation was indispensable for the selection, 
establishment and further characterisation of broad phage cocktails targeting each one 
of the different clinical isolates. For both cases, phages were easily isolated from 
environmental samples enriched with selected strains.  
Plaques produced by the isolated S. aureus phages were generally small and halos, if 
present, were difficult to visualise. On the other hand the average size of plaques 
produced by P. aeruginosa phages was greater and halos could be easily observed. 
This plaque morphology difference could be related to some intrinsic characteristics of 
phage diffusion, the permeability of the agar and the time spent by the phage when 
infecting a host bacteria (276). The presence of halos surrounding the clear plaque 
spot is a good indication that the phage can be efficient in dispersing biofilms, as they  
are caused by the diffusion of enzymatic molecules, perhaps EPS depolymerases, 
produced by the phage. These proteins are then much smaller than a whole phage, 
hence diffusing at a higher rate into the bacterial lawn and causing the degradation of 
bacterial produced polymers. Plaque assays are extremely valuable as a first selection 
method, as we can identify phages that produce a lysogenic cycle or that are not 
efficient in adsorbing to the host cells. It also indicates phages producing biofilm matrix 
degrading enzymes and evaluates if the phage lysate contains more than one phage 
type (277). The latter feature was useful when trying to obtain a pure lysate of the S. 
aureus phages DRA88 and DRA288. When using a host harbouring prophages it was 
noticed that plaque assays were resulting in heterogeneous plaque morphologies as 
well as TEM analysis of the lysate, where Siphoviridae particles could be observed. 
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The majority of prophages found in the S. aureus host have been identified as 
belonging to the Siphoviridae family (278). Hence, it can be suggested that some 
prophage was being excised by the host chromosome. It is important to be aware of 
prophage induction that is an event, even when growing bacteria per se, likely to 
happen and even if occurring at low frequencies, for example prophage excision has 
been documented during the course of a chronic lung infection in CF patients (279). 
Such induction can be caused by external stress factors or be triggered in a 
spontaneous way (280). One might think that is a minor issue, however if considered 
for therapeutic uses, a scale-up of all the manufacturing process will take place causing 
the amount of induced prophages to drastically increase, then the implications are 
significant. If we take into consideration that prophages are strongly related to the 
horizontal transfer of many virulent genes, such as genes for enterotoxin A (281), the 
Panton-Valentine leucocidin (282) or the shiga-toxin (283) and that obviously has been 
contributing to bacterial population evolution, then phage therapeutics should be 
carefully designed. Firstly, bacterial hosts should be free of prophages, eliminating the 
possibility to have excised temperate prophages within the therapeutic lysate. This can 
be achieved by genetically modifying the host’s chromosome or by using a “surrogate” 
strain for phage propagation. The last one has been described where phages targeting 
S. aureus were propagated in a food-grade bacteria, S. xylosus (284). Secondly, the 
bacteria to be targeted in the clinical site most likely will carry several prophages in 
their chromosomes able to be induced and released into the surrounding environment 
and have a role in the introduction or increase of their pathogenicity. This could be 
worrying and could be the opening of Pandora’s Box. Hence, phages used for 
therapeutics should be highly virulent, proliferating and killing the bacterial hosts before 
any prophage has time to excise and assemble. This has however already been 
observed by the use of antibiotics in animal feed (285), hence being able to prevent 
such phenomenon would bring great leverage for the safe use of bacteriophages in the 
clinic. Another event of concern which is related to phage, most particularly in the case 
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of S. aureus bacteria, is the occurrence in their genome of S. aureus pathogenicity 
islands (SaPIs). SaPIs are responsible for carrying genes coding for superantigens: 
causing superantigen-induced diseases, such as toxic shock syndrome (TSS). These 
SaPIs are genetic elements mobilised between bacteria populations by means of a 
phage (also called helper-phages). Phages described so far as SaPI helper-phages all 
belong to the Siphoviridae family (286, 287). Hence, a potential way to avoid such 
events to occur is the avoidance of phages sharing the morphology of the Siphoviridae 
family. 
The composition of the phage cocktails was based on the best combination possible to 
achieve the broadest host range infectivity. The combined host range infectivity of the 
S. aureus cocktail was 73.7 % when assessed against a genetically diverse collection 
of S. aureus isolates. Such broad infectivity range was due to the polyvalent 
performance of both DRA88 and its close related phage K. Phage K is a well-known 
staphylococcal phage that most likely was first isolated by André Gratia almost 100 
years ago (288), the phage attaches specifically to the cell wall teichoic acid (289), 
providing a broad spectrum host range and it can be assumed that phage DRA88, 
given its similarities with phage K and its wide host range, might use the same cell wall 
receptor. Based on TEM analysis and like phage K, DRA88 belongs to the Myoviridae 
tailed-phage family. Adsorption experiments showed that both phages attach to cells in 
a rapid and similar fashion, which is in accordance with several S. aureus-infecting 
Myoviridae phages (290, 291). 
The phage cocktail targeting P. aeruginosa isolates was composed of a larger number 
of phages, six in total and as single phages that were not shown to be polyvalent, at 
least, with regards to the bacterial collection assessed. It is known that P. aeruginosa 
bacterial cells related to a inherited hypermutability behaviour, for example, causing 
strains to be highly diverse in their gene content (292). The phage bacterial receptor 
used by the phages might not be highly conserved and then be subject to more 
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fluctuation. Usually phages targeting gram-negative bacteria use either an outer 
membrane protein, such as a porin, or a sugar moiety of the lipopolysaccharide (LPS) 
(293). It is documented that PB1-like phages use the LPS to attach to the cell, giving to 
these phages a wide infectivity range. However, only DL68 was observed to be 
polyvalent, DL52 and DL60 showed narrow host ranges and this might suggest that 
even using the LPS for bacterial recognition and initial attachment these phages might 
require a second surface component for the establishment of an irreversible 
adsorption, a process observed for several other phages (294) and could explain the 
narrow host range. Hence, a combination of several phages isolated was made in 
order to give the best and broadest host coverage range, resulting in infection of 82 % 
of the isolates tested. TEM analysis revealed two types of morphology, DLA52, DL60 
and DL68 belong to the Myoviridae family and DL54, DL62 and DL64 belong to the 
Podoviridae family. 
An interesting observation for phage DRA88, but also phages DL54 and DL60 was the 
possible formation of phage aggregates. Phage aggregation is observed occasionally 
in nature (295, 296) and is dependent on pH, ionic strength, and the composition of 
ions. Such phenomena could have been influenced by uranyl acetate (pH 4) used to 
stain the phages for TEM observation. DLS measurements for DRA88 (in dH2O, ~pH 
7) were unsuccessful, possibly due to the several sizes found in the sample (singles 
and multiple aggregates); hence, we suspect that phage DRA88 is prone to forming 
aggregates. When phage interacts with bacterial cells, aggregation could impede 
phage access to the cells and hence decrease the rate of adsorption. Phage 
aggregation can be inhibited by optimisation of growth medium composition or by 
stabilising in nano-emulsions, resulting in phages that more efficiently attach to 
bacterial cells (297–299); consequently, this could affect estimation of the PFU, which 
then may not directly correspond with the number of infective particles (MOI). 
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At the genome level, DRA88 was revealed to be a large double stranded DNA (dsDNA) 
phage, usually a common characteristic of Myoviridae staphylococcal phages (257), 
carrying a high gene density and low G+C % content. DRA88 genome exhibits a high 
degree of relatedness to several other phages belonging to the Twort-like group, 
including phage K. Regarding P. aeruginosa phages, all phages were revealed to have 
medium length dsDNA genomes. Phages in this study shared similarities with 
previously sequenced phages and it was possible to identify four distinct groups of 
phages within the cocktail: PB1-like, LUZ24-like, phiKMV-like and N4-like phages, 
which have been considered ideal for use in phage therapy and some of them can be 
found in commercial mixtures already (300), such as the “pyophage” from the Eliava 
Institute (301). DL52, DL60 and DL68 were shown to be homologues of each other and 
several other phages belonging to the PB1-like group of phages, which used for in vivo 
therapy assays has been proved successful in a keratitis mice model for a member of 
this group (261). DL62 phage was revealed to be the smallest genome comprising of 
potential coding regions showing a high degree of relatedness with phages of the 
phage group phiKMV-like, where recently a member of this group was assessed for in 
vivo therapy against hemorrhagic pneumonia in a mink model (302). 
Interestingly, phage DL68 appears to carry the rIIA/rIIB lysis inhibition cassette, in fact 
widely distributed among genomes of phages infecting different host genera (303, 304), 
which enables a delay in the host lysis, but consequently results in a high increase in 
the burst size of the phage. This feature provides phages of this type with a competitive 
advantage over others. It should be important if this type of phage is integrated within a 
therapeutic cocktail product to always perform its propagation separately; otherwise 
such a phage might take over the phage population. However, the role of such a 
cassette remains uncertain and several additional roles have been attributed to it, such 
as being involved in the host resistance mechanism of the abortive infection system 
(305). 
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No virulence or antibiotic resistance factors were identified in the genome, according to 
the data available at the moment, suggesting that either S. aureus or P. aeruginosa 
phage preparations could be safely used to treat infections related to these bacteria. 
However,  the majority of putative coding regions of the DRA88 genome and for the P. 
aeruginosa phages do not have any function attributed yet, which is generally applies 
to the several phages being sequenced at the moment (306). Consequently, there is an 
urgent need for a more comprehensive investigation of phage genomes in order to 
understand phage gene products. Considering phage therapy as a therapeutic 
approach option, it is extremely important that we expand our knowledge regarding 
phage genes and proteins and their respective functions and potentialities, as they can 
be involved in phage-host interaction and even code for novel virulence determinants 
(307). 
Phage therapy has been developing recently under small carefully controlled steps, in 
contrast to the scenario observed early in the century, where the misinformation on 
phage nature led many clinical trials to unsuccessful outcomes. Still, there are 
numerous technical opportunities to improve and understand the phage therapy 
product, such as phage selection criteria, the standards for phage purity and the recent 













Table 3.13: General features of putative ORFs from S. aureus phage DRA88 with best matches 














1 20 358 - 339 Phage protein 99 2E-70 YP_007002124 
2 852 977 + 126 Phage protein 95 3E-03 YP_007002125 
3 1183 1467 + 285 Phage protein 96 8E-60 YP_241032 
4 1542 1733 + 192 Phage protein 100 6E-37 YP_241033 
5 2064 2552 - 489 
HNH homing endonuclease # Phage 
intron 
94 5E-91 YP_241035 
6 2950 3081 + 132 Phage protein 98 4E-20 YP_007112858 
7 3670 4071 + 402 Hypothetical protein 94 1E-72 YP_007112856 
8 4568 4789 + 222 Hypothetical protein 99 2E-44 YP_007112855 
9 5049 5213 + 165 Hypothetical protein 100 4E-29 YP_007112853 
10 5770 6120 + 351 Hypothetical protein 31 2E-06 YP_004301348 
11 6189 6353 + 165 Hypothetical protein 42 1E-04 YP_001504239 
12 6366 6539 + 174 Phage protein 93 9E-28 YP_007002137 
13 6683 6808 + 126 Phage protein 93 8E-18 YP_007002138 
14 6910 7077 + 168 Hypothetical protein 37 2 YP_007112846 
15 7370 8818 + 1449 Hypothetical protein 48 6E-21 WP_016279792 
16 8837 9127 - 291 Hypothetical protein 83 3E-54 YP_007002140 
17 9328 11421 - 2094 Tail fiber protein 71 6E-61 WP_019168862 
18 11463 11699 - 237 Phage protein 82 4E-40 YP_007002141 




20 11960 12205 - 246 Phage protein 94 1E-43 YP_007002145 
21 12393 12878 - 486 Phage protein 94 1E-77 AEJ79651 
22 12871 13311 - 441 Phage protein 94 6E-85 YP_007002150 
23 13325 13867 - 543 Phage protein 100 4E-113 YP_007002151 




25 14382 14834 - 453 Hypothetical protein 43 2E-02 WP_016184223 
26 14851 15255 - 405 Phage protein 99 2E-81 YP_007002153 
27 15258 15959 - 702 Hypothetical protein 99 2E-166 YP_008853985 
28 16748 17296 - 549 Phage protein 100 2E-98 YP_024439 
29 17300 17518 - 219 Phage protein 100 3E-43 YP_241058 
30 17519 17713 - 195 Phage protein 98 5E-37 YP_241059 
31 17703 18440 - 738 Phage protein 99 2E-161 YP_007112830 
32 18629 18856 - 228 Phage protein 90 4E-40 YP_007002161 
33 18858 19247 - 390 Phage protein 100 7E-90 YP_007002162 
34 19341 19514 - 174 Phage protein 100 8E-34 YP_007002163 
35 19555 20037 - 483 Phage protein 98 2E-107 YP_007002164 
36 20087 20629 - 543 Phage protein 94 2E-114 YP_007002165 
37 20629 21159 - 531 Phage protein 98 1E-110 YP_007002166 
38 21162 21326 - 165 Phage protein 100 7E-29 YP_007002167 
39 21329 21616 - 288 Phage protein 49 2E+00 YP_007002168 
40 21616 22461 - 846 Phage protein 98 0 YP_007002169 
41 22474 23592 - 1119 Phage protein 98 0 YP_241071 
42 23745 23960 - 216 Phage protein 96 1E-41 YP_007002171 
43 24064 24480 - 417 Phage protein 99 4E-83 YP_007002172 
44 24612 24914 - 303 Phage DNA-binding protein 100 6E-64 YP_024448 
45 24914 25102 - 189 Phage protein 100 2E-34 YP_007002174 
46 25146 25307 - 162 Phage protein 100 3E-29 YP_241076 
47 25307 27358 - 2052 Phage protein 100 0 YP_007002176 
48 27438 27701 - 264 Phage protein 99 9E-54 YP_007002177 
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49 27718 27891 - 174 Phage protein 100 8E-32 YP_007112812 
50 27898 28476 - 579 Phage protein 100 1E-111 YP_007112811 
51 28469 29062 - 594 Phage protein 82 6E-111 YP_007112810 
52 29055 29951 - 897 Phage protein 100 0 YP_007112809 
53 29951 30175 - 225 hypothetical protein 100 8E-17 YP_007112808 
54 30244 30984 - 741 
Phosphate starvation-inducible protein 
PhoH,predicted ATPase 
100 0 YP_024453 
55 31036 31650 - 615 Phage protein 100 4E-143 YP_024454 
56 31666 32091 - 426 Phage ribonuclease H 100 3E-94 YP_024455 
57 32081 32272 - 192 Phage protein 100 3E-37 YP_241086 
58 32295 32936 - 642 Phage protein 100 5E-123 YP_024456 
59 32926 33156 - 231 Phage protein 100 1E-46 YP_241088 
60 33159 33386 - 228 hypothetical protein 100 8E-45 YP_241089 
61 33501 34193 - 693 hypothetical protein 99 2E-141 YP_024457 
62 34391 35185 - 795 Phage protein 100 6E-178 YP_007112798 
63 35185 35493 - 309 Phage protein 99 2E-64 YP_007002193 
64 35607 36227 - 621 Phage protein 61 5E-41 YP_024458 
65 36290 37780 - 1491 
Phage lysin, N-acetylmuramoyl-L-
alanine amidase 
100 0 YP_024461 
66 37780 38283 - 504 Phage holin 100 5E-116 YP_007112795 
67 38368 38553 - 186 Phage protein 100 1E-33 YP_241098 
68 40100 40318 - 219 Phage protein 100 4E-30 YP_241099 
69 40796 41005 - 210 hypothetical protein 100 2E-42 YP_241100 
70 41018 41350 - 333 Phage protein 100 10E-59 YP_007002199 
71 41363 41689 - 327 Phage protein 100 7E-71 YP_007002200 
72 42249 42515 + 267 Phage protein 100 3E-41 AFV80863 
73 42493 42771 + 279 Phage protein 100 2E-60 YP_241104 
74 42768 43178 + 411 Phage protein 100 2E-91 YP_241105 
75 43193 43546 + 354 Phage terminase, large subunit 100 2E-76 YP_024465 
76 43784 44554 + 771 Phage protein 95 2E-142 YP_007677505 
77 44621 46081 + 1461 Phage terminase, large subunit 100 0 AFN38730 
78 46095 46895 + 801 Phage protein 99 6E-165 YP_007002206 
79 46882 47055 + 174 Phage protein 97 5E-16 YP_240894 
80 47052 47531 + 480 Phage protein 100 7E-98 YP_024467 
81 47648 48775 + 1128 hypothetical protein 100 3E-140 YP_007112782 
82 49013 49201 + 189 Phage protein 100 1E-17 YP_007002210 
83 49219 49590 + 372 Phage protein 100 5E-72 YP_024470 
84 49594 51285 + 1692 Phage protein 100 0 YP_007002212 
85 51479 52252 + 774 Phage protein 100 0 YP_024472 
86 52271 53230 + 960 Phage protein 98 3E-137 YP_007002214 
87 53346 54737 + 1392 Phage major capsid protein 100 0 YP_007002215 
88 54829 55125 + 297 Phage protein 100 8E-26 YP_007002216 
89 55138 56046 + 909 Phage protein 100 0 YP_024475 
90 56060 56938 + 879 Phage protein 100 0 YP_007002218 




92 57577 58413 + 837 Phage protein 100 0 YP_024478 
93 58415 58630 + 216 Phage protein 100 2E-45 YP_240909 
94 58657 60420 + 1764 hypothetical protein 99 0 ABL87117 
95 60493 60921 + 429 Phage protein 100 1E-99 YP_024480 
96 61008 61148 + 141 Phage protein 100 8E-23 YP_007112766 
97 61191 61643 + 453 Phage protein 93 2E-97 YP_007002226 
98 61866 62018 + 153 hypothetical protein 29 2 WP_007845149 
99 62086 62397 + 312 Phage protein 100 6E-66 YP_007002227 
100 62529 62987 + 459 Phage protein 99 2E-104 YP_007002228 
101 63031 63567 + 537 Phage protein 100 6E-124 YP_024484 
102 63623 67678 + 4056 Hypothetical protein 99 0 YP_007002230 
103 67757 70183 + 2427 Hypothetical protein 100 0 YP_007112760 
104 70197 71084 + 888 Phage protein 99 0 YP_007002232 
105 71084 73630 + 2547 
Glycerophosphoryl diester 
phosphodiesterase 
99 0 YP_007112758 
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106 73737 74528 + 792 Phage protein 100 0 YP_024489 
107 74528 75052 + 525 Phage protein 100 3E-121 YP_240925 
108 75052 75756 + 705 Phage protein 100 5E-171 YP_024491 
109 75771 76817 + 1047 Phage baseplate 100 0 YP_024492 
110 76838 79903 + 3066 Phage protein 89 0 YP_007112753 
111 80014 80535 + 522 hypothetical protein 100 4E-122 YP_024494 
112 80557 84015 + 3459 hypothetical protein 100 0 YP_007112751 
113 84064 84222 + 159 Phage protein 87 2E-22 YP_240931 
114 84223 86154 + 1932 Phage capsid and scaffold 71 0 ACB89087 
115 86168 86542 + 375 Phage protein 83 2E-69 YP_024497 
116 86549 87925 + 1377 Phage capsid and scaffold 97 0 YP_007112747 
117 88015 89763 + 1749 DNA helicase, phage-associated 98 0 YP_024499 
118 89775 91388 + 1614 Phage protein 99 0 YP_007002246 
119 91381 92823 + 1443 DNA helicase, phage-associated 99 0 YP_024501 
120 92902 93927 + 1026 Phage recombination exonuclease 96 0 YP_007002248 
121 93927 94304 + 378 Phage protein 93 3E-80 YP_024503 
122 94304 96223 + 1920 Hypothetical protein 96 0 YP_024504 
123 96223 96819 + 597 Phage protein 98 5E-140 YP_007112958 
124 96834 97901 + 1068 
DNA primase / DNA helicase 
3.6.1.-), phage-associated 
99 0 YP_024506 
125 97967 98305 + 339 Phage protein 98 6E-48 YP_240943 
126 98305 98757 + 453 Phage protein 95 7E-81 YP_007002254 
127 98744 99352 + 609 Phage protein 100 8E-147 YP_240945 
128 99369 99761 + 393 Ribonucleotide reduction protein NrdI 99 9E-88 YP_007002257 
129 99776 101890 + 2115 
Ribonucleotide reductase of class Ib 
(aerobic),alpha subunit (EC 1.17.4.1) 
99 0 YP_007002258 
130 101904 102953 + 1050 
Ribonucleotide reductase of class Ib 
(aerobic),beta subunit (EC 1.17.4.1) 
99 0 YP_007112951 
131 102971 103300 + 330 Phage protein 98 5E-71 YP_007112950 
132 103284 103604 + 321 Phage oxidoreductase 100 3E-68 YP_024513 
133 103811 104407 + 597 Phage protein 100 2E-140 YP_007002262 
134 104417 104722 + 306 Phage integration host factor 99 1E-65 YP_024515 
135 104798 107029 + 2232 DNA polymerase I 100 0 YP_007002264 
136 107195 108004 + 810 HNH homing endonuclease 100 0 YP_024518 
137 108238 109098 + 861 DNA polymerase I 100 0 YP_240958 
138 109167 109409 + 243 Phage protein 98 5E-33 YP_240959 
139 109426 109908 + 483 Phage protein 100 1E-114 YP_024519 
140 109995 111266 + 1272 Phage protein 99 0 YP_024520 
141 111326 112582 + 1257 Phage recombinase 100 0 YP_024521 
142 112586 112939 + 354 Phage protein 100 2E-65 YP_240963 




144 113715 114347 + 633 Phage protein 100 2E-149 YP_024523 
145 114371 114883 + 513 Phage major tail protein 99 5E-113 YP_007002272 
146 114898 115107 + 210 Phage major tail protein 99 2E-39 YP_240967 
147 115220 115480 + 261 Phage protein 100 8E-55 YP_007002274 
148 115484 116239 + 756 Phage protein 99 2E-162 YP_024525 
149 116232 117482 + 1251 Phage protein 100 0 YP_007002276 
150 117496 117864 + 369 Phage protein 99 3E-71 YP_007112931 
151 117851 118162 + 312 Phage protein 100 6E-68 YP_024528 
152 118226 118762 + 537 Phage protein 99 2E-116 YP_007002279 
153 118755 119522 + 768 Phage protein 100 0 YP_024529 
154 119500 119946 + 447 Phage protein 100 1E-102 YP_024530 
155 119946 120809 + 864 Phage protein 99 0 YP_240976 
156 121181 121912 + 732 Phage protein 100 1E-172 YP_024531 
157 121930 122388 + 459 Phage protein 100 2E-105 YP_007002284 
158 122453 122896 + 444 Phage protein 100 7E-90 YP_024533 
159 122913 123617 + 705 Phage protein 98 2E-164 YP_007002286 
160 123680 124078 + 399 Phage protein 100 7E-80 YP_007002287 
161 124225 124467 + 243 Phage protein 96 5E-47 YP_240982 
162 124472 125029 + 558 Phage protein 100 5E-129 YP_007112919 
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163 125065 125241 + 177 Phage protein 100 2E-32 YP_240984 
164 125234 125482 + 249 Hypothetical protein 95 2E-46 YP_007112917 
165 125496 125708 + 213 Hypothetical protein 99 2E-41 YP_007002292 
166 125789 126433 + 645 Hypothetical protein 97 8E-112 YP_007002293 
167 126449 126697 + 249 Hypothetical protein 95 4E-27 YP_007002294 
168 126709 126885 + 177 Phage protein 100 2E-31 AFN38398 
169 126878 127174 + 297 Phage protein 98 1E-61 YP_007002295 
170 127222 127404 + 183 Phage protein 98 2E-32 YP_240988 
171 127417 127785 + 369 Phage protein 99 6E-69 YP_007002297 
172 127798 128145 + 348 Phage protein 99 3E-76 YP_007002298 
173 128493 128798 + 306 Phage protein 88 7E-61 YP_007002300 
174 128813 129163 + 351 Phage protein 97 6E-74 YP_240993 
175 129163 129765 + 603 Phage protein 96 2E-138 YP_240994 
176 129784 129972 + 189 Phage protein 85 2E-20 YP_007002303 
177 129977 131029 + 1053 Phage protein 58 6E-52 WP_002508231 
178 131026 131202 - 177 Hypothetical protein - -  not available 
179 131329 131487 + 159 Phage protein 89 4E-12 YP_007002320 
180 131503 131727 + 225 hypothetical protein 96 4E-44 YP_007002321 
181 131740 131940 + 201 Phage protein 98 3E-40 YP_241008 
182 131941 132231 + 291 Phage protein 100 5E-59 YP_007002323 
183 132324 132617 + 294 Phage protein 100 9E-64 YP_007002324 
184 132614 133522 + 909 Ribose-phosphate pyrophosphokinase 84 7E-180 YP_024538 
185 133540 135009 + 1470 Nicotinamide phosphoribosyltransferase 97 0 ACB89165 
186 135088 135333 + 246 Phage protein 99 7E-51 YP_241013 
187 135353 135745 + 393 Phage protein 94 3E-79 YP_007002328 
188 135747 135944 + 198 Phage protein 98 6E-36 YP_007002329 
189 136010 136321 + 312 Phage protein 97 2E-52 YP_241016 
190 136324 136833 + 510 Phage protein 98 2E-115 YP_241017 
191 136835 137173 + 339 Phage protein 84 9E-61 YP_007002334 
192 137170 137286 + 117 Hypothetical protein - - not available 
193 137300 137701 + 402 Phage protein 57 2E-44 YP_024544 
194 137300 138142 + 843 Hypothetical protein 36 2E+00 WP_017622020 
195 138245 138469 + 225 Hypothetical protein - - not available 
196 139106 139254 + 149 Hypothetical protein 36 5E+00 WP_022070173 
197 139308 139601 + 294 Hypothetical protein 49 7E-09 ACB89175 
198 139598 139783 + 186 Hypothetical protein 49 4E-05 YP_241023 
199 140019 140183 + 165 Phage protein 89 2E-24 ACB89176 
200 140183 140470 + 288 Phage protein 96 3E-59 YP_241025 
201 140470 140763 + 294 Phage protein 96 5E-61 ACB89178 
202 140767 141024 + 258 Phage protein 100 1E-45 YP_241027 
203 141132 141371 + 240 Phage protein 96 6E-47 ACB89180 
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Table 3.14: General features of putative ORFs from P. aeruginosa phage DL52 with best 














1 65 466 + 402 Phage protein 96 8E-87 YP_001294433 
2 498 821 + 324 Phage protein 100 3E-74 YP_001294432 
3 818 1021 + 204 Phage protein 100 1E-30 YP_009009036 
4 1027 1338 + 312 Phage protein 96 7E-64 YP_002154157 
5 1587 1934 + 348 Phage protein 97 1E-74 YP_001294430 
6 2038 2970 + 933 Phage protein 99 0 YP_002455942 
7 3072 3659 + 588 Phage protein 99 3E-142 YP_009009031 
8 3677 4114 + 438 Phage protein 97 3E-81 YP_001294427 
9 4200 4979 + 780 Phage protein 100 0 YP_001294426 
10 4982 5383 + 402 Phage protein 90 9E-71 YP_001294425 
11 5428 5778 + 351 Phage protein 99 7E-66 YP_001294424 
12 5778 5996 + 219 Phage protein 100 5E-45 YP_001294423 
13 5993 6376 + 384 Phage protein 98 3E-65 YP_001294422 
14 6414 7796 - 1383 Phage terminase, large subunit 100 0 YP_001294421 
15 7998 8186 + 189 Phage protein 98 1E-22 YP_001294420 
16 8307 8453 + 147 Phage protein 100 9E-12 YP_001294419 
17 8465 8767 + 303 Phage protein 95 3E-60 YP_001294418 
18 8814 9731 + 918 Phage tail length tape-measure protein 99 6E-123 YP_002456023 
19 9734 9922 + 189 Phage protein 97 4E-38 YP_001294508 
20 10002 10187 + 186 Phage protein 98 3E-34 YP_001294507 
21 10312 10512 + 201 Phage protein 98 3E-39 YP_001294505 
22 10509 10724 + 216 Phage protein 99 8E-42 YP_001294504 
23 10721 10924 + 204 Phage protein 61 6E-18 YP_001294503 
24 10908 11120 + 213 Phage protein 90 1E-40 YP_001294502 
25 11149 11796 + 648 Phage protein 93 2E-135 YP_001294501 
26 11940 12098 - 159 hypothetical protein - - not available 
27 12185 12409 + 225 Phage protein 93 1E-42 YP_002154315 
28 12465 12692 + 228 Phage protein 75 4E-32 YP_006200849 
29 12702 12923 + 222 Phage protein 81 2E-33 YP_007002628 
30 12971 13288 + 318 Phage protein 93 5E-69 YP_002456011 
31 13298 13906 + 609 Phage protein 91 2E-106 YP_002456010 
32 14098 14712 + 615 Phage protein 99 7E-92 YP_002154310 
33 14880 15452 - 573 Phage protein 98 1E-119 YP_001294493 
34 16425 18164 - 1740 DNA primase, phage associated 99 0 YP_002456007 
35 18312 18497 - 186 Phage protein 100 6E-14 YP_001294490 
36 18503 19579 - 1077 Phage protein 99 0 YP_002364381 
37 19576 20025 - 450 Phage protein 97 2E-102 YP_007238225 
38 20025 20579 - 555 Phage protein 91 3E-29 WP_023104124 
39 20999 21784 - 786 Phage protein 99 1E-180 YP_002456002 
40 21952 22374 + 423 Phage protein 99 2E-96 YP_002456001 
41 22361 23548 + 1188 DNA helicase, phage-associated 99 0 YP_002456000 
42 23710 24600 + 891 Phage protein 100 2E-68 YP_002154209 
43 24705 25706 + 1002 Phage protein 99 0 YP_002455998 
44 25796 26026 + 231 Phage protein 97 1E-35 YP_002455997 
45 26026 26244 + 219 Phage protein 97 2E-30 YP_002154206 
46 26228 26446 + 219 Phage tail assembly 97 2E-44 YP_001294479 
47 26446 26706 + 261 Phage protein 94 2E-50 YP_002455994 
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48 26718 26924 + 207 Phage protein 96 6E-39 YP_001294477 
49 26924 27841 + 918 Thymidylate synthase thyX 100 0 YP_001294476 
50 27843 28034 + 192 Phage protein 100 4E-35 YP_001294475 
51 28037 29077 + 1041 
3'-phosphatase, 5'-polynucleotide 
kinase, phage-associated 
94 0E+00 YP_002455989 
52 29153 29707 + 555 Phage protein 99 1E-132 YP_001294473 
53 29707 32814 + 3108 DNA polymerase III alpha subunit 99 0 YP_002455987 
54 32807 33217 + 411 Phage protein 100 3E-81 YP_001294471 
55 33214 34773 + 1560 DNA helicase, phage-associated 99 0 YP_001294470 
56 34868 35488 + 621 Phage protein 100 3E-120 YP_002154195 
57 35577 36476 + 900 Phage protein 100 0 YP_002154194 
58 36533 37138 + 606 Phage protein 100 2E-100 YP_001294467 
59 37135 37689 + 555 Phage DNA-binding protein 98 1E-128 YP_002154192 
60 37744 38655 + 912 DNA ligase, phage-associated 96 0 YP_002154191 
61 38935 39186 + 252 Phage protein - - not available 
62 39210 39872 - 663 Lytic enzyme - - not available 
63 39872 40300 - 429 Phage protein - - not available 
64 40302 43196 - 2895 Phage tail fibers - - not available 
65 43201 44715 - 1515 Phage protein - - not available 
66 44712 45965 - 1254 Phage protein - - not available 
67 46022 46453 - 432 Phage baseplate - - not available 
68 46433 46666 - 234 hypothetical protein - - not available 
69 46743 47276 - 534 Phage protein - - not available 
70 47276 48139 - 864 Phage protein - - not available 
71 48139 50721 - 2583 Phage internal (core) protein - - not available 
72 50725 51153 - 429 Phage protein - - not available 
73 51163 51756 - 594 Phage tail fiber protein - - not available 
74 51765 52169 - 405 Phage protein - - not available 
75 52304 52807 - 504 Phage protein - - not available 
76 52817 53245 - 429 Phage protein - - not available 
77 53594 53917 - 324 Phage protein - - not available 
78 53917 54369 - 453 Phage tail fiber protein - - not available 
79 54427 55941 - 1515 Phage protein - - not available 
80 56536 57087 - 552 Phage protein - - not available 
81 57095 57493 - 399 Phage protein 95 2E-85 YP_001294443 
82 57490 57957 - 468 Phage protein 99 6E-76 YP_001294442 
83 57972 58409 - 438 Phage protein 100 4E-103 YP_001294441 
84 58511 59659 - 1149 Phage capsid and scaffold 99 0E+00 YP_002455954 
85 59669 60304 - 636 Phage protein 100 2E-145 YP_001294439 
86 60308 61744 - 1437 Phage protein 100 0E+00 YP_001294438 
87 62259 62396 - 138 Phage protein 98 3E-21 YP_002455951 
88 62393 62599 - 207 Phage protein 99 1E-39 YP_001294436 
89 62619 63455 - 837 Phage minor capsid protein 100 0 YP_002455949 
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Table 3.15: General features of putative ORFs from P. aeruginosa phage DL54 with best 


















2 1637 2035 + 399  Phage baseplate hub 99 5E-90 YP_001671940 
3 2035 3483 + 1449 Phage terminase, large subunit 100 0 YP_001671939 
4 3483 5603 + 2121 Phage portal (connector) protein 100 0 YP_008857866 
5 5633 5848 + 216 Phage protein 100 3E-43 YP_001671937 




7 6859 7812 + 954 Phage capsid and scaffold 100 0 YP_001671935 
8 7861 8181 + 321 Phage protein 100 3E-71 YP_001671934 




10 8822 9013 + 192 Phage protein 100 4E-34 YP_001671932 
11 8997 9245 + 249 Phage protein 100 1E-27 YP_001671931 




13 9891 11432 + 1542 Phage protein 100 0 AGC35290 












17 13601 13831 + 231  hypothetical protein 100 1E-43 YP_009125623 
18 13856 15370 + 1515 Phage protein 100 0 YP_008857852 
19 15521 18688 + 3168 Phage protein 100 0 YP_001671923 
20 18700 19587 + 888 Phage protein 95 0 YP_008857850 
21 19602 19958 + 357 Phage protein 97 2E-76 YP_009007837 
22 20165 20371 - 207 Phage protein 100 2E-22 YP_001671920 
23 20358 20567 - 210 Phage protein 100 3E-42 YP_008857847 
24 20571 20789 - 219 Phage protein 100 8E-44 YP_001671918 
25 20786 21547 - 762 Phage protein 100 0 YP_001671917 
26 21540 21779 - 240 Phage protein 99 2E-50 YP_009125613 
27 21733 22713 - 981 Phage protein 100 0 YP_008857844 
28 22694 23524 - 831 DNA polymerase I 99 0 YP_009007830 







30 24058 24342 - 285 Phage protein 98 4E-58 YP_009125609 
31 24314 24724 - 411 Phage protein 99 4E-92 YP_009007827 




33 25419 27056 - 1638 DNA polymerase, phage-associated 100 0 YP_001671907 
34 27057 27254 - 198 Phage protein 98 2E-37 YP_008857837 




36 27845 28123 - 279 Phage protein 99 7E-57 AGC35267 
37 28114 28275 - 162 Phage protein 100 1E-28 AGC35266 
38 28265 28456 - 192 Phage protein 98 4E-37 YP_001671901 
39 28437 28670 - 234 Phage protein 100 2E-32 YP_008857832 
40 28706 29002 - 297 Phage protein 98 4E-56 YP_009007816 




42 29477 31186 - 1710 
DNA primase/helicase, phage-
associated 
100 0 AGC35261 
43 31187 31564 - 378 Phage protein 100 3E-87 YP_008857828 
44 31564 31962 - 399 Phage protein 100 2E-91 YP_001671895 
45 31962 32846 - 885 Phage protein 99 0 YP_001671894 
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46 32977 33198 - 222 Phage protein 100 4E-44 YP_001671893 
47 33208 34740 - 1533 Phage protein 100 0 YP_008857824 
48 34752 35927 - 1176 Phage protein 99 0 YP_008857823 




50 36465 37265 - 801 Phage protein 98 0 YP_009125589 
51 37262 38218 - 957 Phage protein 99 0 YP_008857820 
52 38237 39199 - 963 Phage protein 98 0 YP_008857819 
53 39270 39398 - 129 hypothetical protein 98 2E-20 YP_009125586 




55 40244 40462 - 219 hypothetical protein 96 4E-43 YP_009125584 
56 40469 40687 - 219 hypothetical protein 49 4E-13 YP_009125583 
57 40689 40901 - 213 Phage protein 83 4E-32 AGC35246 
58 41032 41457 - 426 Phage protein 96 2E-95 YP_001671885 
59 41457 41708 - 252 hypothetical protein 60 9E-14 AGC35244 
60 41705 41875 - 171 Phage protein 100 3E-31 AGC35243 
61 41875 42141 - 267 Phage protein 97 2E-55 YP_001671884 
62 42146 42391 - 246 Phage protein 100 5E-52 YP_008857811 
63 42400 42546 - 147 Phage protein 100 4E-27 NP_775198 
64 42533 42688 - 156 hypothetical protein 100 2E-28 YP_008857809 
65 42699 42974 - 276 Phage protein 100 2E-59 YP_008857808 
66 42976 43209 - 234 hypothetical protein 100 1E-47 YP_001671880 
67 43341 43523 - 183 Phage protein 100 7E-33 YP_001671879 
68 43703 43843 - 141 Phage protein 100 8E-24 NP_775190 
69 43840 44028 - 189 Phage protein 98 9E-35 YP_008857803 
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Table 3.16: General features of putative ORFs from P. aeruginosa phage DL60 with best 














1 53 466 + 414 Phage protein 99 1E-91 YP_002455947 
2 498 821 + 324 Phage protein 98 9E-73 YP_002455946 
3 793 909 + 117 Phage protein 92 1E-14 YP_001294431 
4 1027 1338 + 312 Phage protein 100 3E-68 YP_002455944 
5 1587 1934 + 348 Phage protein 97 1E-74 YP_002455943 
6 2038 2967 + 930 Phage protein 95 0E+00 YP_001294429 
7 3069 3656 + 588 Phage protein 98 8E-140 YP_009009031 
8 3672 4109 + 438 Phage protein 89 7E-73 YP_001294427 
9 4195 4974 + 780 Phage protein 99 0 YP_002154152 
10 4977 5378 + 402 Phage protein 99 6E-61 YP_001294425 
11 5423 5773 + 351 Phage protein 98 9E-65 YP_001294424 
12 5773 5991 + 219 Phage protein 99 4E-44 YP_001294423 
13 5988 6371 + 384 Phage protein 98 2E-82 YP_002455935 
14 6408 7790 - 1383  Phage terminase, large subunit 100 0 YP_001294421 
15 7967 8113 + 147 Phage protein 100 9E-12 YP_001294419 
16 8126 8428 + 303 Phage protein 100 7E-63 YP_001294418 
17 8475 9392 + 918 Phage tail length tape-measure protein 99 2E-123 YP_002456023 
18 9395 9583 + 189 Phage protein 98 8E-38 YP_001294508 
19 9670 9921 + 252 Phage protein 94 5E-50 YP_002154231 
20 9918 10118 + 201 Phage protein 97 7E-38 YP_001294505 
21 10115 10330 + 216 Phage protein 100 2E-42 YP_001294504 
22 10339 10518 + 180 Phage protein 98 2E-33 YP_001294503 
23 10515 10727 + 213 Phage protein 96 1E-42 YP_001294502 
24 10755 11402 + 648 Phage protein 99 1E-143 YP_001294501 
25 11399 11725 + 327 Phage protein 99 4E-72 YP_002154225 
26 11791 12015 + 225 Phage protein 93 1E-42 YP_002154315 
27 12069 12296 + 228 Phage protein 68 1E-25 WP_041598427 
28 12306 12527 + 222 Phage protein 85 9E-36 YP_007002628 
29 12575 12892 + 318 Phage protein 93 8E-69 YP_002456011 
30 12902 13507 + 606 Phage protein 98 7E-116 YP_002456010 
31 13700 14314 + 615 Phage protein 99 1E-93 YP_002154219 
32 14485 15057 - 573 Phage protein 99 3E-120 YP_001294493 
33 16029 17759 - 1731 DNA primase, phage associated 99 0 YP_001294491 
34 17907 18092 - 186 Phage protein 93 7E-06 YP_001294490 
35 19171 19620 - 450 Phage protein 99 6E-103 YP_007002619 
36 19644 21194 - 1551 Phage protein 93 8E-157 YP_006200837 
37 21205 21990 - 786 Phage protein 97 1E-176 YP_002456002 
38 22158 22580 + 423 Phage protein 99 5E-96 YP_002456001 
39 22567 23754 + 1188  DNA helicase, phage-associated 98 0 YP_002456000 
40 23915 24817 + 903 Phage protein 99 4E-68 YP_007238220 
41 24922 25923 + 1002 Phage protein 97 0 YP_002455998 
42 26012 26242 + 231 Phage protein 97 2E-35 YP_001294481 
43 26242 26460 + 219 Phage protein 99 3E-30 YP_007002611 
44 26444 26662 + 219      Phage tail assembly 99 1E-44 YP_001294479 
45 26662 26925 + 264 Phage protein 95 4E-52 YP_001294478 
46 26937 27143 + 207 Phage protein 96 9E-40 YP_001294477 
47 27143 28060 + 918    Thymidylate synthase thyX 97 0 YP_002455991 
48 28062 28253 + 192 Phage protein 98 2E-34 YP_001294475 
49 28256 29305 + 1050 
   3'-phosphatase, 5'-polynucleotide 
kinase, phage-associated 
89 0 YP_002455989 
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50 29380 29934 + 555 Phage protein 100 4E-134 YP_001294473 
51 29934 33041 + 3108  DNA polymerase III alpha subunit  99 0 YP_001294472 
52 33034 33444 + 411   Phage protein 97 2E-78 YP_002154288 
53 33441 35000 + 1560   DNA helicase, phage-associated 99 0 YP_001294470 
54 35083 35715 + 633 Phage protein 100 5E-113 YP_002455984 
55 35804 36700 + 897 Phage protein 100 0E+00 YP_002154194 
56 36757 37362 + 606    Phage protein 100 2E-100 YP_001294467 
57 37359 37928 + 570   Phage DNA-binding protein 88 3E-114 YP_002154192 
58 37983 38894 + 912 DNA ligase, phage-associated 97 0 YP_002455980 
59 39174 39425 + 252 Phage protein 100 2E-39 YP_002154190 
60 39453 40115 - 663 Lytic enzyme 99 1E-159 YP_009124368 
61 40115 40543 - 429 Phage protein - - not available 
62 40546 43440 - 2895 Phage tail fibers - - not available 
63 43445 44959 - 1515 Phage protein - - not available 
64 44956 46209 - 1254 Phage protein - - not available 
65 46266 46697 - 432 Phage baseplate - - not available 
66 46677 46916 + 240 hypothetical protein - - not available 
67 46987 47520 - 534 Phage protein - - not available 
68 47520 48383 - 864  Phage protein - - not available 
69 48383 50965 - 2583 Phage internal (core) protein - - not available 
70 50969 51397 - 429  Phage protein - - not available 
71 51407 52000 - 594 Phage tail fiber protein - - not available 
72 52009 52413 - 405 Phage protein - - not available 
73 52548 53051 - 504 Phage protein - - not available 
74 53061 53489 - 429 Phage protein - - not available 
75 53491 53841 - 351 Phage protein - - not available 
76 53838 54161 - 324 Phage protein - - not available 
77 54161 54613 - 453 Phage tail fiber protein - - not available 
78 54671 56185 - 1515 Phage protein - - not available 
79 56780 57331 - 552 Phage protein - - not available 
80 57339 57737 - 399 Phage protein - - not available 
81 57734 58201 - 468 Phage protein 100 1E-76 YP_001294442 
82 58216 58653 - 438 Phage protein 100 4E-103 YP_001294441 
83 58755 59903 - 1149 Phage capsid and scaffold 99 0 YP_001294440 
84 59913 60548 - 636 Phage protein 99 6E-145 YP_002455953 
85 60552 61979 - 1428 Phage protein 97 0E+00 YP_002455952 
86 62492 62632 - 141 Phage protein 93 2E-19 YP_002455951 
87 62629 62835 - 207 Phage protein 97 1E-38 YP_001294436 
88 62855 63691 - 837 Phage minor capsid protein 98 0 YP_001294435 
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Table 3.17: General features of putative ORFs from P. aeruginosa phage DL62 with best 














1 160 369 - 210 hypothetical protein 53 3 XP_005307517 
2 577 861 + 285 hypothetical protein - - not available 
3 1769 2053 + 285 Phage protein 100 0 NP_877440 
4 2053 2280 + 228 Phage protein 97 0 NP_877441 
5 2291 2830 + 540 Phage protein 100 0 YP_001671945 
6 2999 3118 + 120 Phage protein 97 0 AIK67566 
7 3197 3565 + 369 Phage protein 100 0 YP_001671946 
8 3552 3779 + 228 Phage protein 96 0 YP_009125704 
9 3958 4131 + 174 Phage protein 72 0 YP_002117787 
10 4131 4412 + 282 Phage protein 76 0 YP_008431317 
11 4412 4672 + 261 Phage protein 60 0 YP_002727828 
12 4674 4961 + 288 Phage protein 98 0 YP_001671951 
13 5040 5459 + 420 Phage tail fibers 98 0 YP_001522798 
14 5528 5887 + 360 Phage protein 100 0 YP_001671953 
15 5890 6615 + 726 Phage DNA-binding protein 60 0 YP_001671954 
16 6695 7114 + 420 Phage protein 96 0 YP_656507 
17 7080 7427 + 348 Phage protein 97 0 YP_002117736 
18 7417 7545 + 129 Phage protein 100 0 YP_001522803 
19 7613 8437 + 825 
DNA primase/helicase, phage-
associated 
99 0 YP_001671958 
20 8406 9674 + 1269 DNA helicase, phage-associated 100 0 YP_009125717 
21 9664 10275 + 612 Putative protein - - not available 
22 10275 10772 + 498  DNA ligase, phage-associated - - not available 
23 10793 11221 + 429  DNA ligase, phage-associated - - not available 
24 11224 11553 + 330 Phage protein - - not available 
25 11550 13976 + 2427 DNA polymerase I, phage-associated - - not available 
26 14032 15081 + 1050 Phage protein - - not available 
27 15081 16022 + 942 Phage protein - - not available 
28 16012 16452 + 441 Phage endonuclease - - not available 
29 16449 17495 + 1047 Phage exonuclease - - not available 
30 17505 17876 + 372 Phage protein - - not available 
31 17869 18219 + 351 Phage protein - - not available 
32 18228 20675 + 2448 Phage RNA polymerase - - not available 
33 20849 21100 + 252 Phage protein - - not available 
34 21100 21573 + 474 Putative protein - - not available 
35 21539 21814 + 276 Phage protein - - not available 
36 21826 23358 + 1533 Phage collar - - not available 
37 23362 24330 + 969  Phage capsid and scaffold - - not available 
38 24383 25390 + 1008  Phage capsid and scaffold - - not available 
39 25487 26041 + 555 Phage tail fibers - - not available 
40 26044 28524 + 2481 Phage tail fibers - - not available 
41 28524 29069 + 546 Phage internal (core) protein 99 0 AIK67602 
42 29069 31765 + 2697 Phage baseplate hub; Phage lysozyme 100 0 YP_008431349 
43 31769 35782 + 4014 Phage internal (core) protein 99 0 YP_009125740 
44 35784 36539 + 756  Phage tail fibers 100 0 YP_001671983 
45 36539 36997 + 459 Phage protein 99 0 YP_002117765 
46 36990 37898 + 909 Phage protein 98 0 YP_009125743 
47 37902 38507 + 606 Phage protein 100 0 YP_009125744 
48 38507 38812 + 306 Phage protein 100 0 YP_001522834 
49 38822 40627 + 1806 
Phage terminase, large subunit (T7-like 
direct terminal repeats) 
100 0 YP_009125746 
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50 40624 40824 + 201 Phage protein 98 0 NP_877483 
51 40821 41303 + 483  Phage lysin 99 0 YP_008431358 
52 41261 41590 + 330 Phage protein 98 0 YP_008431359 
53 41565 41678 + 114 Phage protein 100 0 YP_009125750 
54 41680 42093 + 414 Phage protein 98 0 YP_009125751 
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Table 3.18: General features of putative ORFs from P. aeruginosa phage DL64 with best 










E-value Accession no. 
Start Stop 
1 71924 72355 - 432 hypothetical protein 98 2E-97 YP_003358483 
2 71712 71924 - 213 hypothetical protein 99 1E-42 YP_009031858 
3 71455 71715 - 261 hypothetical protein 67 4E-06 AIZ94839 
4 71081 71347 - 267 hypothetical protein 66 6E-19 AFO70586 
5 70216 70878 - 663 hypothetical protein 91 5E-132 AFO70587 
6 69542 69796 - 255 hypothetical protein 99 4E-49 YP_003358398 
7 68943 69134 - 192 hypothetical protein 100 4E-39 AIZ94844 
8 68686 68928 - 243 hypothetical protein 90 2E-44 YP_003358400 
9 68459 68689 - 231 hypothetical protein 99 1E-46 YP_003358401 
10 68208 68459 - 252 hypothetical protein 96 3E-52 AIZ94847 
11 67908 68204 - 297 hypothetical protein 93 2E-62 YP_003358403 
12 67622 67924 - 303 hypothetical protein 88 5E-58 YP_003358404 
13 67415 67618 - 204 hypothetical protein 93 2E-33 YP_003358405 
14 67167 67385 - 219 hypothetical protein 97 8E-30 AFO70508 
15 66937 67170 - 234 hypothetical protein 100 2E-44 AIZ94852 
16 66719 66940 - 222 hypothetical protein 100 7E-43 YP_003358408 
17 66462 66647 - 186 hypothetical protein 98 8E-35 YP_003358409 
18 66080 66370 - 291 hypothetical protein 100 1E-60 YP_009031789 
19 65560 65895 - 336 hypothetical protein 85 9E-58 AIZ94764 
20 65159 65560 - 402 Phage protein 99 4E-94 AIZ94765 
21 64908 65159 - 252 hypothetical protein 98 8E-52 AIZ94766 
22 64468 64908 - 441 hypothetical protein 99 1E-103 AIZ94950 
23 64081 64428 - 348 hypothetical protein 100 5E-80 AIZ94951 
24 63137 64069 - 933 RNA polymerase, phage-associated 98 0 AFO70518 
25 62864 63124 - 261 hypothetical protein 95 2E-52 AIZ94862 
26 62258 62572 - 315 hypothetical protein 88 8E-61 AIZ94863 
27 61953 62225 - 273 hypothetical protein 97 6E-43 AFO70520 
28 60677 61918 - 1242 Phage protein 100 0 AIX13178 
29 60427 60579 - 153 hypothetical protein 100 1E-27 AIZ94866 
30 60130 60354 - 225 hypothetical protein 97 1E-16 YP_003358421 
31 59500 60126 - 627 hypothetical protein - - not available 
32 58949 59503 - 555 hypothetical protein - - not available 
33 58368 58949 - 582 hypothetical protein - - not available 
34 57853 58368 - 516 hypothetical protein - - not available 
35 57632 57856 - 225 hypothetical protein - - not available 
36 57203 57388 - 186 hypothetical protein - - not available 
37 56342 57175 - 834 
ATP-dependent Clp protease ATP-binding subunit 
ClpX 
- - not available 
38 56103 56345 - 243 hypothetical protein - - not available 
39 55001 56071 - 1071 Phage protein - - not available 
40 53243 54472 - 1230 hypothetical protein - - not available 
41 51987 53153 - 1167 RecD-like DNA helicase YrrC - - not available 
42 51460 51987 - 528 hypothetical protein - - not available 
43 48845 51460 - 2616 DNA polymerase I  - - not available 
44 48624 48848 - 225 hypothetical protein - - not available 
45 48194 48664 - 471 
dCMP deaminase, Late competence protein 
ComEB 
- - not available 
46 48022 48162 - 141  hypothetical protein - - not available 
47 47621 48019 - 399  hypothetical protein - - not available 
48 47433 47624 - 192 Phage protein - - not available 
49 44913 47429 - 2517 Phage rIIA lysis inhibitor - - not available 
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50 43162 44901 - 1740 
Phage lysis inhibitor # T4-like rIIA-rIIB membrane 
associated #T4 GC1698 
- - not available 
51 42890 43114 - 225 hypothetical protein 99 3E-24 AFO70543 
52 42489 42689 - 201 hypothetical protein 98 3E-39 AFO70544 
53 42248 42439 - 192 hypothetical protein 100 6E-37 YP_003358443 
54 41701 42255 - 555 hypothetical protein 100 1E-132 YP_003358444 
55 41126 41638 + 513 hypothetical protein 100 4E-106 YP_003358445 
56 40605 41129 + 525 hypothetical protein 100 7E-124 YP_003358446 
57 40366 40608 + 243 hypothetical protein 100 3E-48 YP_003358447 
58 36838 40059 + 3222 Putative tail fiber protein 98 0 YP_003358449 
59 36128 36799 + 672 hypothetical protein 99 2E-160 AIZ94804 
60 35832 36131 + 300 hypothetical protein 97 1E-60 AFO70552 
61 34522 35835 + 1314  Phage tail fiber protein 100 0 AIZ94898 
62 33725 34153 - 429 hypothetical protein 100 1E-98 YP_003358454 
63 33348 33635 - 288 hypothetical protein 99 1E-61 YP_003358455 
64 32336 33346 - 1011 Phage protein 100 0 YP_003358456 
65 30153 32321 - 2169 DNA primase, phage associated 100 0 AFO70557 
66 29370 30104 - 735 Phage protein 100 0 AFO70558 
67 28597 29343 - 747 Phage protein 100 2E-155 YP_003358459 
68 28228 28455 - 228 hypothetical protein 97 1E-45 YP_003358460 
69 27788 28231 - 444 Phage protein 100 1E-87 YP_003358461 
70 27240 27800 - 561 hypothetical protein 100 9E-126 YP_003358462 
71 26791 27228 - 438 hypothetical protein - - not available 
72 26329 26733 - 405 hypothetical protein - - not available 
73 25688 25924 - 237 hypothetical protein - - not available 
74 25374 25691 - 318 hypothetical protein - - not available 
75 25161 25364 - 204 hypothetical protein - - not available 
76 14949 25145 + 10197 Phage protein - - not available 
77 13383 14948 + 1566 hypothetical protein - - not available 
78 12916 13383 + 468 N4 gp52-like protein - - not available 
79 10713 12935 + 2223 Phage protein - - not available 
80 9880 10656 + 777 N4 gp54-like protein - - not available 
81 9022 9687 + 666 Phage protein - - not available 
82 7766 8965 + 1200 Phage protein - - not available 
83 6529 7731 + 1203 MJ0042 family finger-like protein - - not available 
84 6191 6529 + 339 hypothetical protein - - not available 
85 3941 6121 + 2181 Phage portal protein - - not available 
86 3487 3873 - 387 Deoxyuridine 5'-triphosphate nucleotidohydrolase - - not available 
87 3184 3483 - 300 hypothetical protein - - not available 
88 2418 3152 + 735 N4 gp67-like protein - - not available 
89 769 2421 + 1653 Phage protein - - not available 
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Table 3.19: General features of putative ORFs from P. aeruginosa phage DL68 with best 














1 66 467 + 402 Phage protein 100 0 YP_002364325 
2 636 821 + 186 Phage protein 98 0 YP_002364324 
3 818 1021 + 204 Phage protein 97 0 YP_007002562 
4 1027 1338 + 312 Phage protein 100 0 YP_006200780 
5 1587 1934 + 348 Phage protein 99 0 YP_002364322 
6 1954 2454 + 501 Phage protein 100 0 YP_002364321 
7 2557 3489 + 933 Phage protein 100 0 YP_002364320 
8 3591 4178 + 588 Phage protein 82 0 YP_009009031 
9 4195 4632 + 438 Phage protein 100 0 YP_006200775 
10 4719 5498 + 780 Phage protein 100 0 YP_002364316 
11 5501 5899 + 399 Phage protein 97 0 YP_002154151 
12 5943 6293 + 351 Phage protein 99 0 YP_009124329 
13 6293 6508 + 216 Phage protein 100 0 YP_002418812 
14 6508 6891 + 384 Phage protein 99 0 YP_007002551 
15 6928 8310 - 1383 Phage terminase, large subunit 100 0 YP_002418810 
16 8315 8437 - 123 Phage protein 78 0 YP_002154146 
17 8480 8770 + 291 hypothetical protein - - not available 
18 8800 8955 + 156 hypothetical protein 57 0 ERY56378 
19 9011 9313 + 303 Phage protein 98 0 YP_002364309 
20 9368 10054 + 687 Phage capsid and scaffold 99 0 YP_006200858 
21 10057 10245 + 189 Phage protein 88 0 YP_006200857 
22 10332 10583 + 252 Phage protein 100 0 YP_006200856 
23 10580 10780 + 201 Phage protein 100 0 YP_002418895 
24 10777 10992 + 216 Phage protein 99 0 YP_006200854 
25 10989 11198 + 210 Phage protein 100 0 YP_002364393 
26 11230 11874 + 645 Phage protein 100 0 YP_006200852 
27 11875 12204 + 330 Phage protein 97 0 YP_002154316 
28 12266 12490 + 225 Phage protein 97 0 YP_009124310 
29 12544 12765 + 222 Phage protein 100 0 YP_002364388 
30 12818 12946 + 129 Phage protein 98 0 YP_002364387 
31 12980 13129 + 150 Phage protein 98 0 YP_002364387 
32 13140 13835 + 696 Phage protein 100 0 YP_002364386 
33 14025 14636 + 612 Phage protein 100 0 YP_002364385 
34 14804 15373 - 570 Phage protein 100 0 YP_002364384 
35 16337 18076 - 1740 DNA primase, phage associated 99 0 YP_009124396 
36 18224 18409 - 186 Phage protein 100 0 YP_001294490 
37 18415 19491 - 1077 Phage protein 100 0 YP_002364381 
38 19488 19940 - 453 Phage protein 99 0 YP_002364380 
39 19964 21268 - 1305 hypothetical protein 100 0 WP_023099019 
40 21279 22064 - 786 Phage protein 100 0 YP_002364378 
41 22233 22655 + 423 Phage protein 100 0 YP_001294485 
42 22642 23829 + 1188 DNA helicase, phage-associated 100 0 YP_002418875 
43 23991 24875 + 885 Phage protein 99 0 YP_002364375 
44 24980 25981 + 1002 Phage protein 98 0 YP_002418873 
45 26069 26299 + 231 Phage protein 100 0 YP_002364373 
46 26299 26517 + 219 Phage protein 100 0 YP_002154206 
47 26501 26719 + 219 Phage tail assembly protein 100 0 YP_002418870 
48 26752 26982 + 231 Phage protein 100 0 YP_002418869 
49 26990 27196 + 207 Phage protein 100 0 YP_002364369 
50 27196 28113 + 918  Thymidylate synthase thyX 100 0 YP_006200825 
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51 28115 28306 + 192 Phage protein 100 0 YP_006200824 
52 28309 29328 + 1020 
  3'-phosphatase, 5'-polynucleotide 
kinase, phage-associated 
96 0 YP_007238211 
53 29405 29959 + 555  Phage protein 100 0 YP_007002604 
54 29959 33066 + 3108   DNA polymerase III alpha subunit 99 0 YP_006200821 
55 33059 33469 + 411   Phage protein 100 0 YP_007002602 
56 33466 35025 + 1560 DNA helicase, phage-associated 100 0 YP_002364362 
57 35120 35740 + 621 Phage protein 100 0 YP_002154286 
58 35829 36728 + 900 Phage protein 100 0 YP_006200817 
59 36782 37387 + 606 Phage protein 100 0 YP_001294467 
60 37384 37938 + 555 Phage DNA binding protein 99 0 YP_006200815 
61 37993 38904 + 912 DNA ligase, phage-associated 100 0 YP_002154282 
62 39184 39435 + 252 Phage protein 100 0 YP_002364356 
63 39460 40122 - 663 Lytic enzyme 100 0 YP_006200812 
64 40122 40550 - 429 Phage protein 99 0 YP_002154188 
65 40552 43446 - 2895 Phage tail fibers 98 0 YP_009124366 
66 43451 44965 - 1515 Phage protein 97 0 YP_006200809 
67 44962 46215 - 1254 Phage protein 100 0 YP_009008971 
68 46272 46835 - 564 Phage baseplate 99 0 YP_001294458 
69 46993 47526 - 534 Phage protein 99 0 YP_002364349 
70 47526 48389 - 864  Phage protein 100 0 YP_002154273 
71 48389 50965 - 2577 Phage internal (core) protein 100 0 YP_002154272 
72 50969 51397 - 429 Phage protein 100 0 YP_002154180 
73 51407 52000 - 594 Phage tail fiber protein 100 0 YP_002154179 
74 52009 52413 - 405 Phage protein 100 0 YP_002154269 
75 52548 53051 - 504  Phage protein 100 0 YP_002418842 
76 53061 53492 - 432 Phage protein 98 0 YP_002418841 
77 53494 53844 - 351  Phage protein 100 0 YP_002154266 
78 53841 54164 - 324 Phage protein 100 0 YP_002154265 
79 54164 54616 - 453 Phage tail fiber protein 100 0 YP_002154264 
80 54675 56189 - 1515 Phage protein 100 0 YP_007002577 
81 56205 56729 - 525 Phage protein 100 0 YP_007238183 
82 56783 57334 - 552  Phage protein 100 0 YP_002154170 
83 57342 57530 - 189 Phage protein 100 0 YP_002364335 
84 57737 58204 - 468 Phage protein 99 0 YP_002154168 
85 58219 58656 - 438 Phage protein 100 0 YP_002154167 
86 58758 59906 - 1149 Phage capsid and scaffold 100 0 YP_002364332 
87 59916 60551 - 636 Phage protein 100 0 YP_002364331 
88 60555 61988 - 1434 Phage protein 100 0 YP_002364330 
89 62502 62642 - 141 Phage protein 100 0 YP_002418828 
90 62639 62845 - 207  Phage protein 100 0 YP_002418827 
91 62864 63700 - 837 Phage minor capsid protein 100 0 YP_002364327 
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4.1. Chapter summary 
This chapter focuses on the efficacy assessment of the phage cocktails, isolated and 
characterised in the previous chapter, against P. aeruginosa and S. aureus bacterial 
strains on three in vitro models. Planktonic growth bacterial cultures were the first 
model where the phage efficacy was tested. The strains used for the planktonic growth 
represent clinical strains that frequently caused formation of biofilms, strongly related to 
infection initiation and maintenance. Firstly, an in vitro static model for biofilm 
production was evaluated and the phage efficacy tested. Finally, efficacy was assessed 
on an in vitro biofilm flow model, where implementation and optimisation of the system 
were executed. The different models performed represented, in a progressive fashion, 
a closer scenario to what is observed in nature when an infection occurs. Part of the 
biofilm work presented for S. aureus have been published in a scientific journal (244). 
 
4.2. Background 
Following isolation and characterisation of lytic phages, the next logical step is the 
analysis of their lytic performance when growing with the target bacterial strains. 
Commonly, phages are introduced into planktonic bacterial cultures and their growth is 
evaluated throughout a pre-determined period of time. This allows a monitoring of the 
phage efficacy and evaluates how frequently bacterial cells are able to counteract the 
presence of the phage by emergence of bacterial phage resistant mutants. The latter, 
can often be delayed by including a cocktail of phages, allowing the optimisation of the 
best combination of phages to tackle the bacteria of interest.  
Several studies documenting phage isolation and their evaluation on planktonic 
bacterial cultures can be found in the literature. However, evaluation of the phage lytic 
activity against planktonic cultures only is, to some extent, a very limited approach. As 
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discussed in Chapter One, bacterial biofilm communities are the rule rather than the 
exception and likewise, bacterial infections, especially wound infections, get initiated by 
the formation of a biofilm. Within a biofilm, bacterial cells behaviour is switched and 
they are strongly protected from the external environment. For that reason, the 
outcome when phage are infecting bacteria in a broth culture it is often different to the 
one observed when infecting the same strain when growing as a biofilm. Cerca and 
colleagues (238) showed that phage K was able to reduce a planktonic culture of S. 
epidermidis in a period of two hours, however for biofilm it was only possible to observe 
a reduction in biomass 24 hours after infection. This is mainly due to the presence of 
the protective and cell aggregating S. epidermidis extracellular polysaccharide, poly-N-
acetylglucosamine (PNAG) expressed by the cells in the biofilm, but also to the low 
metabolic activity of biofilm cells. Therefore, to more accurately reflect their potential in 
vivo, when assessing the lytic effect of phage it is recommended to study this in biofilm 
models of infection.  
To understand the crucial role that biofilms have in nature, in the hospital, in the 
industry and the environment, several in vitro models for biofilm formation have been 
developed over the years and each one of them is allied with certain advantages and of 
course limitations ( for review see 308). Although in many instances these systems lack 
versatility and are difficult to set up they remain a powerful tool for studying factors that 
affect biofilm formation. In this study we have employed two biofilm models to study 
biofilm reduction and dispersion by phage attack. In vitro biofilm models can be 
subdivided into closed and open systems, such as the microtitre plate model and the 
Robbins device, respectively. Microtitre plate based systems might be the most 
widespread used model for studying biofilms (308). In this closed system biofilms are 
formed on the bottom and the walls of a microtitre plate and are ideal systems for 
screening purposes, where multiple parameters are able to be studied, protocols are 
straightforward and small volumes of reagents are employed. For results assessment, 
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evaluation of biofilm biomass by crystal violet assay and microbial physiology activity 
by XTT or resazurin assay can be easily performed. 
The Robbins device, developed by Jim Robbins at the University of Calgary and later 
modified by McCoy and colleagues (309) and called The Modified Robbins Device 
(MRD), is one of the classical models employed for the study of biofilms (310). It 
consists of a device that contains multiple individual ports placed in a linear fashion 
with each port holding a plug. On the bottom of each plug, a disk can be found that is in 
contact with the lumen of the device. Media and cells are passed through the device 
entering in contact with to the disks and biofilms are formed. Often, Robbins devices 
are coupled to a chemostat so that bacterial cells growing at a defined growth rate and 
nutrient conditions are used as feeding inoculum for the formation of a biofilm (311). It 
has been widely used to study oral biofilms (312) and used as “artificial throat” for the 
study of biofilm formation on laryngeal shunt prostheses (313). 
 
Table 4.1: Description of the main advantages and disadvantages of the in vitro biofilm model 
systems used in the assessment of phage lytic and dispersal activity. 
Biofilm device Advantages Disadvantages Reference 
Microtitre plate 
 High throughput. 
 Cheap. 
 Allows testing of different 
parameters and materials. 
 Direct observation of wells 
under a microscope is difficult. 




 Precise hydrodynamic 
conditions. 
 Operates at continuous 
culture conditions. 
 Low throughput. 









4.3.1. Optimisation and setup of the in vitro biofilm model using the 
Modified Robbins Device 
4.3.1.1. Continuous-culture 
Continuous culture is an approach that provides us the possibility to study bacteria 
under conditions that more closely resemble the manner they grow in nature. The basis 
of the chemostat approach was first described by Monod (315). Hence, when assuming 
steady-state conditions, the bacterial culture grows at a constant rate (parameters, 
such as cell number, volume and temperature are kept constant) and the dilution rate 
(D) equals the specific growth rate (μ) of the organism. Consequently, the bacterial 
growth stage can be easily manipulated and provide a system with defined growth 
rates and constant nutrient conditions for biofilm formation over time that will more 
closely resemble the situation in human bacterial infections.  
In a continuous culture bacterial growth occurs in an equilibrium fashion, where the 
influx of the fresh medium that allows production of new biomass is compensated by 
the efflux of waste medium, which is a mixture of living cells and cell debris. 
The rate of medium flow (F) into the chemostat is related to its volume (V) and is 





           (4.1) 
 
The change in biomass (𝑥) over time during the steady state growth is expressed as: 
 





= 𝜇𝑥 − 𝐷𝑥          (4.2) 
 




= 0, hence 𝜇𝑥 − 𝐷𝑥 = 0 or 𝜇 = 𝐷       (4.3) 
 
Hence, the growth rate can be manipulated as a function of the dilution rate: 
 
𝑅𝑎𝑡𝑒 𝑜𝑓 𝑏𝑖𝑜𝑚𝑎𝑠𝑠 𝑎𝑐𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 = 𝑅𝑎𝑡𝑒 𝑜𝑓 𝑏𝑖𝑜𝑚𝑎𝑠𝑠 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 − 𝑅𝑎𝑡𝑒 𝑜𝑓 𝑏𝑖𝑜𝑚𝑎𝑠𝑠 𝑙𝑜𝑠𝑠 (4.4) 
 
The rate of accumulation is expressed as the derivative of the concentration of 
biomass, with respect to time (t), multiplied by the volume of the reactor: 
 
𝑅𝑎𝑡𝑒 𝑜𝑓 𝑏𝑖𝑜𝑚𝑎𝑠𝑠 𝑎𝑐𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 =  𝑉.
𝑑[𝑏𝑖𝑜𝑚𝑎𝑠𝑠]
𝑑𝑡
      (4.5) 
 
The rate of biomass loss is equal to the outlet flow rate (F) multiplied by the 
concentration of biomass 
 
𝑅𝑎𝑡𝑒 𝑜𝑓 𝑏𝑖𝑜𝑚𝑎𝑠𝑠 𝑙𝑜𝑠𝑠 =  𝐹. [𝑏𝑖𝑜𝑚𝑎𝑠𝑠]       (4.6) 
 
The rate of biomass production can be expressed by the logistic curve of growth, 
where the growth parameters are bacterial specific growth rate (a, h-1) and the carrying 
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capacity (k), defined as the maximum number of bacteria that is reached in the 
stationary phase, all multiplied by the volume to obtain the correct units: 
 
𝑅𝑎𝑡𝑒 𝑜𝑓 𝑏𝑖𝑜𝑚𝑎𝑠𝑠 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 =  𝑉. 𝑎. [𝑏𝑖𝑜𝑚𝑎𝑠𝑠]. (1 −
[𝑏𝑖𝑜𝑚𝑎𝑠𝑠]
𝑘
)    (4.7) 
 





= 𝑉. 𝑎. [𝑏𝑖𝑜𝑚𝑎𝑠𝑠]. (1 −
[𝑏𝑖𝑜𝑚𝑎𝑠𝑠]
𝑘
) − 𝐹. [𝑏𝑖𝑜𝑚𝑎𝑠𝑠]    (4.8) 
 




= 𝑎. [𝑏𝑖𝑜𝑚𝑎𝑠𝑠] (1 −
[𝑏𝑖𝑜𝑚𝑎𝑠𝑠]
𝑘
) − 𝐷. [𝑏𝑖𝑜𝑚𝑎𝑠𝑠]    (4.9) 
 
𝐷 = 𝑎. (1 −
[𝑏𝑖𝑜𝑚𝑎𝑠𝑠]
𝑘
)         (4.10) 
 
In order to calculate the growth parameters, the bacterial growth curve should be fitted 
to a logistic curve that describes the sigmoidal growth curve of the bacterial. Figure 4.1 
shows the fitting of the planktonic bacterial growth of both S. aureus 15981 and P. 
aeruginosa PAO1 to the sigmoidal logistic function and the growth parameters. The 
specific growth rate of both strains was very similar (S. aureus 15981 = 0.49; P. 
aeruginosa PAO1 = 0.51) and hence a dilution rate of 0.1 h-1 was selected to perform 
both chemostat cultures and the growth was slow and close to achieve the stationary-
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phase. Before starting the flow system, the pumps (Ismatec, UK) were calibrated in 
order to obtain the desired flow rate. 




























Equation y = a/(1 + b*exp(-k*x)) 




a 0.48648 0.00452 
























Equation y = a/(1 + b*exp(-k*x)) 




a 0.51341 0.01923 
k 1.11965 0.00907 
Figure 4.1: Bacterial planktonic growth fitting of (A) S. aureus 15981 and (B) P. aeruginosa 
PAO1 to the sigmoidal logistic curve. The sigmoidal logistic curve equation is indicated and the 
parameter a and k, for calculation of the dilution rate are also indicated. 
 
4.3.1.2. Chemostat setup 
A chemostat system was used to generate a continuous bacterial culture in order to 
provide inoculum for use in the Modified Robbins Device (MRD) as described by Jass 
and colleagues (311) with some modifications regarding the equipment and facilities 
available. The chemostat vessel consisted of a 500 ml glass double wall vessel (Tyler 
Research Corporation, Canada) agitated at 300 rpm with a polysulfone cap provided 
with fittings for tubing. For monitoring the temperature (37 °C±0.2) a standard 
temperature probe was fitted to the polysulfone cap and for pH (7.0±0.1) the monitoring 
was performed indirectly, by taking hourly samples and monitoring pH. All the fittings 
A 
B 
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added (tubing and temperature probe) were carefully insulated with Blu-Tack in order 
to avoid contamination from the outside. A 10 ml sample of an overnight culture with 
108 cfu/ml was used to inoculate 500 ml of sterile half strength nutrient broth (TSB or 
LB) within the chemostat. Following inoculation, the stirred chemostat was operated as 
a batch culture for four hours to allow the establishment of the culture. The medium 
volume inside the chemostat was maintained at 500 ml and perfused with sterile 
growth medium at a certain dilution rate (Figure 4.2), determined in the previous 
section for the bacteria being studied. The chemostat was run over 48 hours for the 
culture to achieve the steady-state, meaning a constant population size of 3.01x107 
cfu/ml for S. aureus 15981 and 3.62 x107 cfu/ml for P. aeruginosa PAO1.  
 
Figure 4.2: A – Diagram of the chemostat setup. Green lines represent the inlet tubing and red 
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4.3.1.3. Biofilm formation on the Robbins Device. 
A Robbins device was used to study biofilm formation. The device provided quantifiable 
samples of biofilm that were monitored over time. It consists of hollow rectangular 
stainless steel tubes with 12 evenly spaced sampling ports. Each port allowed the 
insertion of a sampling stud that contained a stainless steel disk that lay flush to the 
inner surface of the lumen being subjected to the flow media and bacteria (Figure 4.3). 
Every stud was dipped into a sterile solution of mucin (100 μg/ml) to improve 
attachment of bacterial cells (316). The MRD was fitted into a thermal liquid regulated 
container (Tyler Research Corporation, Canada) that maintained the internal lumen 
temperature at 37 oC. 
 
Figure 4.3: Diagram of the Robbins device. The stainless steel tube has 12 sampling ports that 
can easily be removed by pulling them up. The device is kept in a thermal liquid regulated 
container (blue line) and the nutrient media flows across the lumen of the device (yellow line), 
entering into contact with the surface of the studs. 
 
Culture growing under steady-state was pumped through the MRD, via the effluent 
tubing (flow rate = 250 μl/min) of the chemostat and biofilms were allowed to develop 
on the surface of the stainless steel disks (Figure 4.4) exposed to the culture for 24 
hours. Over this period the culture feed was replaced by fresh half strength media 
supplemented with 0.1 % D-(+)-glucose (TSBg or LBg) for another 24 hours. At this 
time point, biofilms had been growing for 48 hours and fresh media feeding was 
paused in order to inoculate into the system 10 ml (107 pfu/ml) of phage in an oil-in-
water nano-emulsion suspension and the control. Such emulsion was used to promote 
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the lytic activity of the phage particles, as they provide a more stable environment for 
adsorption to the cells to occur (299). Once the suspension was inside the MRD, which 
time taken was estimated by calculating the velocity (min) of the suspension according 
to equation (14), the inlet and outlet tubing of the MRD were clamped for a period of 20 
min and phages were allowed to adsorb to the bacteria in the biofilms. 
 
𝐹𝑙𝑜𝑤 𝑟𝑎𝑡𝑒 = 𝑉𝑒𝑙𝑜𝑐𝑖𝑡𝑦. 𝑡𝑢𝑏𝑖𝑛𝑔 𝑎𝑟𝑒𝑎       (4.11) 
 
One hour later the inlet and outlet tubing of the MRD were clamped again and four 
random studs were removed in order to sample the biofilm communities formed. The 
removed studs were replaced with new sterile studs. The stainless steel disks were 
unscrewed from the studs and then three were processed for viable bacterial and 
phage counts and the fourth was prepared for analysis in the confocal laser scanning 
microscope (CLSM), which theoretical background and sample preparation have been 
previously described in Chapter Two, Section 2.10.2.2. Studs were removed from the 
MRD at predetermined time intervals: 0, 24 and 48 hours. Figure 4.5 and 4.6 show a 
diagram and images of the model system setup. 
 
 
Figure 4.4: Left - Image showing a stud upside down, where a biofilm can be observed grown 
on the surface of the stainless steel disk. Right – Image showing the different types of 
connectors used to link all the tubing system. 
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4.3.1.4. Bacteria and phage viable counts on MRD disks 
Disks were carefully detached using tweezers from the stud and rinsed twice by 
dipping the disk in 1 ml in of PBS to remove planktonic and loosely adherent cells. The 
disk was placed in 1 ml PBS contained in 1 ml centrifuge tube and sonicated for 6 min 
(60W) before vortexing for 2 min to ensure complete detachment of the biofilm from the 
disk. For enumeration of viable bacterial cells, serial dilutions were performed in FAS 
virucide, and numbers determined using the method previously described in Chapter 
Two, Section 2.11.6. For enumeration of phages present in the biofilm, 100 μl of the 
disrupted biofilm suspension was used to perform serial dilutions and titration was 
performed by using the method previously described in Chapter Two, Section 2.2.5.  
All the manipulation was performed inside a flow cabinet to prevent introduction of 
contamination. The flow system was connected through a long life thermoplastic 
Marprene tubing (Watson Marlow, UK), where a three port tubing of 0.89 mm in 
diameter was used for the pump and 6.4 mm in diameter for the rest of the tubing.  
 
4.3.1.5. Cleaning and sterilisation of the system 
For cleaning the system, a 1 % Helmanex III solution was passed through the system 
for 2 hours under flow rate of 2 ml/min. Following this time period the flow was reduced 
to 500 μl/min and it was left overnight, approximately 18 hours. On the following day, 
distilled water was passed through the system which was left to dry overnight at 50 °C. 
Prior to the experiment, tubing, equipment and connectors (Figure 4.4) were 
autoclaved in autoclaving wrap bags (Westfield Medical, UK) to ensure that the system 
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Figure 4.5: The above pages show a diagram of the Robbins Device system for biofilm 
production and phage treatment. Green lines represent the inlet tubing and red lines represent 
the outlet tubing. Blue lines represent the temperature regulated devices. On day 5 the 
treatment was performed. Inoculation of the phage (A) and control (B) suspensions. I and II 
represent the inlet and outlet clamping for 20 min for phage adsorption. 
 
 











4.4.1. Selection of phage cocktail 
In order to select bacterial isolates prone to form thick biofilms that could after be used 
to test the S. aureus-phage mixture efficacy, a collection of isolates (listed previously in 
Table 3.3 from Chapter Three) was screened. 48 hour-old biofilms were grown and 
stained with crystal violet for biomass assessment (Figure 4.7). Isolate 15981 was used 
as a control as its ability to produce biofilm has been used in other studies documented 
in the literature (317). Surprisingly, all the isolates tested showed a good biofilm 
formation. Some of the strains, such as HT20020635, HT20040991 and Mu3, despite 
the strong biofilm produced, were rejected for further biofilm work because all phages 
from the cocktail were not able to infect them. In order to test the phage cocktail both in 
antibiotic sensitive and resistant strains, the MSSA isolate 15981 and two MRSA 














































































































































































Figure 4.7: Biofilm forming ability screening (Crystal violet stain). A 48-hour biofilm was 
performed for each of the 23 isolates and 15981 was the positive control. All experiments were 
performed four times. Dotted line represents the results obtained with the biofilm producing 
strain 15981 (positive control) and error bars indicate the mean ± standard deviation. 
Chapter Four – Assessment of phage lytic activity and biofilm removal 
153 
 
The selection of the phage cocktail against S. aureus isolates included the assessment 
of the isolated phages when growing together with the bacterial isolates under 
planktonic growth conditions. Phage K and DRA88 showed to be the only phages 
where bacterial growth inhibition was observed, at least in the first 18 hours of 
incubation and were selected. The mutant cells observed for phage DRA88 when 
treating MRSA 252 (Figure 4.9B) were recovered and another screening was 
performed in order to find a phage that would infect these mutant cells and improve the 
performance of the cocktail. Figure 4.8 shows that phage DRA288 was the only phage 
able to infect these mutant cells. However, due to contamination issues described in 
Chapter Three, Section 3.3.1.4.1, phage DRA288 had to be removed from the cocktail. 
 
 
Figure 4.8: Phage sensitivity screening for MRSA 252 resistant mutant of DRA88 in a 96-well 
microplate over 24 hours. Assays were performed in a plate reader and OD590 was read over 
time. A1 – A3: positive control; A4 – A6: negative control. Resistant mutant growing with B1 – 
DRA145; B2 – DRA147; B3 – DRA189; B4 – DRA226; B5 – DRA278; B6 – DRA279; B7 – 
DRA280; B8 – DRA281; B9 – DRA282; B10 – DRA283; B11 – DRA284; B12 – DRA285; C1 – 
DRA286; C2 – DRA287; C3 – DRA288 (□); C4 – DRA289; C5 – DRA290; C6 – DRA291; C7 – 
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4.4.2. Phage lytic assessment in planktonic bacterial cultures 
4.4.2.1. S. aureus phage cocktail assessment in broth bacterial cultures  
The efficacy of single phage DRA88 and phage K and their combination into a phage 
cocktail was assessed when treating bacterial broth cultures. Suspensions from single 
and combined phages at a multiplicity of infection (MOI) of 0.1 were introduced to the 
bacterial culture that had been growing for two hours under planktonic conditions and 
this was allowed to grow for 22 hours further (Figure 4.9). In general, use of single 
phage treatment resulted in less success that when phages were combined. This was 
clearly observed for S. aureus isolate 15981. For all three S. aureus bacterial cultures – 
15981, MRSA 252 and H325 – treated with the phage mixture, cell growth was not 
observed when compared to the bacteria not treated. Actually, an efficient inhibition 
and prevention of bacterial growth can be observed for both 15981 and H325. 
However, the same was not observed for the MRSA 252 isolate, where bacterial 
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Figure 4.9: Dynamic of S. aureus bacteria with single phage and phage mixture in liquid 
cultures over 24 hours of incubation at 37°C. Absorbance readings at 590 nm were taken in a 
microtitre plate reader. S. aureus isolates 15981 (A), MRSA 252 (B), and H325 (C) growing with 
only SM buffer (○), with single DRA88 (▼), with single phage K (Δ), and with the phage mixture 
in SM buffer (■) and also a negative-control SM-only buffer (●) are shown in the figure. Assays 
were performed three times, and OD590 was expressed as the mean ± standard deviation. 
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4.4.2.2. P. aeruginosa phage cocktail assessment in broth bacterial cultures 
The efficacy of each of the single six phages and their combination into a cocktail was 
assessed when treating a bacterial broth culture of P. aeruginosa PAO1. Suspensions 
containing the phages were prepared to achieve a MOI of 0.1 in the culture and 
introduced after 2 hours of incubation of the latter. Growth continued for a further 22 
hours. Figure 4.10 shows that for all single phage suspensions it was observed that 
eventually there was a regrowth of the PAO1 culture between 8 hours and 13 hours 
after phage treatment (time points: 10 h – 15 h). On the other hand, by using the 
suspension of the phage cocktail no regrowth and a full inhibition of the bacterial 
culture was observed when compared to the bacteria growing without phage. 
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Figure 4.10: Dynamic of P. aeruginosa PAO1 bacteria with single phage and phage cocktail in 
liquid cultures over 24 hours of incubation at 37°C. Absorbance readings at 600 nm were taken 
in a microtitre plate reader. P. aeruginosa PAO1 isolate growing with only SM buffer (■), with 
single DL52 (■), DL54 (■), DL60 (■), DL62 (■), DL64 (■) DL68 (■) and with the phage cocktail in 
SM buffer (■) and also a negative-control SM-only buffer (■) are shown in the figure. Assays 
were performed three times, and OD600 was expressed as the mean ± standard deviation. 
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4.4.2.3. Bacterial mutants’  
The efficacy of the phage cocktail regarding its concentration and the time point when 
applied to a bacterial broth culture of P. aeruginosa PAO1 was assessed. Phage 
suspensions were prepared to achieve MOIs ranging from 0.01 to 100 of phage to 
bacteria. The bacterial broth cultures were phage treated at 0 hours, 2 hours and 4 
hours of incubation time and growth continued for further 22 hours. Figure 4.11 shows 
that the bacterial culture where the phage cocktail was added at the start of the 
incubation time, only MOI 100 and 10 resulted in bacterial growth inhibition, lower MOIs 
resulted in bacterial regrowth (time point = 15 hours).  
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. 
Figure 4.11: Dynamic of P. aeruginosa PAO1 bacteria with phage cocktail at different MOIs and 
added at different time points to the liquid cultures over 24 hours of incubation at 37°C. Green 
line indicates when the phages were added, 0, 2 or 4 hours. Absorbance readings at 600 nm 
were taken in a microtitre plate reader. Assays were performed three times, and OD600 was 
expressed as the mean ± standard deviation 
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When the phage cocktail was added 2 hours after incubation all MOIs resulted in 
bacterial regrowth (time point = 15 hours), where MOI 100 shown to slow down this 
regrowth. For the bacterial suspension treated 4 hours after incubation a more 
successful inhibition of the bacterial regrowth by the cocktail was observed for all MOIs, 
although complete elimination of the bacteria was not observed during the incubation 
time assayed. 
 
4.4.3. Phage lytic assessment on an in vitro biofilm model (closed 
system) 
4.4.3.1. S. aureus biofilm eradication  
For this experiment 48 hour-old biofilms produced by three S. aureus isolates were 
established in 96-well microtitre plates. Although all isolates were strong biofilm 
producers, MRSA 252 and H325 isolates produced biofilms with more fragile structures 
when compared to isolate 15981. This could be observed when performing the 
mechanical washing steps as these biofilms were more susceptible to disruption. The 
established biofilms were treated with either single or combined phage suspensions at 
an MOI of 10 and the biofilm was assessed by crystal violet staining and intensity 
measured in a plate reader at OD600 (Figure 4.12 and 4.14). Results showed a clear 
reduction following phage inoculation compared to the non-phage inoculated wells (P < 
0.05). A decrease in biofilm biomass from the mixture compared with the single phages 
after 48 hours of treatment was observed for all cases; although this reduction was not 
significant, it could be easily observed by eye (along with the CV stained wells). 
Established biofilms were also treated only with the phage combination, but this time 
employing two different MOIs, 1 and 10, and the biofilm biomass was assessed at the 
time points 0, 2, 4, 24 and 48 hours (Figure 4.13). For S. aureus 15981 biofilms treated 
with a MOI of 10, at 4 hours after phage inoculation, there were already 50 % biofilm 
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biomass reduction (P < 0.05). After 48 hours of treatment, the biomass of the biofilm 
was almost completely disrupted (MOI of 10, P = 4.82x10-3; MOI of 1, P = 1.47x10-5). 
For S. aureus MRSA 252, biofilms were eliminated by more than 50 % (MOI of 10, P = 
0.003; MOI of 1, P = 0.012) after 48 hours of treatment. Biofilms produced by H325 
were not initially as strong as the other isolates, however it was still possible to observe 
a reduction of the biofilm over 48 hours when the phage suspension at a MOI 10 was 
inoculated (P = 0.049). For the MOI 1, a reduction of the biofilm biomass was observed 
after 24 hours of treatment, however, at 48 hours (P = 0.034) a regrowth of the biofilm 
was observed. 
 
Figure 4.12: Normalised biofilm biomass treated with single phage K, DRA88, and the phage 
mixture after 48 hours at an MOI of 10 (OD590 reading after CV staining). S. aureus isolates: 1, 
15981; 2, MRSA 252; 3, H325. Mean values (standard deviations) for the three strains treated 
with phage K were 0.63 (± 0.10), 0.30 (± 0.16), and 0.27 (± 0.06); those for DRA88 were 0.11 (± 
0.04), 0.18 (± 0.08), and 0.29 (± 0.03); and those for the phage mixture were 0.06 (± 0.02), 0.15 
(± 0.02), and 0.23 (± 0.02). Assays were performed three times, and the means ± standard 
deviations are indicated. Statistical significance of biofilm reduction was assessed by performing 
Student’s t test. P values are indicated (*, 0.05). Reprinted from reference (244) and used with 
permission. 
 




Figure 4.13: Normalised biofilm biomass treated with the phage mixture over 48 hours at two 
different MOIs (OD590 reading after CV staining). S. aureus isolates: 15981 (A), MRSA 252 (B), 
and H325 (C). Assays were performed three times, and the means ± standard deviations are 
indicated. Statistical significance of biofilm reduction was assessed by performing Student’s t 
test. P-values are indicated (*, 0.05). Reprinted from reference (244) and used with permission. 
 
 
Figure 4.14: Visualisation of wells stained with 0.1 % crystal violet after 48 hours of phage 
treatment at an MOI of 10. Shown are the biofilm wells treated with PBS, phage K, DRA88, and 
phage mixture at 0 h (A) and 48 h after (B). Experiments were performed in triplicate. Reprinted 
from reference (244) and used with permission. 
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4.4.3.2. P. aeruginosa biofilm eradication  
The literature provides several protocols for growth of P. aeruginosa biofilms in 
microtitre plates (308) and the main parameter changing is the medium used for the 
growth. Therefore, a preliminary assessment was performed in order to choose the 
best medium and conditions to achieve the production of a strong biofilm by P. 
aeruginosa PAO1 strain. LB and YPD medium supplemented with D-(+)-glucose (LBg 
and YPDg) at four different strengths were prepared: 20 %, 50 %, 80 % and 100 % and 
biofilms were established in a 96-well microtitre plate (Figure 4.15). For YPD it was 
observed an improvement in biofilm formation with the increase in medium strength. 
However and interestingly, LB medium at 50 % of its strength was seen to allow the 
formation of a stronger biofilm, showing almost twice biofilm biomass density than 
when using YPD (P < 0.05). For this reason LB at 50 % was selected to perform further 
experiments. 
 
Figure 4.15: Biofilm biomass produced by P. aeruginosa PAO1 on a 96-well microtitre plate 
when grown in different concentrations of LB and YPD nutrient media over 48 hours. Shown are 
the OD600 readings after crystal-violet staining. Statistical significance comparing both media 
was assessed by performing Student’s t test. P-value is indicated (*, 0.05). 
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Hence, 48 hour-old biofilms produced by the P. aeruginosa PAO1 were established in 
96-well microtitre plates. Washing steps were performed carefully, as although the 
biofilms were stronger than the ones produced by S. aureus; the mechanical wash step 
was still able to disrupt biofilms that were very viscous, due to high polysaccharides 
content. Established biofilms were treated with the phage cocktail at two different 
MOIs, 1 and 10, and their biomass density assessed at the time points 0, 2, 4, 24 and 
48 hours, by crystal violet staining followed by OD600 measurements (Figure 4.16). A 
clear reduction of 80 % of the biofilm biomass was observed only in the first 4 hours of 
phage treatment for MOI 1 and more than 95 % for MOI 10 (P < 0.05). At 24 hours, 
although biofilm biomass was still lower than that observed for the PBS control biofilm 
wells for both MOI cases (MOI of 10, P = 0.015; MOI of 1, P = 0.003) (Figures 4.16A 
and 4.17), there was biofilm regrowth compared to the time point at 4 hours and by the 
end of the experiment at 48 hours, the biofilm biomass measured was greater than the 
biomass of the control biofilms. In parallel, an XTT assay was performed to evaluate 
the metabolic activity of the cells in the biofilm when treated with a phage cocktail 
suspension at MOI 10 during 48 hours. A decrease of the metabolic activity in the first 
4 hours of treatment (P < 0.05) could again be observed (Figure 4.16B and 4.17), 
which was followed by a regrowth in the next incubation hours. Although in this case, 
by 48 hours the regrowth biofilm did not surpass the biomass of the biofilms inoculated 
only with PBS, showing lower numbers (P < 0.05). In another similar experiment, 
biofilms were disrupted and both bacterial and phages numbers were estimated. The 
same behaviour was observed, where in the first 4 hours of treatment there was a clear 
reduction of the viable number of cells, followed by a regrowth measured at 24 hours. 
By 48 hours a cell number reduction of ~1log could be observed, however this was 
also observed for the disrupted control biofilm and could not be related to the phage, 
but was, perhaps, due to a saturation of the biofilm environment (Figure 4.16C). 
Regarding the phage numbers in the biofilm, it was observed that at time point 4 hours 
a decrease in their concentration, most likely due to many of the phages being 
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adsorbed to the cells and not present in the surrounding environment. At 24 hours and 
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Figure 4.16: P. aeruginosa PAO1 biofilm treated with the phage cocktail over 48 hours. (A) 
Normalised biofilm biomass treated with the phage cocktail at two different MOIs (OD600 reading 
after CV staining). (B) Normalised cell metabolic activity in the biofilm treated with the phage 
cocktail at MOI 1 (OD600 reading after XTT assay). (C) and (D) show the estimation of numbers 
of viable bacterial cells and phage particles in the biofilms treated with the phage cocktail. 
Assays were performed three times, and the means ± standard deviations are indicated. 
Statistical significance of biofilm reduction was assessed by performing Student’s t test. P-
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Figure 4.17: Visualisation of wells stained with 0.1 % crystal violet after 24 hours of phage 
treatment, at an MOI of 10 and 1. Also, wells where the XTT reaction was performed can be 
observed after 4 hours of phage treatment at MOI 10. Experiments were performed in triplicate. 
 
4.4.3.3. Biofilm eradication by synchronised use of phage and antibiotic 
The synchronised effect of biofilm reduction when using the phage cocktail and an 
antibiotic was explored for S. aureus and P. aeruginosa.  The antibiotics used for this 
study were vancomycin for S. aureus 15981 and ofloxacin for P. aeruginosa PAO1. 
Vancomycin, a bactericidal antibiotic drug for S. aureus (318), inhibits the cell wall 
synthesis by preventing the peptide subunits NAG and NAM from being incorporated 
into the peptidoglycan. Ofloxacin stops the DNA replication of Gram-positive and 
Gram-negative bacteria, by inhibiting DNA supercoiling of DNA gyrase and making it a 
powerful bactericidal (319). A preliminary test was performed to assess the minimum 
inhibitory concentration (MIC) of these antibiotics when cultures were growing under 
planktonic conditions. Results showed the MIC of vancomycin for S. aureus 15981 was 
1 μg/ml and for P. aeruginosa PAO1 it was 0.25 μg/ml. Later, 48 hour-old biofilms were 
established in 96-well microplates and in a gradient scale were treated with different 
MOIs of phage cocktail (100 to 0.01) and antibiotic concentrations (128 μg/ml to 2 
μg/ml) over 24 hours (Figure 4.18). Regarding the biofilm produced by S. aureus 15981 
a more successful eradication of the biofilm was observed when treatment was done 
only by phage at MOI 10, followed by biofilms treated with MOI 10 an antibiotic 
concentrations between 16 μg/ml and 2 μg/ml were used, with biofilm biomass 
reduction in the range 46 % and 65 %. In general, any other case where the combined 
use of phage and antibiotic was employed resulted in a lower disruption of the biofilm 
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or an enhancement of the biofilm growth. For the biofilm produced by P. aeruginosa 
PAO1 the major biofilm disruption was achieved when using only ofloxacin. 
 
Table 4.2: Antibiotic MIC performed by the microdilution method. 
Antibiotic Isolate MIC (μg/ml) 
Vancomycin S. aureus 15981 1 





Figure 4.18: Biofilm biomass treated with gradient concentrations of antibiotic and phage 
cocktail over 24 hours. Results were normalised against the PBS treated biofilm (OD600 reading 
after CV staining). Lighter pink indicates higher levels of biofilm disruption (lower biofilm 
biomass) and darker pink lower levels of biofilm disruption (higher biofilm biomass). A – S. 
aureus 15981 treated with phage mixture and vancomycin. B – P. aeruginosa PAO1 treated 
with phage cocktail and ofloxacin. Experiments were performed three times. 
A 
B 
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4.4.4. Phage lytic assessment on an in vitro biofilm model (open system) 
A flow system for biofilm formation was performed in order to assess the quantitative 
and structurally changes produced by phage cocktail treatment over a period of 48 
hours. A bacterial culture growing under continuous constant conditions in a 
chemostat, with a dilution rate of 0.5, was used to feed a Robbins device for 24 hours. 
Over this time, flowing bacterial cells were allowed to attach to the surface of the 
stainless steel coupons. After 24 hours, the chemostat was replaced by fresh half 
strength media supplemented with 0.1 % of D-(+)-glucose for biofilm growth and 
maturation over 48 hours. Figure 4.19 shows the biomass recovered from the biofilm 
grown on the coupons at different time points. By 48 hours the biofilm produced was 
stronger and similar to the one observed at 72 hours. For that reason, an incubation 
























   
Figure 4.19: S. aureus 15981 biofilm increase on the surface of stainless steel coupons over 72 
hours. (A) number of viable cells recovered from the disruption of the biofilm. Assays were 
performed three times, and the means ± standard deviations are indicated. (B) Image of biofilms 
at 24 hours (left) and 48 hours (right) stained with LIVE/DEAD stain at a magnification of 20x. 
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4.4.4.1. S. aureus 15981 biofilm eradication and dispersion 
A 48 hour-old biofilm of S. aureus 15981 grown from a steady-state culture and allowed 
to develop under dynamic conditions was treated with an emulsion suspension of the 
phage mixture at a MOI 0.1 and assessed regarding its eradication and dispersion by 
counting the number of viable cells present and by visualisation of a stained specimen 
under confocal microscopy. Results showed a clear dispersion and reduction of 
biofilms attached to the stainless steel coupons compared to the ones treated with a 
PBS in emulsion suspension only (Figure 4.20C) and by 48 hours of phage treatment 
such difference was significantly different (Figure 4.20A, P = 0.003). A reduction of the 
biofilm structure of the control experiment from the first day of treatment to the end can 
be observed, whether by colony counting the disrupted biofilms or by direct 
visualisation using the confocal microscope. The biofilm height measured for the phage 
treated biofilm was 19.64 μm, SD±4.83 at 0 hours and 12.02 μm, SD±1.34 at 48 hours; 
for the PBS treated biofilm 21.98 μm, SD±4.67 compared to 15.82 μm, SD±2.64. 
Disrupted biofilms were also used to enumerate phages and it was observed a ~2log 
increase in their number over the 48 hours of treatment (Figure 20B). Such observation 
supports the fact that biofilms reduction and dispersion was a consequence of the 
phage addition and infection. Control biofilms were also screened for the absence of 
phages and rules out any possible contamination. Also, the phage injected into the 
system was at a concentration of 107 pfu/ml, however phages recovered by the 
disruption of the biofilms were in the order of 105 pfu/ml, mainly caused by the dilution 
effect, but also many phages will not attach efficiently to the bacterial cells and be 
washed out from the system. 










































Figure 4.20: S. aureus 15981 48 hour-old biofilm grown under flow conditions in the Robbins 
device and treated with a phage in emulsion suspension or PBS in emulsion suspension 
(control) for 48 hours. A - Number of viable cells recovered from the disruption of the biofilms, B 
– Number of phage particles recovered from the disputed biofilms, C – 3D images of the 
biofilms observed under the confocal microscope stained with LIVE/DEAD stain at a 
magnification of 20x. Live (green) and dead (red) bacterial cells can be observed on the surface 
of the stainless steel disk. Enumeration assays were performed three times, and the means ± 
standard deviations are indicated. Statistical significance of biofilm reduction was assessed by 
performing Student’s t test. P-values are indicated (*, < 0.05). 
 
4.4.4.2. P. aeruginosa PAO1 biofilm eradication and dispersion 
A continuous growing culture of P. aeruginosa PAO1 was also established to allow the 
production of a 48 hour-old biofilm under dynamic flowing conditions. The biofilm was 
then treated with an emulsion suspension of the phage cocktail at an MOI 0.1 and the 
biofilm was monitored and assessed regarding its eradication and dispersion using the 
same approaches used for the S. aureus biofilm previously described.  
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Figure 4.21: P. aeruginosa PAO1 48 hour-old biofilm grown under flow conditions in the 
Robbins device and treated with a phage in emulsion suspension or PBS in emulsion 
suspension (control) for 48 hours. A - Number of viable cells recovered from the disruption of 
the biofilms, B – Number of phage particles recovered from the disputed biofilms, C – 3D 
images of the biofilms observed under the confocal microscope stained with LIVE/DEAD stain 
at a magnification of 20x. Live (green) and dead (red) bacterial cells can be observed on the 
surface of the stainless steel disk. Enumeration assays were performed three times, and the 
means ± standard deviations are indicated. Statistical significance of biofilm reduction was 
assessed by performing Student’s t test. P-values are indicated (*, < 0.05; ***, < 0.001). 
 
Results showed a clear reduction of the biofilm and by 24 hours of phage treatment this 
reduction was significantly different from the PBS treated biofilms (Figure 4.21A, P = 
0.003) and by 48 hours such reduction was even more evident (P = 0.00008). Under 
the confocal microscope the biofilm reduction and dispersion was also observed 
(Figure 4.21C) and by 48 hours the presence of a biofilm on the stainless steel disks 
was barely visible with only a few dispersed bacterial aggregates. The biofilm height 
measured for the phage treated biofilm was 29.01 μm, SD±3.04 at 0 hours and 10.87 
μm, SD±2.00 at 48 hours; for the PBS treated biofilm 25.57 μm, SD±4.03 compared to 
A C 
B 
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25.22 μm, SD±1.83. Such results are reinforced by the observation of an increase in 
the number of phages present in the disrupted biofilms by ~3logs (Figure 4.21B). Also, 
here the initial concentration of phage particles recovered from the disrupted biofilms 
was lower than the amount injected. 
 
  




In this chapter the phage lytic potential of the phage cocktails, isolated and 
characterised in Chapter Three, targeting S. aureus and P. aeruginosa isolates was 
investigated in three in vitro model systems: planktonic growth, biofilm growth in a 
static system and biofilm growth in a dynamic flow system. 
The planktonic growth of phages with the bacterial isolates showed a different outcome 
when the same isolates were plated on an agar plate and the phage suspension 
spotted on. The bacterial lawn on a plate mimics a static environment, where under 
planktonic conditions bacteria and phage are in a dynamic environment. In this 
environment, adsorption of phage to bacteria is more challenging to occur and results 
from occasional random encounters. Moreover, planktonic conditions allow observing 
the bacteria-phage dynamic over time and where mutational events in both bacteria 
and phage particles are likely to occur. This makes it possible to select phages that are 
able to overcome the evolution of phage resistance in the bacterial population. 
Several studies have demonstrated that the use of a phage cocktail brings not only 
advantages regarding how broad a cocktail can be, but also in terms of preventing or 
delaying mutations in the population that can result in phage resistant clones and 
failure of the therapeutic (320, 321). When a bacterial population is growing with a 
single phage type, this can be translated in a one-to-one race and perhaps only a 
single mutation maybe needed to confer resistance to the phage. On the other hand, a 
phage cocktail where different receptors and pathways for infection are used, poses a 
more problematic situation for bacterial cells. The probability for a mutation to occur in 
a natural isolate is in the order of 10-8 (322) and as a result there is the need for 
bacteria undergo multiple mutations to achieve resistance. Bacterial broth cultures 
growing with the phage cocktails showed an elimination of bacterial cells growth and 
suppression of resistant mutants for both S. aureus and P. aeruginosa strains tested. 
However, for S. aureus MRSA 252 that was not entirely correct; after 18 hours of 
Chapter Four – Assessment of phage lytic activity and biofilm removal 
172 
 
growth bacterial cells were able to counteract the infectivity of the phage present in the 
culture, possibly due to the presence of phage-receptor-mutated clones. Such 
situations can be overcome or delayed by including additional phage types to the 
therapeutic mixture, which is a task to undertake that is easier (more rapid and likely to 
succeed) than the discovery of a new antibiotic. However, the likely scenario in vivo is 
that reducing the initial bacterial load could be enough to bring the bacterial numbers 
under control so that an antibiotic drug or the action of the immune system could clear 
the infection in an effective way (323). Such bacterial mutation emergence can be, 
however, manipulated by studying and optimising the optimal phage concentration to 
treat the culture. The results of testing a range of different phage cocktail MOIs added 
to a planktonic culture, where the arms race between bacteria and phage can be easily 
observed, suggest better results in suppressing the regrowth by adding lower phage 
concentrations. This has been previously observed (324, 325). More successful results 
were achieved by adding phages later on to the growing planktonic culture; this might 
be related to a slower metabolic state of bacteria when compared to the growth at the 
start of the incubation time, suggesting a lower chance for bacteria mutational events 
or instead be related at some extent to the existence of a resistant sub-population or to 
a random fluctuation model followed by the interaction of phage and bacteria and the 
appearance of resistant bacteria (326). 
More than 60 % of all infections are related to the formation of biofilms, as previously 
discussed in Chapter One. Hence, although assessment of phage lytic activity on 
bacterial planktonic growth reveals to be a significant assay it is important that biofilm 
model studies are investigated when testing a new antibacterial therapeutic and phage 
cocktails are required to go through those studies. Some studies already on S. aureus 
and P. aeruginosa strains suggest the significant potential use of phages to reduce 
and/or eliminate biofilms produced by those strains. This is the case for phage K, 
where biofilms produced by S. aureus isolates showed a significant decrease in their 
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biofilm biomass when treated with phage (220, 238). Also, cocktails of isolated phages 
have been successfully tested on biofilms produced by P. aeruginosa isolates, such as 
PAO1 (240), and also assessed for prevention of biofilm formation on indwelling 
medical devices, such as catheters (216). In this chapter, it is shown that phage 
cocktails were able to significantly reduce the biofilm biomass produced by S. aureus 
and P. aeruginosa. The first biofilm model system was performed under static 
conditions on a polystyrene surface for 48 hours and phages were added to the formed 
biofilms. For the isolate S. aureus 15981 the eradication effect started promptly after 
addition of the phage mixture and after 48 hours of treatment the biofilm was almost 
completely disrupted. To date very few studies have been performed regarding phage 
cocktail treatments, especially to treat S. aureus biofilms and in particularly those 
formed by MRSA isolates. Kelly and colleagues (220) have shown the efficacy of using 
a cocktail of phage K and its derivatives on the eradication of S. aureus biofilms 
produced by non-human clinical isolates. In this chapter, prevalent S. aureus human 
clinical isolates, that also included MRSA types, were used for the biofilm assessment 
of the phage mixture. For P. aeruginosa PAO1 the biofilm biomass disruption after 
addition of the phage cocktail was quickly observed in the first six hours of treatment. 
24 hours later, although the biofilm biomass was still lower than the biofilm PBS-
treated, it was clearly higher than the previous endpoint. By 48 hours the biofilm 
showed a completely regrowth with a biomass higher than the non-treated biofilms. 
Biofilm destruction was shown not only by the crystal violet biomass staining, but also 
when assaying the metabolic activity and the number of viable cells of the biofilm, and 
after 24 hours the reduction was followed by regrowth. This was not caused by a lack 
of phage particles, because phages were recovered from the disrupting of the biofilms. 
A decrease in phage numbers can be observed in the first 4 hours of treatment, where 
phages by then have been able to not only disrupt the biofilm matrix releasing bacterial 
cells, but by infecting the cells. By 24 hours of treatment a clear proliferation of the 
phages was observed. Similarly, for S. aureus H325 a regrowth of the biofilm was 
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observed after 24 hours of treatment when using the lower MOI. Such regrowth has 
also been observed elsewhere (240) and it might be a consequence of a longer 
interaction of the phage with the bacteria, also helped by a slower metabolic activity of 
the bacteria in the biofilm where phages proliferation is slowed down, resulting in the 
emergence of phage resistant clones in the bacterial population (327). For all cases the 
higher MOI showed to be more rapid in reducing the biofilm biomass and also better 
preventing the biofilm regrowth, observed for S. aureus H325 and P. aeruginosa PAO1.  
Comparing the effect of the phage cocktails on broth cultures to biofilms, a more 
positive and rapid effect was observed on eliminating the bacterial load of broth 
cultures than that on biofilm, which was disrupted at a slower pace. This scenario was 
hypothesised to be due to the metabolic state of the cells. In a biofilm, cells can be in a 
low metabolic activity state and phages cannot proliferate as efficiently and as quickly 
when compared to actively growing cells (238). This has been also been shown for 
antibiotic drugs where bacteria in biofilms can be much more resilient than those in 
planktonic culture (208). Such an observation was explained as not mainly due to a low 
penetration of the antibiotic through the EPS matrix, but mainly due to the low 
metabolic activity of cells and oxygen limitation, particularly the inner areas of the 
biofilm, impairing the action of the drug (328). This was actually observed, when 
treating the biofilms produced by S. aureus 15981 with vancomycin, only a 
concentration 128 times higher than the effective concentration used in the planktonic 
state were able to disrupt around ~30 % of the biofilm biomass. For some other cases, 
the biofilm biomass showed an increase when compared to biofilms also receiving 
phage treatment suggesting that the addition of the antibiotic might have resulted in 
antibiotic resistance development. In a study it was shown that this increase in 
antibiotic resistance was due to a lower penetration of the drug to the insides of the 
biofilm and cells were gradually exposed to the antibiotic molecule, which triggered 
stress-induced changes in their metabolic and transcriptional processes and so 
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selected for resistance, however interestingly such low penetration was not found to be 
attributed to the production of the slime polysaccharide matrix (329). The biofilm 
produced by P. aeruginosa PAO1 treated with ofloxacin on the other hand was almost 
completely disrupted by using four times higher the concentration for the MICs. Phage 
treated biofilms showed greater disruption when treated with lower MOIs, following the 
same trend observed for the biofilm studies shown in Figure 4.16A, perhaps a high 
selective pressure (MOI100) gives an advantage to the already resistant types in 
population, that will multiply using the resources made available after elimination of the 
sensitive cells (by the phage). When applying a low selective pressure (MOI0.1), 
sensitive cells are slowly eliminated and resources are shared for longer among 
resistant and sensitive cells. It can be hypothesised thus in such scenario, resistant 
cells do not multiply as quickly and phages meanwhile have the opportunity to undergo 
evolutionary changes able to counteract resistance. 
Bacteria are able to adapt to different habitats and S. aureus and P. aeruginosa are no 
different (as previously described in Chapter One). Such flexibility is made possible 
through phenotypic changes employed by the bacteria, usually by expression or loss of 
cellular components, allowing them to better adapt (330). Some of these changes will 
have a direct effect on bacterial attachment to surfaces, how biofilm communities are 
formed and how resilient they are to external stresses, such as phages and antibiotics 
(331). For this reason, when studying biofilms it is important to provide a controlled 
bacterial culture when colonising to produce biofilms on surfaces (311). The in vitro 
closed biofilm system of microtitre plates misses out such controlled environment, 
where the inoculated bacterial cells proliferate and grow as agglomerates that 
eventually stack together forming a biofilm. However, the environment over 48 hours, 
even with the addition of fresh nutrient media, changes through the experiment 
perhaps reaching a saturated situation. This is in contrast to the situation of a biofilm 
model produced using a bacterial culture growing in a chemostat, in which levels of 
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bacterial cells, their products and waste and media components are constant. Such a 
controlled environment allows bacteria to grow at a constant growth rate. It is know that 
the bacterial growth rate interferes with the different expression of cell wall proteins and 
secretion of extracellular polysaccharides (332) that will ultimately be implicated in the 
adhesion process of bacterial cells to a surface  (333). The key point is that the growth 
rate can be easily manipulated to achieve slow growth rates, where expression of cell 
wall proteins is enhanced and bacterial communities resemble at a higher level an in 
vivo situation. Also, the MRD provides biofilm produced under a dynamic environment; 
hence such communities are more likely to be better protected from external surfaces 
and better attached to the surface and cells to each other. 
Biofilms produced on the MRD flow system were revealed to be strong structures 
composed of a majority of live cells, but where dead cells and possibly water channels 
could also be observed. The attachment to the coupons surface was improved by 
dipping those surfaces into a mucin solution, as mucin promotes biofilm formation 
(334). The mucus layer is largely composed of mucin oligosaccharides (335) that 
represent binding sites for the bacterial cells adhesins, similar to those in the airways of 
cystic fibrosis patients (336). Others workers have used media supplemented with 
human plasma solution to stimulate the growth of S. aureus biofilms (337). The results 
showed that S. aureus formed very robust and reproducible biofilms under static 
conditions; with strain 15981 producing the strongest, most stable biofilm in polystyrene 
plate wells. For this reason, this strain was selected for further study including its use in 
the dynamic flow model. The phage suspensions when applied to the formed biofilm 
were able to disrupt and disperse the bacterial cells. However, such disruption 
compared to the one observed for the static model took longer to occur. As mentioned 
above, this might be related to the structure of the biofilms produced from a continuous 
culture and matured under flow conditions that will resemble more a natural biofilm. It 
was also observed, however that the biofilm receiving the control treatment also 
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showed a gradual dispersion over the 48 hours of treatment. The presence of phages 
was ruled out after assessing those biofilms for the presence of study phage. Hence, 
such disruption might be related to the several sampling interruptions to the flow 
system, where the flow was paused. This somehow might have interfered with the 
structure of the biofilms. Lastly, a bubble trap was not used and therefore bubbles 
passing through the MRD could have caused biofilm disruption. This, on the other 
hand, was not observed for the control biofilm produced by P. aeruginosa PAO1 where 
a maturation of the biofilm was observed over the experiment. Interestingly, the biofilm 
disruption outcome observed by the 48 hours of treatment was almost complete and a 
regrowth of the biofilm, promoted by bacterial resistance to phage, was not observed. It 
has been noted that P. aeruginosa biofilms produced by a chemostat culture coupled 
with a flow device system was shown to have greatly upregulated the expression of a 
large number of cellular proteins when compared to planktonic growth (338). Hence, 
this result suggests a more promising and successful use of the P. aeruginosa phage 
cocktail as a therapeutic weapon. Also, emphasizing the importance of testing the 
phage cocktails in different biofilm models, as expression of polysaccharides, cell 
signalling and ultimately resilience to external stresses is strongly affected by a myriad 
of factors and strategies, where the success of a therapeutic might be strongly 
dependent.  
The studies performed in this chapter suggest that the use of phage cocktails, in this 
case for S. aureus and P. aeruginosa could provide practical alternatives to antibiotic 
treatments for combating such biofilm related infections and in particular the 
devastating effects of biofilm related MRSA and CF infections. Even with the 
contribution of these studies to the effectiveness of bacteriophage therapy to fight 
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5.1. Chapter summary  
In the previous chapter the phage cocktails were characterised and their lytic and 
biofilm eradication potential were assessed on in vitro models. In this chapter the 
phage cocktails targeting S. aureus and P. aeruginosa are used on an in vivo Galleria 
mellonella infection model, where both phage treatment and protection are studied. 
 
5.2. Background 
In vitro studies provide a valuable first understanding of the efficacy of a phage 
cocktail, however in accordance with what happens to any other prospective 
therapeutic product it is even more important to assess this efficacy on in vivo infection 
models. In vivo models comprise advanced multifactorial environments that might 
reveal unpredicted interactions not observed in a modest in vitro model system. In an in 
vivo model, factors such as the distribution pattern of phages, the target bacteria itself 
establishing an infection and interacting with the host, the phages needing to get 
access to the cells, the presence of an active immune system and phage loss by 
excretion, all influence the final therapeutic efficacy of the phage product. 
Mammalian models, such as mouse models have been extensively used to test phage 
efficacy (339–341), however such models are associated with significant cost, 
appropriate infrastructures and  ethical issues. Insect infection models on the other 
hand are valuable alternatives showing reliable results. Insects are provided with 
advanced systems for fighting antimicrobial disease. Although these are much simpler 
than the mammalian systems, they are still complex (342), making them  similar to 
mammals and pertinent models to test new antimicrobials. When facing a bacterial 
invasion, the haemocyte cells in the haemolymph are able to phagocytise the invaders. 
At the moment six types of haemocytes have been reported (343). Furthermore, there 
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are the production of a humoral immune response involving the synthesis of 
antimicrobial peptides, such as lysozyme (344), and a heat-shock protein (345). Also 
processes, such as haemolymph clotting, wound healing and melanisation are 
strategies employed by the insect to overcome a threat. The last one relates to the 
activation of the prophenoloxidase cascade, performed by serine-proteases. When 
activated, phenoloxidase initiates the biosynthesis of quinolones to melanin pigment, 
which is deposited on the insect cells and around the invading pathogen as a defensive 
strategy (346, 347). 
Regarding Galleria mellonella (the greater wax moth), this infection model brings 
several advantages. The caterpillar larvae are easy to handle and it is possible to 
perform several injections with fair accuracy (about 2 cm long and 250 mg on average), 
they are able to live in a wide range of temperatures, including 37 °C, making it 
possible to perform studies that simulate mammalian situations. They are susceptible 
to numerous human pathogens making it possible to get positive correlation with an 
infection in mammals (348). Purchase of the worms is cheap and they are easily stored 
at 4 °C in a cold room, hence there is no need for an animal facility. When testing a 
new antimicrobial, record of larvae survival numbers is possible by direct observation. 
When dead, larvae show lack of movement and turn black due to deposition of melanin 
on the tissues. Finally, the use of G. mellonella larvae for research testing is ethical 
approval-free, making it a very appealing model for a first attempt before testing on a 
more complex in vivo model (349). 
The wax moth larva G. mellonella as a model has been used already to examine 
several host-pathogen interactions, including bacterial virulence studies for S. aureus 
(350), P. aeruginosa (348)  and Bacillus cereus (351), but fungus virulence has also 
been studied, such as Candida albicans (352). Also experimental antimicrobial agent 
assessment using G. mellonella infection models was studied previously (353, 354) 
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and phage therapy has recently been reported, where infections caused by 
Burkholderia cepacia and Cronobacter sakazakii were studied (355, 356). 
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5.3. Materials and Methods 
5.3.1. Bacterial strains and preparation of inoculum 
Phage therapy was assessed on two infection models using S. aureus MRSA 252 and 
P. aeruginosa PAO1 strains. Clinical isolates were also used in further tests and 
included S. aureus H560, 15981, H137, HT2004-0991 and 97.1948.S, the first two 
have a MSSA genotype and the other three are MRSA isolates. Regarding P. 
aeruginosa two clinical isolates were used, PA45291 and BC00907, isolated from 
bacteraemia and cystic fibrosis samples, respectively. Bacteria were grown overnight in 
TSB or LB, depending if the bacteria were S. aureus or P. aeruginosa, and on the 
following day a 1:100 dilution was performed in order to establish a subculture. The 
subculture was incubated until mid-log phase once they achieved an OD ~1.0 and 
washed once in PBS.  Cells were resuspended in PBS to give a final concentration of 
1x108 cfu/ml and diluted accordingly in PBS to the required inoculum size for each 
experiment. The cell number was always confirmed by a standard colony assay on 
agar plates. 
 
5.3.2. Phage cocktail preparation and titration 
Phage cocktails were prepared for use against S. aureus (phage strains DRA88 and 
Phage K) and P. aeruginosa (phage strains DL52, DLA54, DL60, DL62, DL64 and 
DL68). The phage strains had shown lytic efficacy against all S. aureus and 
P.aeruginosa as previously described in Chapters III and IV. Phage suspensions were 
propagated on the respective host, i.e. S. aureus RN4220 and P. aeruginosa PAO1 
and PEG-precipitated (phage propagation and PEG-precipitation were previously 
described in Chapter Two Section 2.2.4. and Section 2.4.1.1.). All the necessary 
dilutions were performed in SM buffer. For the titration of the bacteriophage content in 
Chapter Five – Assessment of phage effect on the survival of Galleria Mellonella 
184 
 
the haemolymph, a similar methodology to the propagation was followed. The several 
dilutions were mixed with the host bacterial cells and 3 ml of soft agar was added and 
poured onto agar plates. After an overnight incubation, plaques were counted to 
determine phage titre. 
 
5.3.3. G. mellonella phage therapy assay: treatment and protection 
Larvae of G. mellonella were obtained from Livefood UK Ltd (Somerset, UK). Larvae 
were stored at 4 °C used within 1 week of receipt. A modified methodology developed 
by Peleg et al. (357) was used to infect each larvae. Briefly, larvae were surface 
sterilised before injection with a Fat Aid pre-injection swab containing 70 % ethanol.  A 
pair of tweezers was used to immobilise the larvae and with a 26 gauge syringe 10 µl 
of required bacterial inoculum was delivered into the larval haemolymph behind the last 
proleg (Figure 5.1). For the treatment model, phage suspension was delivered behind 
the last proleg on the opposite side to the infection two hours post-infection. For the 
protection experiment phage suspension was given two hours pre-infection. All 
experiments used 15 larvae per treatment. For all the experiments a positive control 
group, where the larvae were infected and treated with PBS solution, and two negative 
control groups were also included: one group injected with PBS only, assessing the 
impact of any negative effect from the injection procedure, and one group injected with 
phage suspension only, assessing toxicity of the phage cocktail. Larvae were placed 
into petri dishes and incubated at the desired temperature, being examined regularly 
and recorded as dead when they did not move in response to touch. Kaplan-Meier 
survival curves were plotted using OriginPro 8.0 Software and statistical analysis was 
performed by using the Log-rank (Mantel-Cox) statistical test with 95 % confidence 
interval. 
 




Figure 5.1: A – Surface sterilisation of larvae before injections; B – Injection of larvae in the last 
proleg; C – Mixture of dead (black) and alive larvae on the petri dish. 
 
5.3.4. Heat-killed bacteria experiment 
Bacteria were grown overnight in TSB and on the following day a 1:100 dilution was 
performed in order to establish a subculture. The subculture was incubated until mid-
log phase once they achieved an OD ~1.0 and washed once in PBS. Bacterial cells 
were killed by heat at 95 °C for 10 min. 
 
5.3.5. Bleeding larvae haemolymph 
In order to follow the kinetics of bacteria and phage in the larvae haemolymph larvae 
were bled out. Experimental groups were established and the proper injections made 
and every 0, 8 and 24 hours the concentration of phages and bacteria was measured. 
To bleed the larvae, tweezers were used to make an incision and the content of the 
larvae was collected to a centrifuge tube. Three larvae were used for each time point. 
Recovered volumes of haemolymph ranged from 20 to 40 μl.  All phage dilutions were 
performed in SM buffer and bacterial dilutions were performed in FAS virucide as 
described in Chapter Two, Section 2.11.6, in order to degrade all the phages in the 
haemolymph that could interfere with the bacterial numbers. To rule out the possibility 
A 
B C 
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of PAO1 cells evolving phage resistance during the in vivo infection, re-isolated PAO1 
cells were subjected to plaque assay to confirm susceptibility.   




5.4.1. Survival curves for S. aureus infection and phage treatment 
The effect of S. aureus MRSA 252 on the survival of the larvae was shown to be dose 
dependent, where a lower survival rate was observed for the higher inoculum of S. 
aureus. We injected three groups of larvae with OD 1, 0.5 and 0.1, corresponding to 
approximately 4.5x106, 2.25x106 and 4.5x105 cells injected per larvae (Figure 5.2).  The 
survival rates at 48 hours after larvae infection were 40 %, 60 %, 93.33 %, respectively. 
At 72 hours post-infection survival rates were reduced to 33.33 %, 40 %, 73.33 %, 
respectively. Larvae were also injected with the phage cocktail at a concentration of 106 
virus per larvae in order to investigate if there was a toxic or antigenic reaction by the 
larvae defence mechanisms. Survival numbers remained at 100 % throughout all 
experiments. For the treatment experiments, larvae were infected with S. aureus 
MRSA 252 and 2 hours later the phage cocktail was injected. Figure 5.3 shows the 
survival rates for larvae infected at OD 0.1 (5.3.A) and OD 1 (5.3.B) that received 
phage treatment at MOI 1. Surprisingly, we did not observe an improvement of larvae 
survival for the group receiving phage treatment. Larvae treated with phage showed a 
more rapid killing than the ones not receiving treatment. For an OD 1 24 hours post-
infection, phage treated larvae showed a survival rate of 66.67 % vs 73.33 % for the 
positive non-treated control group. For the OD 0.1, the group receiving treatment 
showed a survival rate of 86.67 % compared to 100 % survival of the non-treated 
group. The same effect was also observed for an OD 0.5 when treated with two 
different MOIs – 10 and 1. Figure 5.4 shows the survival rates, where only 40 % of 
larvae treated with MOI 10 were alive after 24 hours post-infection and after 48 hours 
both MOIs had resulted in 60 % death of larvae compared to the non-treated group 
with 70 % of larvae alive. 
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Figure 5.2: Survival of G. mellonella larvae infected with different inoculum concentrations of S. 
aureus MRSA 252 and with phage cocktail only. OD, optical density. 
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Figure 5.3: Survival of G. mellonella larvae infected with different inoculum concentrations of S. 
aureus MRSA 252, treated 2 hours post-infection with phage cocktail at MOI 1. A – OD 0.1, B – 
OD 1.0. OD, optical density. 
 
5.4.2. Effect of heat-killed S. aureus MRSA 252 cells on larvae survival 
Previously it was shown that heat-killed S. aureus bacteria did not result in larvae killing 
(350), however because we are using a different S. aureus strain we wanted to verify if 
the more rapid death of larvae was only due to a strong immunogenic response to 
bacterial cell lysis by the phage, but also due to the bacterial cell wall itself. S. aureus 
MRSA 252 subculture (~OD 0.5) was inactivated by heat and injected in the larvae. 
Two other groups were set up with S. aureus MRSA 252 (~OD 1.0), the positive control 
B A 
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group (bacterial cells and PBS) and the treatment group (bacterial cells and phage 
treatment). After 48 hours post-infection, the group injected with the bacteria killed by 
heat remained with a 100 % survival rate (Figure 5.4). The inactivation of the bacteria 
is not causing the larvae killing. 


















 MRSA 252 OD 0.5 + PBS
 MRSA 252 OD 0.5 + MOI 10
 MRSA 252 OD 0.5 + MOI 1
 MRSA 252 heat killed
 
Figure 5.4: Survival of G. mellonella larvae infected with different inoculum concentrations of S. 
aureus MRSA 252, treated 2 hours post-infection with phage cocktail at MOI 1 and infected with 
S. aureus MRSA 252 heat killed. OD, optical density. 
 
5.4.3. Effect of ex-vivo phage lysed MRSA 252 cells on larvae survival 
To investigate if the more rapid death of larvae was due to a strong immune response 
to bacterial cell debris, composed of exotoxins and surface proteins, and resultant from 
the phage lytic cycle infection, S. aureus MRSA 252 cultures in mid-log phase showing 
approximate ODs of 1.0, 0.5 or 0.1 were incubated with the phage cocktail at MOI 1 
and incubated for approximately 4 hours until when the culture was not showing signs 
of turbidity. Other S. aureus MRSA 252 mid-log phase cultures at the same ODs, but 
not challenged by the phage were also performed. Groups of larvae were injected 
either with the lysed cultures or active culture. Treatment groups were also performed 
(bacterial cells and phage cocktail). In this experiment, bacterial injections and phage 
administration were performed one after the other. For all the three experiments 72 
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hours post infection (Figure 5.5), larvae infected with bacterial cells lysed showed 
survival rates higher than 80 % (OD 1.0 – 93.33 %, OD 0.5 – 93.33 %, OD 0.1 – 86.67 
%). Survival rates for larvae receiving a phage treatment after infection were lower than 
47 % for all cases (OD 1.0 – 33.33 %, OD 0.5 – 46.67 %, OD 0.1 – 33.33 %). Hence, 
bacterial debris caused by the lysis of bacterial cells did not cause the low survival 
rates observed when treatment is applied in vivo.  
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Figure 5.5: Survival of G. mellonella larvae infected with different inoculum concentrations of S. 
aureus MRSA 252, treated 2 hours post-infection with phage cocktail at MOI 1 and infected with 
S. aureus MRSA 252 lysate. A – OD 0.1, B – OD 0.5 and C – OD 1.0.  OD, optical density. 
 
5.4.4. Clinical isolates of S. aureus 
To verify if the observed rapid killing effect on larvae infected with S. aureus MRSA 252 
and treated with phage may also be observed for other S. aureus bacteria we infected 
larvae with a group of five clinical isolates (MSSA and MRSA included) and treated 
A B 
C 
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them with phage at MOI 1. After 24 hour of larvae infection for all the phage treated 
groups mortality rates were 100 %. For larvae infected with clinical isolates H137 
(MRSA) and 15981 (MSSA) observed survival was 30 % and 50 %, respectively, when 
not treated with phage (Figure 5.6). The clinical strains all showed higher virulence in 
comparison to MRSA 252. 
 



















Figure 5.6: Percentage of G. mellonella survival infected with S. aureus clinical strains at 24 
hours in treated and non-treated groups. 
 
5.4.5. Phage treatment of S. aureus infection at different temperatures 
Another strategy was used in order to test if the strong immune response to the 
bacterial debris was caused by phage cell lysis, we established parallel experiments 
run at two different temperatures – 26 °C and 37 °C. The lower temperature should 
slow down the proliferation of the bacteria as well as the immune response to the 
infection and cell debris. The phage MOIs administered were also lowered for both 
experiments – 0.1, 0.01 and 0.001 – resulting in lower cell burst. Hence, larvae infected 
with S. aureus MRSA 252 at OD 1 and incubated at 26 °C or 37 °C for infection to 
establish and treated after 2 hours with the different phage MOIs. Larvae were infected 
with S. aureus MRSA 252 (~OD 1.0) and survival of larvae was followed over 48 hours. 
The uninfected groups (PBS only) did not result in larvae death, although in some 
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cases 10 % mortality was observed, probably by chance. For the group studied at 26 
°C, for all infected larvae, a lower mortality rate was observed than the one observed 
for the group kept at 37 °C (Figure 5.7AB). For example, after 48 hours the survival 
rate at 26 °C for infected larvae not treated was 55 % compared to no survival at 37 °C.  
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MRSA 252 OD 1 + PBS 
MRSA 252 OD 1 + MOI 0.1 
MRSA 252 OD 1 + MOI 0.01 
MRSA 252 OD 1 + MOI 0.001 
 
Figure 5.7: Survival of G. mellonella larvae infected with S. aureus MRSA 252 at OD~1.0 
treated 2 hours post-infection with phage cocktail at MOI 0.1, 0.01 and 0.001, incubated at two 
different temperatures (A – 26 °C, B – 37 °C). C - C. Percentage of G. mellonella survival at 24 
hours. OD, optical density. 
 
At 26 °C we observed that the phage cocktail showed some success at maintaining 
larvae survival. After 24 hours untreated larvae showed a survival rate of 60 % and 
when treated with phage there was a survival improvement; 75 %, 65 % and 80 % for 
MOIs 0.1, 0.01 and 0.001, showing better protection was observed at lower phage 
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10 % survival for the untreated larvae and 20 % for the larvae treated with MOI 0.01. 
MOIs 0.1 and 0.001 showed a 5 % and 10 % survival rate (Figure 5.7C), however the 
survival curves were not statistically significant different (P > 0.05). 
 
5.4.6.  Phage protection of S. aureus infection at different temperatures 
A similar experiment performed to study the phage cocktail treatment efficacy was 
performed to assess the infection protection efficacy on the larvae. For this purpose, 
larvae were administered phage at varying MOIs - 0.1, 0.01 and 0.001 – and 
incubated, one group at 26 °C and other at 37 °C. Here the viral particles were allowed 
to distribute along the host system. Two hours later, all larvae were infected with S. 
aureus MRSA 252 and their survival was observed over 48 hours. For this experiment 
the uninfected groups (PBS only) also did not result in larvae death, although 10 % 
mortality was observed for group kept at 37 °C. For the group kept at 26 °C  (Figure 
5.8A) only the larvae receiving a prophylactic phage dose of MOI 0.1 showed a more 
successful reduced mortality rate when compared to the non-treated group, 80 % vs 50 
% at 24 hours (P = 0.02) (Figure 5.8C). The other two phage doses didn’t show any 
protection effect, both 45 % of survival rates. For the group incubated at normal 
mammalian temperature all three prophylactic phage doses showed an improvement of 
larvae survival compared to the non-treated group (Figure 5.8B). At 24 hours, the 
untreated group only showed 10 % larvae survival compared to 20 %, 15 % and 25 % 
for MOIs 0.1, 0.01 and 0.001, respectively (Figure 5.8C). Still, the survival curves were 
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MRSA 252 OD 1 + MOI 0.01 
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Figure 5.8: Survival of G. mellonella larvae infected with phage cocktail at MOI 0.1, 0.01 and 
0.001 and infected with S. aureus MRSA 252 at OD 1 two hours after incubated at two different 
temperatures (A – 26 °C, B – 37 °C). C - Percentage of G. mellonella survival at 24 hours. OD, 
optical density. 
 
5.4.7. Survival curves for P. aeruginosa infection and phage treatment 
In this study phage and infection interactions were examined under a treatment model.  
Larvae were infected with either 10 or 100 cells of P. aeruginosa PAO1, confirmed by a 
colony plate assay, and left to allow an infection to establish for two hours. Varying 
MOIs of phage were then administered and death was observed over 48 hours.  No 
mortality was recorded in the PBS controls and non-treated larvae died quicker when 
infected with 100 cells vs 10 cells. Administration of phage prolonged the survival of the 
larvae in a dose dependent manner, but no survival was eventually seen in all groups 
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treated larvae, but 40 % survival for those infected with 10 cells and treated with an 
MOI of 10 compared with 20 % survival with those infected with 100 cells at the same 
MOI (Figure 5.9C). A statistically significant difference was observed between the 
treated and non-treated survival curves (P < 0.0001). 
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PAO1 + PBS 
PAO1 + MOI 10 
PAO1 + MOI 1 
PAO1 + MOI 0.1 
100 cells/larvae  
Figure 5.9: Kaplan-Meier survival curves of G. mellonella infected with (A) 100 cells or (B) 10 
cells of P. aeruginosa PAO1 and treated with phage at varying multiplicities of infection two 
hours post-infection. C. Percentage of G. mellonella survival at 24 hours. 
 
5.4.8. Phage protection from P. aeruginosa infection  
A phage protection model was also performed to assess its efficacy on larvae survival. 
Larvae were given varying prophylactic doses of phage two hours prior to infection with 
P. aeruginosa PAO1.  Similarly to the treatment experiment, larvae infected with 100 
cells died quicker than those infected with 10 cells when given PBS two hours before 
C 
A B 
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infection (Figure 5.10). At 24 hours, survival rates ranged from 80 % in larvae given an 
MOI of 100 to 35 % in those given an MOI of 0.1 (Figure 5.10C).  Survival ranged from 
90 % to 60 % in Galleria given MOIs of 100 and 1, respectively. A statistically 
significant difference was observed between the treated and non-treated survival 
curves (P < 0.0001). 
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Figure 5.10: Kaplan-Meier survival curves of G. mellonella infected with (A) 100 cells or (B) 10 
cells of P. aeruginosa PAO1 and pre-treated with phage at varying multiplicities of infection two 
hours pre-infection. C. Percentage of G. mellonella survival at 24 hours. 
 
5.4.9. Clinical isolates of P. aeruginosa 
To validate the model of phage therapy with P. aeruginosa we decided to test the 
protection assay with two clinical strains isolated from cystic fibrosis patients 
experiencing acute and chronic episodes of P. aeruginosa infections. With the 
C 
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PA45291 acute strain all infected larvae were dead by 24 hours whereas a 60 % 
survival was observed at 28 hours in the group which were pre-injected with phage at 
an MOI 10 (P < 0.0001).  When larvae were infected with the BC09007 chronic strain 
there was little death at 24 hours (90 % survival) for the infected non-protected larvae, 
but 100 % survival in the phage protected group.  By 40 hours all larvae were dead 
(Figure 5.11).  
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Figure 5.11: Survival curves of G. mellonella infected with 10 cells of (A) acute P. aeruginosa 
PA45291 or (B) chronic P. aeruginosa BC09007 and pre-treated with phage at an MOI 10 two 
hours pre-infection. 
 
5.4.10. Comparison of single and double phage treatment of P. 
aeruginosa infection 
To verify if the unsuccessful treatment or infection protection by the phage was the 
cause of larvae death at the end of experiments where all larvae eventually died, we 
administered a second dose of phage two hours after the first treatment dose. The first 
dose showed an MOI 100 compared to the bacterial inoculum injected in the larvae and 
the second dose had the same concentration, although at the moment of the second 
dose (four hours after infection) the concentration of bacteria most probably had 
triplicated. We observed no difference on the survival rates of the larvae challenged 
with one and two phage treatments, both showing at 26 hours and 48 hours post-
B A 
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infection 73.33 % and 6.67 % survival compared to no survival in the non-treated group 
(Figure 5.12). This suggests that the cause of larvae death was not a lack of phage. 
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 PAO1 + MOI100
 PAO1 + MOI100(x2)
 
Figure 5.12: Survival curves of G. mellonella infected with 100 cells P. aeruginosa PAO1 and 
single or double treated with phage at an MOI 100 with two interval from each injection. 
 
5.4.11. Kinetics of P. aeruginosa infection and effect of phage treatment 
In order to understand the kinetics of a P. aeruginosa infection within G. mellonella 
(Figure 5.13), larvae were infected with 100 cells using the protection model of 
infection. Bacteria and phage were quantified at three set time points by bleeding the 
haemolymph of the larvae. No endogenous P. aeruginosa cells or phage particles with 
lytic activity against P. aeruginosa PAO1 were detected in the uninfected controls for all 
the time points. For the larvae which were given only P. aeruginosa PAO1, control 
group, the numbers of cells isolated from the haemolymph increased over the duration 
of the experiment.  By 24 hours all larvae were dead and numbers of P. aeruginosa 
were in the order of 108 cfu/larvae. The second group of larvae were given a 
prophylactic dose of phage 2 hours before the infection and phage and bacteria were 
then quantified over the course of infection.  Numbers of P. aeruginosa PAO1 were 
comparable to that of the non-treated larvae after 8 hours infection, but were three 
orders of magnitude lower at 24 hours compared with the group lacking phage 
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prophylaxis. These larvae were alive at 24 hours.  Numbers of phage increased over 
the duration of the infection reaching a peak titre at 24 hours of 108 pfu/larvae. 
Bacterial colonies from both groups were grown and challenged with the phage cocktail 
in vitro under planktonic conditions (Figure 5.14). PAO1 from lab stock was used as a 
control. We observed that bacteria recovered from the treated group had possibly 
undergone a mutation that had improved their fitness, resulting in a faster growth. The 
bacteria recovered from the untreated group showed a similar growth curve as PAO1 
from the stock. However, all three cultures when growing in the presence of the phage 
showed no signs of resistance. 








































Figure 5.13: in vivo kinetics of P. aeruginosa infection within G. mellonella with and without 
phage treatment. 
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Figure 5.14: Dynamics of bacterial colonies recovered from non-treated and phage treated G. 
mellonella larvae when grown with the phage cocktail in planktonic cultures. 
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5.5. Discussion  
Antibiotic resistance among human bacterial isolates is a worrying fact nowadays that 
is commonly seen and is becoming the rule rather than the exception. S. aureus and P. 
aeruginosa are at the top of the list with resistance profiles for more than one antibiotic 
class. Both bacteria are known to cause systemic infections (358, 359) that usually end 
up in the patient’s death if not effectively treated (360). Phage therapy is considered an 
encouraging novel therapeutic alternative to antibiotics, especially for those bacteria 
showing increased resistance to the main antibiotics available. As with any other 
therapeutic product, phage therapy is required to be assessed on in vivo models. 
However, as a first line assessment, using in vivo models might provide some hurdles, 
such as the lack of appropriate facilities and obtaining ethical approval. The G. 
mellonella infection model usually provides an additional intermediate step between in 
vitro and in vivo mammalian studies. 
Two models of infection were performed for both S. aureus and P. aeruginosa – 
infection treatment and infection protection by use of phage cocktails. For the first 
situation, infection was allowed to establish for 2 hours prior to administration of phage, 
for the second situation phages were administered 2 hours prior infection. 
The strain P. aeruginosa PAO1 proved to be more virulent than the strain S. aureus 
MRSA 252 in the G. mellonella model, where only 10 cells per larvae were required to 
result in death in 24 hours. For the S. aureus strains  an inoculum of 105-106 cells/per 
larvae was required for an infection to be established and cause larvae death, which is 
in accordance to previous studies (354). Similar numbers have been recorded for 
Helicobacter pylori infections on G. mellonella, with a requirement of 106-107 cells, and 
Acinetobacter baumannii requiring at least 104 cells per larvae (361, 362). A low 
infectious dose will result in reduced endotoxin and other bacterial debris being 
released upon phage infection into the host, causing a quieter activation of the immune 
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responses. This may be the explanation for the outcomes observed for larvae infected 
with S. aureus. When phages were added at MOI 1 or 10 larvae death was more rapid, 
suggesting that the burst of the bacteria in such a short time was causing a greater 
immune response not manageable by the host. Five different clinical isolates were also 
tested, with the treatment model, and the same pattern was always observed. 
However, when using S. aureus MRSA 252 such faster death was not observed when 
administering MOIs lower than 1 and it was even more successful when the incubation 
temperature was at 26 °C. At this low temperature also the bacteria replicate slower 
and probably are less virulent (350). Therefore, phage proliferation would consequently 
occur more slowly as would the release of bacterial debris and endotoxin-like material. 
If this is the scenario occurring then the host is not confronted with such a massive 
quantity of cell debris and antigenic material and activation of the host defences 
develops at a slower pace. The G. mellonella model is considered a model for studying 
systemic infections, therefore these results are important in case of a human 
bacteraemia, and where the event of an anaphylactic shock is an event to avoid as will 
result ultimately in the patient’s death. The situation certainly is different if dealing with 
a local infection, such as a burn wound, where the infection is restrained and easier to 
handle and resolve. Endotoxins apart from their high toxicity are known to be highly 
immunogenic. Usually endotoxin refers to the gram-negative lipopolysaccharide (LPS) 
and gram-positive bacteria do not have LPS. However, gram-positive bacteria produce 
several cellular toxins such as exotoxins (previously discussed in Chapter One), 
especially in their log-phase when they are actively growing.  This is clearly the case 
with several S. aureus strains which produce a number of exotoxins. These exotoxins 
are highly immunogenic in mammals and so it can be hypothesised that this is the 
phenomenon that we are observing when the bacteria lyse (363). When performing 
lysis ex vivo, however the same mortality effect was not observed. This might suggest 
the production of an intermediate compound during the lysis that is released causing 
the massive shock, which when lysis is performed ex vivo is not present anymore (due 
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to lack of stability, for example). Another hypothesis is that the immune system is to 
deal with the invasion as soon as the lysate is injected. When performing both infection 
and treatment injection perhaps the bacteria had time to spread along the host, phage 
particles then would have to find the bacteria. During the time for phage to attach to 
bacteria, the bacterial cells themselves are proliferating, increasing the number of cells 
as well the amount of cell debris (upon cell burst). A heat-inactivated bacterial inoculum 
was also given to a group of larvae, in order to rule out the contribution of the antigenic 
cell wall of live bacteria to the strong immune response observed. However, as 
expected, such contribution was not observed. Heat causes changes to the surface of 
the bacteria making them less susceptible and less immunogenic (364). In conclusion, 
the results suggest the existence of a thin equilibrium when using G. mellonella 
infected by S. aureus cells and treated with phage, where a high number of phage 
particles in relation to bacterial cells cause the death of the host, but a low number of 
phage particles is not enough to protect the host from the pathogenic bacteria. It was 
also noticed that, although the ODs injected were always approximately equal to 1 the 
survival rates for larvae was very variable, sometimes displaying a 50 % death during 
the first 24 hours and at other time only at 48 hours. This was not seen for P. 
aeruginosa strains injected into the model. Such a fact may be related to the injection 
procedure where 10 μl is difficult to accurately administer. Hence, if we administered a 
couple of extra μl, the cell concentration will greatly differ for S. aureus strains. For 
example, in the case of P. aeruginosa strains – 10 μl contain 10 cells and 12 μl will 
have 2 more cells. For S. aureus strains - 10 μl contain 1x106 and 12 μl have 2x105 
more bacteria. This applies to the phage injections as well. In conclusion, to accurately 
perform experiments for S. aureus, where we clearly need to have a perfect equilibrium 
between amount of phage and bacterial cells, the G. mellonella model might not be 
suitable for assessing phage treatment for a S. aureus systemic infection.  
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Regarding P. aeruginosa, experiments were shown to be more successful in terms of 
phage therapy. At all MOIs of phage there was a prolonged survival of the larvae 
regardless whether 10 or 100 bacterial cells were used as the inoculum, although the 
survival rates were higher when administering the lower inoculum. Probably the 10-fold 
higher inoculum of 100 cells vs 10 cells had meant that the infection had become more 
firmly established within the two hour time frame therefore reducing the efficacy of the 
phage to prolong survival. The protection assay showed the ability of phage to protect 
from infection using a prophylactic administration of phage two hours prior to infection.  
When compared with the treatment model, prophylactic administration of phage 
resulted in greater survival after 24 hours at all comparable MOI values.  Presumably 
this increased efficacy was the result of phage being able to distribute throughout the 
haemolymph over the two hour period prior to infection, whereas in the treatment 
model the bacteria will have had opportunity to establish and begin to express toxins.  
Interesting was the observation of greater survival among larvae which received the 
higher inoculum of 100 cells, compared with 10 cells.  This may have been due to the 
higher number of bacterial cells resulting in an increased chance of bacteria and phage 
interaction resulting in a more rapid amplification of the phage. For all P. aeruginosa 
experiments eventually larvae succumbed to the infection resulting in death by 30 
hours post-infection. For this reason, the kinetics of bacterial cells throughout the 
infection as well as the phage numbers (in the treated experiments) was explored in 
vivo. The most striking observation was the comparison between numbers of P. 
aeruginosa cells in the phage treated and untreated larvae. At 24 hours the phage had 
kept the number of bacterial cells to 1000-fold less than the non-treated larvae, but 
even in the presence of high titres of phage there had still been active growth, and 
therefore infection, from the P. aeruginosa over the duration of the experiment. The 
death observed could suggest a lack of available phage to target the remaining 
bacterial cells. However, the kinetics assay showed that this was not the case due to 
the high titre of phage within the haemolymph, although the MOI had shifted from 100 
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to less than 1 by 24 hours. Such hypothesis was also ruled out by an experiment where 
larvae were given a second dose of phage four hours after an initial dosing, but there 
was no difference when compared with the single dose control. One possibility for the 
continual survival of PAO1 in the presence of a high titre of phage was the evolution of 
phage resistance within the larvae. This was ruled out after observation of no bacterial 
growth when co-cultivating P. aeruginosa single colonies, recovered at 24 hours after 
phage treatment, and a suspension of phage cocktail. A final explanation for the 
survival would be the unavailability of P. aeruginosa cells due to intracellular 
localisation. P. aeruginosa is known to have the ability to invade epithelial cells which 
might protect them from attack by the phage (365) and in these experiments only 
bacterial numbers were examined within extracted haemolymph. This highlights one of 
the limitations of phage therapy on pathogens which are able to exist and replicate in 
an intracellular environment. Phages, unlike some antibiotics, are not diffusible across 
membranes and perhaps combination therapy with antibiotics which can enter host 
cells such as a fluoroquinolone or tetracycline would have aided in clearance. This 
potential intracellular survival strategy would also explain why the protection model 
showed improved survival compared with the treatment model where the P. aeruginosa 
will have had time to establish within cells before larvae received a dose of the phage.  
However, there must have been a degree of extracellular replication of cells within the 
haemolymph to allow for the observed propagation of the phage over time. Another 
possibility could be the escape of bacterial cells close to tissue being protected from 
the phage infection (246). Finally, the effectiveness of the phage model on clinical 
isolates of P. aeruginosa was also assessed regarding phage protection.  An acute and 
a chronic CF infection causing isolates were used. Here, the acute isolate resulted in 
rapid death of larvae within 24 hours and the chronic isolate was less virulent at 24 
hours compared with the acute and PAO1 strains, but 100 % mortality was then seen 
by 40 hours.   
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In conclusion we present data for the use of the G. mellonella as a simple, robust and 
cost-effective model for initial examination P. aeruginosa targeted phage therapy, but 
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6.1. Conclusions  
The aim of this thesis was to select suitable, safe and efficacious phage candidates 
against S. aureus and P. aeruginosa clinical strains and to validate their ability to 
reduce and control bacterial biofilms produced by the bacteria aforementioned. With 
those aims, this thesis was divided into two main chapters.  
The first one (Chapter Three) describes the whole process of phage isolation, after 
which phages shown to be lytic with broad host ranges were selected and their detailed 
characterisation was performed. The sensitivity assays against clinical isolates proved 
to be valuable not only to discard phages employing lysogenic cycles, but also to better 
select phages able to infect as broader range of isolates as possible, whether because 
the phage strategy to infect the cell is fairly conserved within the bacterial group (S. 
aureus phages) or because the combination between several phages covers the 
majority of the clinical isolates (P. aeruginosa phages), a feature  required for a phage 
therapeutic cocktail as  in an infection situation where immediate treatment is required, 
and the pathogen might not be fully identified. To characterise the phages regarding 
their morphology, TEM analysis was performed as this also helped to discard 
Siphoviridae type phages that were to be avoided in the case of S. aureus phages and 
also to assure the purity of the phage suspension. For further characterisation, a whole 
genome sequencing and analysis of the isolated phages was performed as this is a 
prerequisite in a post-genomic era when isolating and studying phages that are 
potentially to be applied therapeutically. Genome sequencing can reveal not only what 
genes are present and their function, but also their organisation into the genome. This 
is then valuable for comparisons with previously isolated and studied phages, allowing 
identification of the morphology and to allocate them into an existing group or in the 
case of a unique phage, create a new taxonomic group. Also, it tells us of the presence 
of factors enabling the phage to produce a lysogenic infection which in the case of this 
thesis would rule out the phage for therapeutic use, and to a certain level, the presence 
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of toxin or antibiotic resistance genes can be evaluated. Genome sequencing can be of 
value in the future for development and production of phage-based products such as 
lysins or depolymerases, and also for genetic modification of phages. Phages DRA88, 
a Myoviridae, together with phage K formed the cocktail to target S. aureus strains. 
Regarding P. aeruginosa strains, a cocktail made of six phages was established, where 
DL52, DL60 and DL68 belong to the Myoviridae family and all belonging to the same 
group (PB1-like group) sharing high similarities, and DL54, DL62 and DL64 belong to 
the Podoviridae family, but all three in different groups. No virulence or toxin factors 
were identified; however genes with no attributed function remain as the majority of the 
genome. Hopefully, with the availability nowadays of an easy access to sequencing 
(fast and relatively cheap) a growing number of phage sequences have been 
generated and this will help to better understand phages and their relationships. With 
continuous and deeper study of phage genes and protein structure, these unknown 
gene functions can be identified.  
The following chapter (Chapter Four) assessed the ability of the selected cocktails to 
inhibit or reduce bacterial growth while this takes place under planktonic conditions, but 
it goes further exploring the lytic aptitude for reducing and dispersing biofilm 
communities, whether those were performed under static conditions or dynamic ones. 
Such reduction was observed whether the isolates carried antibiotic resistance factors 
or not. The growth of phage with bacteria under planktonic conditions allows observing 
of their dynamics and how fast resistance can be achieved by the bacteria to the 
phages. However, the bacterial biofilm mode of living is the rule in nature and obviously 
the same is observed when, for example, a wound infection occurs, and therefore the 
biofilm mode must be included when studying lytic phages. The two biofilm models 
established allowed the observation that both cocktails were efficient in bringing down 
established biofilm communities, however at a slower pace than the one observed for 
planktonic cultures and even slower when comparing the static to the dynamic biofilm 
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systems, where the last one was shown to be removed at a slower speed. The flow 
model was performed to achieve a more realistic resemblance to an in vivo situation. 
Both cocktails proved to powerfully reduce the number of bacterial cells attached to the 
stainless steel surfaces, although the effect was more significant in the case of the P. 
aeruginosa cocktail when treating the PAO1 biofilm. 
These two chapters were then followed by Chapter Five, where the phage cocktails, 
already assessed for their suitability and efficacy for potentially treating infectious 
diseases caused by biofilm production, are assessed for the ability to treat systemic 
infections from S. aureus and P. aeruginosa in an in vivo larvae infection model. Here, 
the phage cocktails were not assessed for biofilm removal, but rather for a bacteraemia 
where the infection is established and spread through the system of the larvae. For the 
case of S. aureus, the high level of bacterial cells that had to be injected to cause a 
lethal infection was so high that it enabled us to observe a positive phage influence 
towards the treatment of the larvae. And often the opposite was observed, when the 
phages were applied a higher mortality was observed, most probably due to the high 
number of cells being burst in a short period of time. This relates to the fact that when 
treating bacteraemia, the endotoxin release should be taken into account and carefully 
considered for in vivo animal models to avoid an anaphylactic shock in the patient. 
Perhaps phage therapy would have a better outcome when treating localised infections 
and maybe other approaches should be used when treating systemic infections, for 
example the use of genetically modified phages that kill the bacterium but do not cause 
it to burst. In the case of P. aeruginosa it was possible to observe that the phage 
extended the survival of the larvae, although not being able to fully treat and allow the 
larvae to recover from the infection. Hence, the G. mellonella model can be considered 
a very good model before going to higher animal systems to study bacterial infections 
that only need a low infectivity dose. 
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This work shows how phages can be employed as an alternative to reduce and treat 
bacterial infections, especially those ones growing under a biofilm community and 
showing antibiotic resistant profile. However, not all the isolates have been tested with 
these phage cocktails and there might be a situation where the phage cocktail might 
not be enough for complete infection removal, and synchronisation with other 
alternatives, such as bacteriocins for example, is the key. Even an antibiotic drug will 
help   by bringing the bacterial cell numbers down to a level where the immune system 
can deal with and resolve the infection. 
The main focus of this thesis was the reduction and control of biofilms involved in 
infections; however it could even be extended to treat decontamination of hospital 
equipment or indwelling devices that would benefit from an additional method of 
sterilization. Such use of phages might reduce the need for antibiotic drugs in the case 
of treatment of human diseases as well as reduce the amount of chemicals and 
detergent used to treat wastewater and decontaminate medical devices. 
 
6.2. Further work 
The work presented in this thesis can be seen as a starting point for several other lines 
of investigation to achieve a deeper understanding of the potential of phage to treat 
bacterial infections. 
Regarding the S. aureus cocktail, considering that both phages are highly similar it 
would be worthwhile to isolate and add another phage type, perhaps targeting those 
isolates resistant to the other two phages. Regarding P. aeruginosa, the phage cocktail 
can be further characterised, such as the growth parameters of each phage can be 
studied and the cocktail can be tested using clinical isolates, by performing treatment of 
planktonic cultures and biofilm communities. 
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It would be interesting to further analyse the aggregation phenomenon observed, by 
using long tailed phages, such as DRA88 (Myoviridae) and short tailed ones, such as 
DL62 (Podoviridae) using the DLS technique. This could be achieved by changing the 
buffer compositions, such as the concentration of ions, pH or temperature and measure 
their size in the suspension. To complement such a study, it would be interesting to 
perform plaque assays in order to estimate their titre and analyse if the composition of 
therapeutic phage suspension can have an effect on how efficiently phages can attach 
and infect bacterial cells.  
Also, a preliminary study coupling the use of phage with antibiotic has been performed 
here, this can be taken further by performing a large screening involving several 
antibiotics, phages and clinical isolates. Not only antibiotics can be included in such a 
study, but other alternatives being investigated at the moment, such as antimicrobial 
peptides could be included in the study and possible bacterial biofilm reduction 
synchronisation effects explored. 
The biofilms performed on the Modified Robbins Device can be better improved and 
several parameters can be investigated, for example by studying different clinical 
isolates, but also by using different growth media with a composition resembling more 
a realistic infection environment, for example a burn wound or a leg ulcer wound 
infection. Also, for better biofilm maturation it is recommended to allow the experiment 
to run for longer, perhaps two to four additional days, with the inclusion of a bubble trap 
at the start of the device, removing possible air bubbles that often are formed and once 
inside the lumen of the device can disrupt parts of the formed biofilms. Besides the 
Robbins Device, other dynamic systems can also be implemented to study the action 
of the phages on biofilms, such as the flow cell. 
Finally, it should be noted that the next sensible step would be the performance of dual 
species biofilms with P. aeruginosa and S. aureus, the main bacteria present in biofilm 
wound infections, where the use of both phage cocktails could be employed and their 
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eradication efficacy explored. Further down the line and in a more complex way, 
isolation of phages to Klebsiella pneumonia and Acinetobacter baumannii would allow 
the study of the potential of multispecies phage cocktails to eliminate multispecies 
biofilms. 
The sequencing of the phages genomes can allow a more thorough investigation and 
manipulation of the genomes could be an option to improve the polyvalent character of 
a phage, for example in the case of P. aeruginosa, it would benefit from having phages 
less host specific. Also, a screen looking for depolymerases enzymes within the 
genome could be employed and protein expression and purification of those enzymes 
could be used to study their effect on eliminating or dispersing biofilms by themselves. 
Lastly, a sensible investigation step would be testing the phage cocktails on in vivo 
animal models, such as a murine model, where a thermal injury could be induced to 
establish then an infection and phage cocktail applied to the infected area. Monitoring 
of such experiment could give very promising results on the use of these phage 
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a  b  s  t  r  a  c  t
The  Galleria  mellonella  infection  model  was used  to assess  the  in  vivo  efﬁcacy  of phage  therapy  against
laboratory  and clinical  strains  of  Pseudomonas  aeruginosa.  In a  ﬁrst  series  of  experiments,  Galleria  were
infected  with  the  laboratory  strain  P.  aeruginosa  PAO1  and  were  treated  with  varying  multiplicity  of infec-
tion  (MOI)  of  phages  either  2 h  post-infection  (treatment)  or  2 h pre-infection  (prevention)  via injection
into  the  haemolymph.  To  address  the  kinetics  of  infection,  larvae  were  bled  over a period  of 24  h  for
quantiﬁcation  of  bacteria  and phages.  Survival  rates  at  24 h  when  infected  with  10 cells/larvae  were
greater  in the  prevention  versus  treatment  model  (47%  vs.  40%,  MOI =  10;  47% vs. 20%,  MOI  = 1; and  33%
vs.  7%,  MOI =  0.1).  This  pattern  held  true  when  100  cells/larvae  were  used  (87%  vs. 20%, MOI =  10;  53%
vs.  13%,  MOI  =  1; 67%  vs. 7%,  MOI  = 0.1).  By 24  h post-infection,  phages  kept  bacterial  cell  numbers  in  the
haemolymph  1000-fold  lower  than  in the  non-treated  group.  In  a  second  series  of  experiments  using
clinical  strains  to further  validate  the  prevention  model,  phages  protected  Galleria  when infected  with
both  a bacteraemia  (0% vs. 85%)  and  a cystic  ﬁbrosis  (80%  vs.  100%)  isolate.  Therefore,  this  study  validates
the  use  of  G. mellonella  as a  simple,  robust  and  cost-effective  model  for  initial  in  vivo examination  of  P.
aeruginosa-targeted  phage  therapy,  which  may  be  applied  to other  pathogens  with  similarly  low  infective
doses.
Crown  Copyright  © 2015  Published  by Elsevier  B.V.  All  rights  reserved.
1. Introduction
Multidrug-resistant bacterial pathogens pose an ever-
increasing threat to human health. This problem is in part
due to a lack of novel antibiotics approved for use over the last
few decades, resulting in an urgent need to identify new avenues
for treating bacterial infections, especially those caused by Gram-
negative pathogens [1]. Pseudomonas aeruginosa is an opportunistic
pathogen that is a leading cause of infection among burn victims
and patients with cystic ﬁbrosis (CF). It is also responsible for a
large number of healthcare-associated infections. To make matters
worse, P. aeruginosa is associated with hypermutability and, due to
high antibiotic selective pressure, has given rise to the emergence
of multidrug-resistant strains in the population; thus, concerns
about available effective treatments are growing [2,3]. In the
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UK, resistance to two or more antibiotics among P. aeruginosa
isolated from the lungs of CF patients has risen to 40% [4]. This is a
worrying statistic as colonisation of the CF lung with P. aeruginosa
is a predictor of poor prognosis and is associated with a two- to
three-fold increased risk of death over an 8-year period [5]. For
this reason, novel anti-infectives are needed.
Facing such a scenario, interest in phage therapy in Western
society has experienced a resurgence after research into this area
fell out of favour following the discovery of antibiotics. Bacterio-
phages (or phages) are viral particles able to infect bacterial cells
with high speciﬁcity, taking over cellular function to replicate their
genomes. Upon maturation, the bacterial cell wall is lysed to release
viral progeny.
Phage therapy can be broadly subdivided into four main cate-
gories [6]: (i) conventional phage therapy using mainly lytic phages
to lyse target bacterial species; (ii) modiﬁed phage therapy using
genetically altered phages with favourable properties, such as non-
lytic replication to avoid the possibility of endotoxic shock when
bacterial cells are lysed; (iii) treatment with enzymes derived
from phages, such as administration of endolysins to selectively
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degrade the bacterial peptidoglycan cell wall; and (iv) the con-
cept of combination therapy with phages and antibiotics, where
phages exhibit properties to degrade polysaccharide components
of bioﬁlms therefore allowing antibiotics to penetrate and elicit an
action [7].
Although in vitro systems allow for a reductionist approach to
examining phage interactions with target bacteria, they do not take
into account a more complex in vivo system. Mammalian mod-
els are an excellent means of testing phage therapy but require
ethical approval, signiﬁcant infrastructure and funds. The Galleria
mellonella model ﬁlls the void between these two systems, pro-
viding a cheap, reliable and ethics-free system for testing novel
antimicrobials [8]. Here we describe the ﬁrst use of the G. mellonella
model to evaluate the efﬁcacy of phage therapy both for treatment
and prophylaxis of P. aeruginosa infection.
2. Materials and methods
2.1. Bacterial strains and preparation of inoculum
Phage therapy was assessed using P. aeruginosa PAO1 and
two low-passage clinical isolates (PA45291 and BC09007) iso-
lated from bacteraemia and CF samples, respectively. Bacteria were
grown to mid-log phase in Luria–Bertani (LB) broth (Sigma-Aldrich,
Dorset, UK) and were washed once in phosphate-buffered saline
(PBS). Cells were re-suspended in PBS to a ﬁnal concentration of
1 × 108 CFU/mL and were diluted accordingly in PBS to the required
inoculum size for each experiment.
2.2. Phage cocktail preparation and titration
All six distinct phages were propagated on P. aeruginosa PAO1
strain and were combined to establish a cocktail suspension. The
genomic sequence of the six phages can be found in the National
Center for Biotechnology Information (NCBI) GenBank database
under accession nos. KR054028–KR054033, with a full descrip-
tion of the phages detailed elsewhere (submitted). Brieﬂy, 100 L
of phage lysate and 100 L of host growing culture were mixed
and left for 5 min  at room temperature. Following incubation, 3 mL
of LB soft agar (Sigma-Aldrich) containing 0.65% bacteriological
agar (Sigma-Aldrich)was added and poured onto agar plates. Fol-
lowing overnight incubation at 37 ◦C, plates displaying conﬂuent
lysis were selected and 3 mL  of SM buffer [5 M NaCl, 1 M MgSO4,
1 M Tris–HCl (pH 7.5), 0.01% w/v gelatine] and 2% (v/v) chloro-
form (Sigma-Aldrich)were added before incubation at 37 ◦C for 4 h.
High-titre phage solution was removed from the plates, centrifuged
(8000 × g, 10 min) to remove cell debris and then ﬁlter-sterilised
(pore size, 0.22 m).  A polyethylene glycol (PEG) (Sigma-Aldrich)
puriﬁcation step was further added to remove any possible bacte-
rial debris from the suspensions. Brieﬂy, 10% (w/v) PEG (MW 8000)
was added to the lysate and left overnight at 4 ◦C. The next day,
the solution was centrifuged (4000 rpm, 30 min) to obtain a PEG-
–phage pellet. The pellet was re-suspended gently in 1 mL  of SM
buffer and was vortexed thoroughly. The ﬁnal solutions were stored
at 4 ◦C. All of the necessary dilutions were performed in SM buffer.
For titration of the bacteriophage content in the haemolymph, a
similar methodology to the propagation was followed. Several dilu-
tions were mixed with host bacterial cells and 3 mL  of soft agar was
added and poured onto agar plates. Following overnight incubation,
plaques were counted to determine the phage titre.
2.3. Galleria mellonella phage therapy assay
Larvae of G. mellonella were obtained from Livefood UK Ltd.
(Rooks Bridge, UK). Larvae were stored at 4 ◦C and were used
within 1 week. A modiﬁed methodology developed by Peleg et al.
was used to infect each G. mellonella [8]. Brieﬂy, G. mellonella
were surface-sterilised with a FASTAID pre-injection swab (Sigma-
Aldrich) containing 70% ethanol (Sigma-Aldrich). Using a pair of
tweezers, each G. mellonella was  restrained and, using a 26 G
Terumo syringe (VWR International, Lutterworth, UK), 10 L of
inoculum containing either 100 or 10 cells of P. aeruginosa was
delivered into the larval haemolymph behind the last proleg. For the
treatment model, phage suspension was delivered behind the last
proleg on the opposite side to the bacterial injection site 2 h post-
infection, and for the prevention experiment phage suspension was
given 2 h pre-infection. All experiments used 15 larvae per treat-
ment. A positive control group (larvae infected and treated with
PBS solution) and two  negative control groups (one group injected
with PBS only, assessing the impact of any negative effect from the
injection process; and one group injected with phage suspension
only, assessing toxicity of the phage cocktail) were also included.
Larvae were placed into Petri dishes and were incubated at 37 ◦C.
G. mellonella were examined hourly after 15 h post-infection and
were recorded as dead when they did not move in response to
touch.
2.4. Bleeding larval haemolymph
The prevention model was used to follow the kinetics of bacte-
ria and phage interactions within the larval haemolymph over time.
The phage cocktail, or PBS, was  administered 2 h prior to infection
and the phage titre was initially quantiﬁed within the haemolymph
at the time of infection (time zero). G. mellonella were infected
with 100 cells of P. aeruginosa PAO1 and at 8 h and 24 h three G.
mellonella were sacriﬁced and bled following incision made with
forceps to quantify phage and P. aeruginosa both in phage- and
PBS-treated G. mellonella.  Titrations of haemolymph were made in
SM buffer for phage counts. Quantiﬁcation of PAO1 was done by
preparing serial dilutions of haemolymph in 10 mM ferrous ammo-
nium sulfate (FAS) (Sigma-Aldrich) for inactivation of extracellular
phage. Bacteria were enumerated by total viable count of FAS dilu-
tions onto LB agar. Inactivation of phages by FAS was  conﬁrmed
prior to experimental procedure (data not shown). To rule out the
possibility of PAO1 evolving phage resistance during in vivo infec-
tion, re-isolated PAO1 were subjected to plaque assay to conﬁrm
susceptibility.
2.5. Statistical analysis
Kaplan–Meier survival curves and log-rank (Mantel–Cox) sta-
tistical test were performed using GraphPad Prism (GraphPad
Software Inc., La Jolla, CA).
3. Results
3.1. Treatment of infection
In this study, two models of phage and infection interactions
were examined. The ﬁrst was  a treatment whereby G. mellonella
was infected with either 10 or 100 cells of P. aeruginosa PAO1 and
left to allow an infection to establish for 2 h. Varying multiplicity
of infection (MOI) of phage were then administered and mortality
was observed over 48 h. No mortality was  recorded in the PBS con-
trols. However, G. mellonella treated with PBS died quicker when
infected with 100 cells compared with 10 cells. Administration of
phage, displaying lytic activity against PAO1 in vitro, prolonged the
survival of G. mellonella in a dose-dependent manner, but 0% sur-
vival was  eventually seen in all groups by 30 h (Fig. 1A and B). At
24 h there was 100% mortality in the infected and untreated G. mel-
lonella, but 40% survival for those infected with 10 cells and treated
with a MOI  of 10 compared with 20% survival in those infected with
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Fig. 1. Kaplan–Meier survival curves of Galleria mellonella infected with (A) 100 cells or (B) 10 cells of Pseudomonas aeruginosa PAO1 and treated with phage at varying
multiplicity of infection (MOI) 2 h post-infection. (C) Percentage of G. mellonella survival at 24 h. PBS, phosphate-buffered saline.
100 cells at the same MOI  (Fig. 1A and B). A statistically signiﬁcant
difference was seen between the survival curves as determined by
log-rank (Mantel–Cox) test (P < 0.0001).
3.2. Prevention of infection
The second model examined the effect of prevention of infec-
tion whereby G. mellonella was given a prophylactic dose of phage
2 h prior to infection with P. aeruginosa PAO1. Similarly to the treat-
ment experiment, G. mellonella infected with 100 cells died quicker
than those infected with 10 cells when given PBS 2 h before infec-
tion (Fig. 2A and B). At 24 h, survival ranged from 80% in G. mellonella
infected with 100 cells and given a MOI  of 100 to 35% in those given a
MOI  of 0.1 (Fig. 2A). Survival ranged from 90% to 60% in G. mellonella
infected with 10 cells and given MOIs of 100 and 1, respectively
(Fig. 2B). A statistically signiﬁcant difference was seen between
the survival curves as determined by log-rank (Mantel–Cox) test
(P < 0.0001).
3.3. Kinetics of Pseudomonas aeruginosa infection and effect of
phage treatment
To understand the kinetics of a P. aeruginosa infection within G.
mellonella, larvae were infected with 100 cells using the preven-
tion model of infection. Bacteria and phage were quantiﬁed at set
time points by bleeding the haemolymph. Recovered volumes of
haemolymph ranged from 20 L to 40 L, but numbers were stan-
dardised upon analysis. No endogenous P. aeruginosa or phage with
lytic activity against P. aeruginosa PAO1 were detected in the unin-
fected controls. For G. mellonella that were given P. aeruginosa PAO1
only, the number of cells isolated from the haemolymph increased
over the duration of the experiment. By 24 h, all G. mellonella were
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Fig. 2. Kaplan–Meier survival curves of Galleria mellonella infected with (A) 100 cells or (B) 10 cells of Pseudomonas aeruginosa PAO1 and pre-treated with phage at varying
multiplicity of infection (MOI) 2 h pre-infection. (C) Percentage of G. mellonella survival at 24 h. PBS, phosphate-buffered saline.
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dead and number of P. aeruginosa were in the order of 108 CFU/mL.
The second group of G. mellonella was given a prophylactic dose of
phage 2 h prior to infection and then phage and bacteria were quan-
tiﬁed over the course of the infection. The number of P. aeruginosa
PAO1 was comparable with that of the non-treated G. mellonella
after 8 h of infection, but were three orders of magnitude less at
24 h compared with the non-treated G. mellonella.  These G. mel-
lonella were alive at 24 h. The number of phages increased over the
duration of the infection, reaching a peak titre at 24 h of 108 PFU/mL.
3.4. Low-passage clinical isolates of Pseudomonas aeruginosa
To validate the model of phage therapy with P. aeruginosa, we
sought to test the model with low-passage clinical strains isolated
from patients with bacteraemia or CF (Fig. 4A and B). With the
PA45291 bacteraemia strain, all infected G. mellonella were dead by
24 h, whereas there was 60% survival at 28 h in the group treated
with phage at a MOI  of 10. When G. mellonella were infected with
the BC09007 CF strain there was little mortality at 24 h (90%) when
given PBS as treatment, but there was 100% survival in the phage-
treated group. By 40 h, all G. mellonella were then dead.
4. Discussion
To avoid a scenario whereby society is plunged back into a pre-
antibiotic era, there is an urgent need to identify novel antibacterial
agents. Phage therapy offers a novel non-antibiotic approach to
help in this battle. Phage therapy offers a different mode of action
compared with antibiotics and therefore antibiotic-resistant orga-
nisms can still be susceptible to phages. In addition, phages are
highly selective and will therefore not wipe out the host microbiota,
unlike antibiotics, as well as being deemed safe in trials [9–11].
The G. mellonella infection model provides a system that can
bridge the gap between in vitro studies and more advanced mam-
malian studies, giving initial proof-of-principle data. Mammalian
models are crucial for testing the efﬁcacy of phages prior to human
trials, but drawbacks include the need for sufﬁcient infrastructure,
substantial costs as well as the need for ethical approval. G. mel-
lonella larvae have been used to examine numerous host–pathogen
interactions ranging from studies of pathogenicity to antimicrobial
activity, with a small number of these examining the potential for
phage therapy [12–14].
The P. aeruginosa PAO1 strain proved to be highly virulent, with
only 10 cells per G. mellonella required to result in mortality at 24 h.
This is a very low infective dose in this model, with organisms such
as Staphylococcus aureus requiring 105–106 cells/G. mellonella for
mortality, Acinetobacter baumannii requiring >104 and Helicobac-
ter pylori requiring 106–107 cells for establishment of infection
[15–17]. This low infectious dose is of particular interest as it
reduces the chances of endotoxic shock due to rapid lysis of high
numbers of Gram-negative bacterial cells.
Two models of therapy were examined. The ﬁrst was  a treat-
ment methodology whereby an acute 2-h infection was allowed
to establish prior to administration of phage. At all MOIs of phage
there was prolonged survival of G. mellonella regardless of whether
10 or 100 bacterial cells were used as the inoculum. Although there
was increased survival compared with the control, there was a
difference in survival depending on the number of cells in the inocu-
lum. Presumably the 10-fold higher inoculum of 100 cells versus 10
cells meant that the infection had become more established within
the 2-h time frame therefore reducing the efﬁcacy of the phage to
prolong survival.
The second model examined the ability to prevent infection
using prophylactic administration of phage 2 h prior to infec-
tion. When compared with the treatment model, prophylactic
Fig. 3. In vivo kinetics of Pseudomonas aeruginosa PAO1 infection within Galleria
mellonella with and without phage treatment. MOI, multiplicity of infection.
administration of phage resulted in greater survival after 24 h
at all comparable MOI  values. Presumably this increased efﬁcacy
was the result of phage being able to distribute throughout the
haemolymph over the 2-h period prior to infection, whereas in the
treatment model the bacteria will have had opportunity to estab-
lish and begin to express toxins. Interesting was the observation of
greater survival among G. mellonella that received the higher inocu-
lum of 100 cells compared with 10 cells. This may  have been due
to the higher number of bacterial cells, resulting in an increased
chance of bacteria and phage interaction resulting in a more rapid
ampliﬁcation of the phage.
In both models, phage-treated G. mellonella eventually suc-
cumbed to the infection, resulting in mortality by 30 h post-
infection. For this reason, we  explored the kinetics of both the
P. aeruginosa infection as well as the effect of phage on bacterial
numbers in vivo. The most striking observation was the compar-
ison between numbers of P. aeruginosa in the phage-treated and
untreated G. mellonella.  At 24 h the phage had kept the number of
P. aeruginosa to 1000-fold less than the non-treated G. mellonella,
but even in the presence of high titres of phage there had still been
active growth, and therefore infection, from P. aeruginosa over the
duration of the experiment. We  had previously hypothesised that
the reason for eventual mortality was the lack of available phage
for clearance. From Fig. 3 it is clear that this is not the case owing
to the high titre of phage within the haemolymph, although the
MOI  had shifted from 100 to <1 by 24 h. This hypothesis was also
ruled out by an experiment where G. mellonella was  given a second
dose of phage 4 h after an initial dosing, but there was  no difference
when compared with the single dose control (data not shown). One
possibility for the continual survival of PAO1 in the presence of a
high titre of phage was  the evolution of phage resistance within
the G. mellonella.  This was ruled out after observation of no bacterial
growth when co-cultivating P. aeruginosa single colonies, recovered
at 24 h after phage treatment, and a suspension of phage cocktail
(data not shown). The ﬁnal explanation for the survival could be
the intracellular localisation of P. aeruginosa.  In these experiments
only bacterial numbers within extracted haemolymph were exam-
ined. Pseudomonas aeruginosa is known to have the ability to invade
epithelial cells, which would protect from attack by the phage [18].
This highlights one of the limitations of phage therapy on pathogens
that are able to exist and replicate in an intracellular environment.
Perhaps combination therapy with antibiotics that can enter host
cells, such as a ﬂuoroquinolone or tetracycline, would have aided
in clearance, but this was  beyond the scope of this study. This
potential intracellular survival strategy would also explain why
the prevention model showed improved survival compared with
the treatment model, whereby the P. aeruginosa will have establish
within cells before the G. mellonella received a dose of the phage.
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Fig. 4. Kaplan–Meier survival curves of Galleria mellonella infected with 10 cells of (A) Pseudomonas aeruginosa PA45291 (bacteraemia isolate) or (B) P. aeruginosa BC09007
(cystic  ﬁbrosis isolate) and pre-treated with phage at a multiplicity of infection (MOI) of 10 at 2 h pre-infection. PBS, phosphate-buffered saline.
Although we hypothesise that the lack of P. aeruginosa clearance
was due to intracellular localisation, there must have been a degree
of extracellular replication of cells within the haemolymph to allow
for the observed propagation of the phage over time.
Finally, we looked to demonstrate the effectiveness of the phage
model on clinical isolates of P. aeruginosa.  To do this, the prevention
model was repeated with clinical isolates from a bacteraemia and
a CF infection. Here the acute isolate resulted in rapid mortality of
the G. mellonella within 24 h, with 85% survival when given phage
at a MOI  of 10. Interestingly, the CF isolate was less virulent at 24 h
compared with the bacteraemia and PAO1 strains, but 100% mor-
tality was then seen by 40 h. In conclusion, we present data for the
use of G. mellonella as a simple, robust and cost-effective model for
initial examination of P. aeruginosa-targeted phage therapy.
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